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INTRODUCTION
There is a continuous need to monitor and evaluate the effectiveness and safety
of medicines when they are used in daily clinical practice after their release for
marketing [1, 2]. Safety is a key issue in the appraisal of drug therapy outcomes
[3-5]. Drug related problems are probably one of the most frequently occurring
and significant health hazards [6].
Recently, the withdrawal of five drugs from the US market in a 12-month period
has raised concerns about the role of pre- and postmarketing regulations with r-
spect to drug safety. Friedman et al have reviewed these cases and came to the
conclusion that the approval dates of these removed drugs were scattered over the
last decades, making a time association between the recently established reduc-
tion of review time at the FDA and the drug withdrawals not very likely [3]. Bal-
ancing the risks and benefits of drug treatment is one of the most challenging re-
sponsibilities of all stakeholders in pharma (prescribers, industry, pharmacists
regulators, academia) [4, 5].
The effectiveness, safety, and patterns of use of a drug in real life may be differ-
ent than as assessed in clinical trials due to differences in prescribing physicians
and patients. Key differences between clinical trials and the ‘real world’ are the
limited patient numbers, restrictions in the patient populations (e.g. pregnant
women, children, elderly and those predisposed to develop adverse events are
frequently excluded) and the limited duration of drug use in clinical studies [4].
Effectiveness and safety when used for indications or in dosages other than ini-
tially tested remain unknown and knowledge about interactions with concomi-
tantly used drugs due to multiple pathology is not always complete. Moreover,
physicians’ prescribing habits are often unknown at the time of market entry and
may vary over time due to commercial promotion, cost containment measures,
changing attitudes and guidelines of therapeutic evidence [7].
Postmarketing surveillance aims to monitor and evaluate both the beneficial and
adverse effects of drugs after approval for general use. The Health Council in the
Netherlands has defined postmarketing surveillance (PMS) as ‘The systematic
surveilance and scientific study of all intended and unintended effects of medi-
cines on human health, after their release for marketing’ [8]. Spontaneous re-
porting systems have been shown to be effective in revealing unusual or rare ad-
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verse events [4]. However, spontane us reports alone do not provide sufficient
evidence to conclude that an adverse event is indeed drug related. Recently,
McNeil et al demonstrated the limitations of spontaneous reporting in relation to
the antibiotic agent flucloxacillin [9]. There were such reports from Australia,
New Zealand and UK suggesting flucloxacillin-associated jaundice, but these
data were insufficient to test the hypothesis of a causal association. Spontaneous
reports should be supplemented by analytical studies, monitoring of cohorts of
users of new drugs, using record-linkage to track their subsequent outcomes, and
to interpret the results of such analyses in the context of variability of drug expo-
sure [7].
Several designs can be applied to investigate medicines after approval for mar-
keting, either descriptive or analytical, and either non-experimental or experi-
mental [2, 10-14].
Record-linkage has made a significant contribution to postmarketing surveillance
of drugs, which involves linking drug exposure to outcome data (effectiveness,
safety, economics) [10-12]. Even patient reporting can play an important role in
pharmacovigilance, as reporting by patients may lead to earlier notice of adverse
events [15].
There are many significant features of drug exposure and related outcomes to be
studied in postmarketing surveillance, such as time dosing of medicines in daily
use, prescription patterns, dynamics of indications and off-label use.
Examples of such topics in postmarketing evaluation of medicines include also
fine-tuning of dosage recommendations, a reappraisal of indicat ons (extension or
restriction), drug use and drug users characteristics, assessment of long-term effi-
cacy, assessment of side effects detection of unexpected side effects and interac-
tions, long-term safety, study of potential risk groups, detection of unexpected
beneficial effects, further pharmacological and mechanistic studies, and finally
cost-effectiveness studies [2, 7].
Illustrations of such approaches comprise a postmarketing study regarding the
teratogenetic metabolite of acitretin [16]. Furthermore, the introduction of drugs
with a new pharmacological profile especially requires postmarketing urveil-
lance of adverse events, as illustrated by the case of ibopamine [14].
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Automated databases and field cohort studies in postmarketing urveillance
One of the most productive approaches in postmarketing surveillance has been
the use of automated databases including ample data on drug exposure, clinical
characteristics of patients and health outcomes. The European scene of the auto-
mated databases is fairly straightforward [2]. In The Netherlands, Herings et al
have developed the PHARMO Record Linkage System, in the United Kingdom
GPRD and MEMO are widely recognised as valuable sources for postmarketing
studies, in Odense (Denmark) the so-called OPED database has been shown to be
an important asset and in Italy the county of Friuli has developed a relevant data-
base for pharmacoepidemiologic work [2, 10, 12]. In North-America (including
Canada) there is ample opportunity to approach automated databases for post-
marketing surveillance (e.g. large number of HMOs, Saskatchewan, Medicaid)
[2]. However, automated databases frequently have important limitations re-
garding reliability and completeness of records on baseline health and disease
status, longitudinal clinical data (e.g. course of disease, data on hypertension,
cholesterol level) and health behaviour (smoking, drinking, OTC drugs) [4, 17].
In case of postmarketing surveillance of a newly launched drug, there are three
other reasons why automated databases may be not the first choice for conduct-
ing postmarketing surveillance studies:
1. Selection: Adoption of a new drug by physicians is highly variable and often
unpredictable due to differences in prescribing attitudes, formulary policies,
and marketing practices.
2. Size: In general, the introduction of a new drug on the Dutch market hardly
ever leads to a population of first users exceeding the size of 15-20,000 in the
first year after marketing. Currently PHARMO for instance, covers around
2% of the Dutch population and thus can only provide information on a
group of between 300 and 400 patients in the first year.
3. Access: Many databases have a lag time between data recording and avail-
ability for research (although advances in IT have led to significant im-
provements here).
Thus, the limitations of automated databases and the specific features of new
drug prescribing have fostered the development of alternative strategies for
building field cohorts of recipients of a new drug and performing follow-up
monitoring and evaluation [17].
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Since the early days of such field cohort studies in the late 80s, concerns have
been expressed about industry bias, seeding pressure in the form of pushing pre-
scriptions, and ethical issues related to industry sponsored postmarketing c hort
studies [18-21]. Discussions began regarding whether studies performed with
marketed drugs, where the physicians get paid for their participation, were scien-
tifically justified or were simply to increase sales [22].
One of the first ‘whistleblowers’ here was Inman. He blamed industry for the
promotional nature of their postmarketing surveillance studies and expressed
concerns about the consequences of physicians’ participation in such studies with
respect to the response rate to contribute to the prescription-event monitoring
(PEM) system organised by the Drug Safety Research Unit in UK [18]. Inman
found that general practitioners (GPs) heavily involved in promotional postmar-
keting studies were frequent prescribers of the drugs under investigation in such
studies. There was a consistent inverse relation between the number of prescrip-
tions per individual GP and the response rate to PEM. The overall response
among GPs was 53%, but the heaviest 10% of prescribers returned only 44% and
the heaviest 1% returned only 34% of PEM questionnaires.
Waller et al published an important analysis on industry sponsored postmarketing
studies in 1992 [23]. They concluded that such studies, because of weak study
design and problems with recruitment, had made only a limited contribution to
the assessment of drug safety to date. Based on the recommendations of Waller et
al several attempts have been made to design better and scientifically more rigor-
ous postmarketing surveillance models. This development has led to the estab-
lishment of European guidelines for Safety Assessment of Marketed Medicines
(SAMM) [24]. These guidelines were developed in draft form in 1993 by a joint
committee with members with a clinical, regulatory, academic or pharmaceutical
industry background in order to provide basic rules to ensure good study design.
A legal framework is given in Council Regulation (EEC) No 2309/93 (Title 2,
Chapter III) and Council Directive 75/319/EEC as amended (Chapter Va) [25].
The obligations apply to all authorised medicinal products, are clarified in the
draft-Notice to Marketing Authorisation Holders and incorporate among other
things that the design of company sponsored postmarketing surveillance studies
will depend on the objectives of the study, which must be clearly defined in the
study protocol. Specific safety concerns to be investigated should be identified in
the protocol and explicitly addressed by the proposed methods. Although the
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SAMM guidelines cover different designs of studies (observational cohort stud-
ies, case-control studies, case-surveillance and clinical trials) they have mainly
been used for the conduct of cohort studies [26, 27].
At present, several European countries have published guidelines for the conduct
of postmarketing studies in accordance with the above-mentioned guidance of the
European Union. Promotional activities conducted under the guise of postmar-
keting studies remain unacceptable. The field of such studies shows a continuous
process of ‘trial and error’ of finding the right balance between scientific work,
involvement of health practitioners and patients and promotional activities. Al-
though the SAMM guidelines provide a useful format for finding the right bal-
ance, postmarketing practice has shown several cases of studies leading to debate
and critique. Ayres et al have reported from a postmarketing surveillance study to
evaluate the safety of a non-chlorofluorocarbon metered dose salbutamol inhaler
[28]. This study was conducted according to the SAMM-guidelines and was a
comparison of safety in patients using prescribed metered doses of salbutamol
delivered by inhalers using either hydrofluoroalkane or chlorofluorocarbon as the
propellant. There were no significant differences in hospitalisations and reports
of adverse effects between the hydrofluoroalkane and chlorofluorocarbon inhaler
groups. Although the study design successfully fulfilled the recommendations of
the SAMM guidelines, several authors have criticised the study for being to pro-
motional, and for being unethical [29, 30].
On the other hand one sees an increasing visibility of industry in types of post-
marketing surveillance studies resulting in clinically relevant findings [31, 32].
Although general maturity is not yet established, there is an increasing awareness
among industry pharmacovigilance and pharmacoepidemiology professionals to
continue in challenging their marketing colleagues to improve standards within
the industry. Moreover, academic pharmacoepidemiology has increased its con-
tribution significantly to drug safety studies and is now representing a strong
partner in solving important drug risk questions [33, 34].
PERSPECTIVE OF THE STUDY
With this background of interest in postmarketing research and the recognised
additional value of results of postmarketing surveillance studies, Aventis Pharma
B.V. and Janssen-Cilag B.V. took the initiative to set up the Peptic Survey proj-
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ect. Peptic Survey was a postmarketing surveillance study with lansoprazole, the
second proton pump inhibitor (PPI) introduced on the Dutch market at the end of
1993 by the previously mentioned pharmaceutical companies [35]. At the time of
product launch, the drug was indicated for the treatment of reflux oesophagitis
and healing of gastric and duodenal ulcers. The drug was introduced at first as a
30 mg capsule, while in January 1996 a 15 mg capsule was launched for the same
indications. At the time of introduction, lansoprazole had been evaluated in sev-
eral thousands of patients enrolled in clinical trials. The widespread use of PPIs
justified a thorough assessment of the safety of these drugs. The study started
soon after the introduction of lansoprazole on the Dutch market. All objectives
were clearly defined in the study protocol and/or amendments of the protocol.
Objectives
The primary objectives of this study were to assess the safety and effectiveness
of lansoprazole in a population composed of naturally occurring groups of users
and to evaluate the patterns of use of lansoprazole in daily practice. Secondary
objectives were to identify factors related to non-reponse to lansoprazole, head-
ache or diarrhoea during lansoprazole use and to evaluate the use of lansoprazole
as part of a Helicobacter pylori (H. pylori) eradication therapy.
Design
The study was a prospective, open label, observational follow-up study carried
out in naturally occurring users of lansoprazole in the Netherlands. The total du-
ration was aimed to be at least two years, and in fact was extended to 4 years and
3 months. The study protocol was designed in the fall of 1993, whereas European
guidelines for the design of company sponsored postmarketing surveillance
studies at first became available in December 1993.
Nevertheless, the design incorporated five of the six recommendations of the
European SAMM guidelines, namely:
1. A population as representative as possible of the general population of users,
and not selected. No in- or exclusion criteria were considered;
2. The medicinal product must be prescribed in the usual manner;
3. Patients must not be prescribed the medicine in order to include them;
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4. The decision to prescribe must be clearly separated from the decision to in-
clude the patient in the study;
5. The protocol stipulated the maximum number of patients to be entered by a
single physician [24].
The recommendation to include an appropriate comparator group was not fol-
lowed. This was due to two reasons; firstly, at the time of initiation of our study
only one other PPI was available on the Dutch market, which limited our choice.
Secondly, for reasons of efficiency we chose to make use of internal comparisons
in the analyses. As advised in the guidelines an independent scientific advisory
group was appointed to monitor the data and to oversee the study.
For day-to-day management a project team was installed. This team consisted of
an independent chairman, a project leader of Aventis Pharma B.V., a member of
Janssen-Cilag B.V. (during the first phase) and a member of the independent
Contract Research Organisation Kendle. The Medical Ethical Committee of the
Utrecht University Medical Centre approved the protocol. The highest standards
of professional conduct and confidentiality were maintained throughout the
study. All data and documents were kept in strict confidence and in accordance
with the privacy regulations.
Study population
All GPs, internists and gastro-enterologists in The Netherlands were invited to
participate in the study (Appendix I). In order to avoid inclusion bias, participat-
ing physicians and pharmacists were remunerated with only a modest fee,
equivalent to the reimbursement of their time spent to complete the record forms
or generate the medication histories. GPs could include a maximum of 20 pa-
tients per two years follow-up time, while specialists were allowed to include not
more than 50 patients in the same period. It was estimated tha  5,000 to 10,000
patients, to whom lansoprazole was prescribed in daily practice, might participate
in this study following the recommendations available at that time. All proce-
dures of patient inclusion, data recording and monitoring were designed not to
influence normal prescribing practice. Lansoprazole was prescribed without any
form of intervention or randomization. The patients' pharmacist, as part of rou-
tine pharmaceutical care, provided the medicines.
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All patients having used, or using lansoprazole, could be included in the study at
the first visit or any later follow-up visit after lansoprazole was prescribed. The
decision to prescribe was therefore clearly separated from the decision to include
the patient in the study. Furthermore, patients could not be prescribed the medi-
cine in order to include them, but must be natural occurring lansoprazole users.
Patients were informed about the project and agreed to participate by giving their
written informed consent to allow access to all relevant clinical and medication
data and storage and analyses of these data (Appendix II). No further selection
criteria were considered. All lansoprazole users could be included independent of
for example, age, indication for use, co-morbidity, and use of co-medication. To
maintain patient anonymity patients were identified by an identification code
only. All data and documents related to patients included were kept in strict con-
fidence and in accordance with Dutch privacy regulations.
Data were collected at the inclusion visit and at follow-up visits during lansopra-
zole therapy by reviewing the medical file and by patient questionnaire. Data
collection was designed not to influence daily practice. No supplementary diag-
nostic tests were requested from the physician with regard to the indication.
Complete medication histories were constituted through pharmacy records six
months retrospectively and during the lansoprazole therapy. Computerization of
pharmacy records, and thus the compilation of medication histories, is almost
universal in the Netherlands. The majority of patients are designated to a single
pharmacy for all reimbursed prescription drugs. In our study, the physician re-
quested the appropriate pharmacy to collect the pharmacy records.
For a subset of patients included after December 31st 1995 additional evaluation
forms regarding headache, diarrhoea and/or lack of effectiveness were completed
by the physician and, where applicable, after consultation with the patient in
question. In addition, for all patients during the total study period where lanso-
prazole was used as part of a H. pylori eradication therapy, dditional evaluation
forms were completed by the physician.
To ensure the collection of accurate, consistent, complete and reliable data par-
ticipating physicians were instructed and monitored in completing the forms at
regular intervals by representatives of the pharmaceutical companies and/or the
independent Contract Research Organisation.
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All data collected by the participating physicians and pharmacists were entered in
databases, validated and analysed by the independent Contract Research Organi-
sation in conjunction with the Department of Pharmacoepidemiology and Phar-
macotherapy of the Utrecht Institute for Pharmaceutical Sciences (UIPS). In-
quiries were made in case of inconsistencies, incorrect data, and missing data.
The decision to communicate or to publish depended upon the scientific merit
and interest in the findings and was agreed by the independent scientific advisory
group. The authors of all publications were not associated with the sponsors of
the study.
During the first two years data of 5,669 patients were analysed, resulting in two
chapters of the thesis (Chapters 2.1 and 4.2). The second two years another 4,339
patients were included. The total number of 10,008 patients comprised the source
of all other chapters.
OUTLINE OF THE THESIS
In Chapter 2 of the thesis the general response to PPI therapy of the project Pep-
tic Survey is given. The design of the study is described in detail and the results
of the primary objectives regarding safety, effectiveness and patterns of use are
captured in Chapter 2.1. Since PPIs have a high efficacy, we were interested to
identify possible co-factors associated with lack of effectiveness during lansopra-
zole use (such as compliance, diagnosis and acid-relatedness of complaints). For
this reason we compared patients with lack of effectiveness on treatment (‘non-
responders’) versus control patients without lack of effectiveness on treatment
(‘responders’) in Chapter 2.2.
In Chapter 3 drivers of PPI treatment were the key elements of our investigation.
In Chapter 3.1 we investigated the increasing amount of combined prescriptions
of NSAIDs and PPIs. We assessed how frequently PPIs were prescribed in com-
bination with NSAIDs in order to prevent acid related disorders and to treat
NSAID induced acid related disorders. In Chapter 3.2 we investigated whether
the study has led to selection bias regarding inclusion of patients in the study and
whether the design of this study was susceptible to driving prescriptions.
The role of H. pylori and the role of PPIs in the eradication of H. pyl rihave be-
come very important in the last years. In addition to existing results of clinical
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trials, a study was set up to investigate the characteristics and the effect of time of
H. pylori eradication therapy in daily clinical practice of lansoprazole users. This
research is captured in Chapter 4.1.
Therapies combining antibiotics and PPIs, including dual, triple and quadruple
schedules have been shown to be effective in clinical trials to eradicate H. pylori
in peptic ulcer patients, whether this results in improved symptoms in clinical
practice remains unclear. In Chapter 4.2, we investigated continued use of lanso-
prazole treatment after H. pylori eradication therapy and evaluated possibly re-
lated determinants of such continuation in daily clinical practice.
In Chapter 5, the safety of lansoprazole in 10,008 users was assessed. Frequen-
cies and incidence densities were calculated for all adverse events and the pattern
in time was given, as can be read in Chapter 5.1. In addition, two subsets were
used to investigate two frequently reported adverse events during lansoprazole
use, namely headache and diarrhoea. Besides the high prevalence, these adverse
events often lead to a discontinuation of a PPI. These subsets were used to inves-
tigate the frequency and characteristics of the adverse event during lansoprazole
use and to possibly find relevant co-factors associated with the occurrence of the
adverse event by comparing patients with the occurrence of the adverse event to
those without. These results are given in Chapter 5.2 and 5.3.
Chapter 6 gives a summary of the findings and a discussion of the implications of
our results.
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SUMMARY
Background: Right after the introduction of the proton pump inhibitor (PPI) lan-
soprazole (PrezalÒ) a 2-years follow-up study was started to evaluate patterns of
use, safety and effectiveness of this drug in naturally occurring groups of patients
in the Netherlands. Medical data were recorded by participating physicians while
medication listings were provided by pharmacists.
Methods: The study was designed according to the SAMM guidelines. The only
inclusion criterion was the use of lansoprazole prior to entry into the study.
Results: A total of 5,669 lansoprazole users were included by 374 general practi-
tioners (GPs) and 117 specialists. Lansoprazole was mostly prescribed in patients
with reflux oesophagitis (55.1%), ‘gastritis’ (26.8%) and duodenal ulcers
(11.4%), sometimes as part of Helicobacter pylori (H. pylori) eradication therapy
(8.5%). For their complaints most patients (91.1%) had previously used acid-
related drugs. Improvement or disappearance of complaints was achieved in
88.9% and 90.5% of patients after 4 and 8 weeks of treatment, respectively. Diar-
rhoea (4.1%), headache (2.9%) and nausea (2.6%) were the most frequently re-
ported adverse events.
Conclusion: The patterns of use of lansoprazole in daily practice deviated from
the recommendations in the information leaflet. Nevertheless, lansoprazole was
found to be safe in this naturally occurring group of users. Effectiveness ap-
peared to be comparable to results found in clinical trials in the registered indica-
tions for lansoprazole.
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INTRODUCTION
Healing of peptic lesions can be achieved by using a variety of medications. The
most commonly used agents are the H2- rec ptor antagonists and the newer PPIs.
Lansoprazole (PrezalÒ) is a new PPI which produces prolonged decrease of gas-
tric acidity [1, 2]. The drug has been introduced on the Dutch market at the end
of 1993 as a 30 mg capsule indicated for the treatment of reflux oesophagitis and
healing of gastric and duodenal ulcers.
At the time of introduction, lansoprazole had been evaluated in several thousands
of patients enrolled in clinical trials. These trials showed that the drug is highly
effective in healing of duodenal ulcers (94-98% at week 4), gastric ulcers (87-
96% at week 8) and reflux oesophagitis (85-88% at week 4) when administered
at therapeutic dosages [1, 3-5].
Lansoprazole provides effective symptom relief in those patients of 90-100% at
week 4 [1]. Healing rates in those patients are much higher compared to rates in
patients using H2-receptor antagonists [2, 3, 6-8]. In addition, healing rates of
gastric ulcers, duodenal ulcers and reflux oesophagitis with lansoprazole 30 mg
were equivalent or better compared to healing rates of omeprazole, the first PPI
that was available, in a dose of 20 mg [4, 9-11]. Treatment of patients with reflux
oesophagitis with lansoprazole 30 mg was as effective as with omeprazole 40 mg
with respect to healing as well as symptom relief [12]. Furthermore, it has been
shown that the 15-mg and 30-mg lansoprazole doses do effectively prevent recur-
rence of erosive oesophagitis in a 12-month period [13].
At present, the role of the drug is also being investigated in H. pylori eradication
therapy, showing that one-week triple therapy (lansoprazole in combination with
amoxicillin and clarithromycin) and four-day quadruple therapy (lansoprazole in
combination with bismuth, tetracycline and metronidazole) have high cure rates
of respectively over 90% and 98% [1, 14, 15].
Incidences of adverse reactions as estimated from clinical trial data are similar to
those of other PPIs and H2-receptor antagonists [2, 4, 7, 11]. The most common
events include headache (4.7%), diarrhoea (3.2%), abdominal pain (2.2%), phar-
yngitis (1.8%) and skin disorders (1.7%) [ ].
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From clinical trials, it can be stated that lansoprazole is highly effective and well
tolerated by most patients, although data from treatment in ‘daily practice’ are
still scarce. Clinical research only gives partial insight into the effectiveness,
safety and patterns of use of a drug such as demographics, prescription indica-
tions, dosage regimens, co-morbidity, drug exposure and co-medication [16].
Limitations of clinical trials include the relatively small number of patients, pa-
tients having less co-morbidity and/or co-medication, a short duration of the
studies and different circumstances under which the drug is administered. These
limitations have fostered the development of this prospective follow-up study
with lansoprazole. In order to design sound post-marketing follow-up studies it is
essential not to influence the decisions of a physician prescribing drug therapy.
Guidelines for Safety Assessment of Marketed Medicines (SAMM) have been
developed by a joint committee with members with a clinical, regulatory, aca-
demic or pharmaceutical industry background in order to provide basic rules to
ensure good study design. This study was according to these SAMM guidelines.
The aim of this study was to assess the safety and effectiveness of lansoprazole in
a population composed by naturally occurring groups of users and to evaluate the
patterns of use of lansoprazole in daily practice.
MATERIALS AND METHODS
This prospective, open, observational follow-up study was carried out by GPs
and specialists (internists/gastro-enterologists) in naturally occurring users of lan-
soprazole in the Netherlands during the first two years after marketing (1994-
1995).
Design
The study protocol was designed according to the SAMM guidelines [17] in-
cluding a population as representative as possible of the general population, a
non-interventional design and a clear separation in time between the prescribing
of the drug and the inclusion of the patient in the study (illustrated in Figure 1).
The protocol has been approved by the Medical Ethical Committee of the Utrecht
University Medical Centre. The highest standards of professional conduct and
confidentiality were maintained throughout the study. GPs could include a
maximum of 20 patients per two years follow-up time, while specialists were
allowed to incorporate not more than 50 patients. All lansoprazole prescribing
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GPs, internists and gastro-enterologists were asked to participate. In order to
avoid inclusion bias participating physicians and pharmacists were remunerated
with only a modest fee equivalent to the reimbursement of their time spent to
complete the record forms or generate the medication histories. Additional safety
evaluation was conducted analysing patients with adverse events (cases) com-
pared to patients without adverse events (controls) from all lansoprazole users in
this study.
Figure 1
Procedure of inclusion of patients in study
Prescription visit Informed consent and Follow-up visit(s)
Inclusion in study and
First evaluation
time
Patient Selection
All patients having used or using lansoprazole could be included in the study at
the first or any later follow-up visit after lansoprazole was prescribed. Patients
agreed to participate by giving their written informed consent allowing to have
access to all relevant clinical and medication data and storage and analyses of
these data. No further selection criteria were considered. So all lansoprazole us-
ers could be included, independent of e.g. age, indication of use, co-morbidity,
use of co-medication. To maintain patient anonymity, patients were identified by
an identification code only. All data and documents related to patients included,
were kept in strict confidence and in accordance with the official privacy regul-
tions.
Measurements
Data were collected at the visit of inclusion and at each follow-up visit during
lansoprazole therapy with a maximum follow-up of two years by reviewing the
medical file and by patient-questionnaire. The data collection did not in any way
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influence normal procedures. No additional diagnostic tests were requested from
the physician regarding the diagnosis and measurement of effectiveness.
Patient characteristics including age, gender, smoking habits, alcohol intake and
pregnancy were recorded. Information obtained on medical status at the time of
first lansoprazole prescription included indication, endoscopic examination (if
available) and relevant medical history. Characteristics and patterns of use of lan-
soprazole that were recorded included type of prescriber, daily dose of lansopra-
zole, previous therapy for acid-related complaints, concomitant over-the-counter
(OTC) therapy and date of end of therapy. Effectiveness of lansoprazole therapy
was recorded analogous to normal procedures at the physician: changes in the
indication-related complaints by the patient, assessment of change in general
well-being of the patient and the assessment by the physician on whether a pa-
tient was cured from the indication for which lansoprazole was prescribed.
The procedures on which the assessment of effectiveness by the physician was
based (endoscopy, symptoms, x-rays, other) were recorded, however no stan-
dardised symptom scores were collected, adhering to daily practice routines. To
assess safety-aspects of use of lansoprazole all (adverse) events (including onset,
duration, severity, association with lansoprazole, action taken) irrespective of
being linked to lansoprazole therapy were documented during the follow-up pe-
riod. The severity and association of adverse events were reported assessed by
the physician.
Complete medication histories of patients over six months before starting therapy
and during follow-up were retrieved at the local pharmacy. Computerisation of
pharmacy records, and thus the compilation of medication histories, is almost
universal in the Netherlands. The majority of patients (78%) is designated to a
single pharmacy for all reimbursed prescription drugs [18]. Prescribed drugs
were coded according to the Anatomical-Therapeutic-Chemical (ATC) classifi-
cation [19].
To ensure the collection of accurate, consistent, complete and reliable data par-
ticipating physicians were instructed and monitored in completing the forms at
regular intervals. Data verification checks and cross checks were p rformed after
data-entry by trained datamanagers. Inquiries were made about inconsistencies,
incorrect data, and missing data. Missing values remained in 0.1%.
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Analysis
Results were tabulated in absolute values and/or percentages. Baseline compari-
sons were calculated using c2-tests, crude and adjusted odds ratios with a confi-
dence interval of 95%. Adjusted odds ratios were calculated using conditional
logistic regression. Statistical significance was assumed at p-values < 0.05. All
statistical analyses were performed using SAS and EGRET statistical packages.
RESULTS
Patient enrolment started in January 1994 following the introduction of lansopra-
zole in The Netherlands in September 1993. In total 166 specialists and 595 GPs
agreed to participate of which actually respectively 70% (n=117) and 63%
(n=374) included patients in this study. Main reasons for non-participation were
lack of time, lack of interest and few lansoprazole prescriptions. The voluntary
participation rate of pharmacists was 74.4%. Over a period of 24 months, follow-
up data of 5,741 patients were gathered. Of these patients, 72 (1.3%) were not
evaluable for analysis (either no informed consent was obtained or no separation
in time between first prescription and inclusion in study was maintained) thus
making 5,669 eligible patients for the study. An average number of 9 patients
were included per GP and 19 patients per specialist.
Demographics
In Table 1 the general characteristics of the study population are shown. Overall
mean age was 54.2 years (range: 14-96); men had a mean age of 51.2 years
(range: 14-94), while women were significantly older with a mean age of 56.9
years (range: 15-95).
Four patients included in the study used lansoprazole during their pregnancy.
One patient used lansoprazole during the first month of her pregnancy, one dur-
ing the sixth month, one intermittently during the sixth and ninth month and one
during the last three months. All patients gave birth to healthy infants. The ma-
jority of the included patients (71.6%) were non-smokers. Only 10.6% were
heavy smokers (³ 15 cigarettes/cigars per day). Most patients reported no use of
alcohol (56.6%) or less than 5 units of alcohol per day (41.1%). Alcohol use was
reported twice as frequent in men compared to women and was highest in pa-
tients of 30-60 years of age in both sexes.
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Table 1
General characteristics of the study population
N=5,669 %
Men 2,751 48.5
Women 2,918 51.5
Age (years)
     0-30 398 7.0
     30-45 1,309 23.1
     45-60 1,847 32.6
     60-75 1,573 27.7
     > 75 542 9.5
Co-morbidity at the time of lansoprazole prescription
known from physician
     None 3,347 59.0
     Gastrointestinal (excl acid-related disorders) 409 7.2
     Cardiovascular 499 8.8
     Endocrine 251 4.4
     Respiratory 184 3.2
     Musculoskeletal 154 2.7
     Psychiatric 119 2.1
Co-medication at the time of lansoprazole prescription
known from pharmacy * 4,219 100.0
     None 2,169 51.4
     Gastrointestinal (excl lansoprazole) 1,041 24.6
     Cardiovascular 488 11.6
     Endocrine 207 4.9
     Respiratory 225 5.3
     Musculoskeletal 216 5.1
     Psychiatric 721 17.1
* Of 1,450 patients (25.6%) no information from pharmacy was available.
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Co-morbidity was assessed by the physician at the date of inclusion of the pa-
tient. Furthermore, co-medication as found in medication histories collected in
the pharmacy was used as an indication of co-morbidity (Table 1). Gastrointesti-
nal (other than acid-related disease) co-morbidity was highly prevalent in this
population (7.2%). Cardiovascular (8.8%), endocrine (4.4%) and respiratory dis-
ease (3.2%) were also frequently seen. The most frequently reported underlying
diseases included hypertension (5.1%), asthma /COPD (2.4%) and diabetes mel-
litus (2.2%). Co-morbidity reported by the physician was in general consistent
with the medication histories derived from the pharmacists. However, the physi-
cians reported psychiatric co-morbidity in 2.1% of the patients, whereas accord-
ing to the pharmacies 16.7% used psychiatric drugs. This can be explained by the
fact that frequently used drugs for sleeping disorders and anxiety were scored in
the category psychiatric co-medication, while physicians did not report this as co-
morbidity.
Patterns of use
Patients had an average follow up of 120 days, during which they used lansopra-
zole for an average period of 98 days. The most frequently reported indication
(Table 2) for which lansoprazole was prescribed was reflux oesophagitis (re-
ported in 55.1% of all patients), followed by ‘gastritis’ (26.8%) and duodenal
ulcers (11.4%). Furthermore, the combined indication reflux oesophagitis plus
‘gastritis’ was frequently reported (7.5%). In 8.5% of all patients the lansoprazole
prescription was part of a H. pylori eradication therapy. This was most frequently
seen in patients with ‘duodenitis’ (26.5%), duodenal ulcers (25.2%), and gastric
ulcers (19.4%). In comparison with GPs, specialists prescribed lansoprazole sig-
nificantly more often in patients with gastric ulcers, reflux oesophagitis, ‘duode-
nitis’ and as part of H. pylori eradication therapy and less frequent in patients
with ‘dyspepsia’, peptic ulcers and ‘gastritis’. Duodenal ulcers were equally often
diagnosed by GPs and specialists. In 71.0% of the patients lansoprazole was pre-
scribed for indications mentioned in the information leaflet. In the other 29.0%
lansoprazole was prescribed for indications not registered in The Netherlands
such as ‘gastritis’, ‘dyspepsia’ and ‘duodenitis’.
Little over half of the diagnoses (50.3%) were based on an endoscopy. In 85.3%
of the patients evaluated by specialists and in 27.4% of the patients evaluated by
GPs an endoscopy was performed. In patients with peptic ulcers or reflux
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oesophagitis diagnosis was based on an endoscopy in 53.3% of all cases, while in
patients with reported ‘gastritis’, ‘duodenitis’ or ‘dyspepsia’ endoscopy was used
in only 39.2% of the cases.
Table 2
Indication of lansoprazole use at inclusion
Total
%
(N=5,669)
GPs
%
(N=3,425)
Specialists
%
(N=2,244)
Indication†
     Reflux oesophagitis 55.1 51.2 60.9 **
     Duodenal ulcer 11.4 11.6 11.0
     Gastric ulcer 3.8 2.2 6.4 **
     Peptic ulcer 3.2 4.7 0.9 **
     ‘Gastritis’ 26.8 31.4 19.8 **
     ‘Dyspepsia’ 11.2 12.9 8.5 **
     ‘Duodenitis’ 4.7 2.7 7.6 **
     Other 9.3 8.2 10.9 **
Endoscopy performed 50.3 27.4 85.3 **
Part of H. pylori  eradication 8.5 6.0 12.4 **
* p-value < 0.05 comparing specialists with GPs
** p-value < 0.01 comparing specialists with GPs
† Totals may exceed 100% because of multiple answers possible
In 60.4% of the patients lansoprazole was evaluated by a GP, in 32.9% by an i-
ternist, in 6.1% by a gastro-enterologist and in 0.5% of patients by another spe-
cialist. Of all patients 95.3% had a daily regimen of 30 mg prescribed. Patients
with a daily dose of £15 mg (0.3%) had prescriptions of 30 mg lansoprazole
every two or three days, or on demand. In 4.3% of patients a daily dose of ³60
mg was prescribed, of which 41.3% were prescriptions for the eradication of H.
pylori. A majority of the patients (76.4%) still used lansoprazole at the time of
first evaluation. Patients who had discontinued therapy before the first evaluation
took place (23.6%) had used the drug with a mean duration of 24 days and 42.1%
of these patients stopped lansoprazole use within the first two weeks.
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Table 3
Previous acid-related drug use in 5,669 lansoprazole users
Total
%
(N=5,669)
GPs
%
(N=3,425)
Specialists
%
(N=2,244)
None 8.9 10.3 7.0 **
Previous use of lansoprazole 16.0 18.5 14.2 **
Other previous acid related drug use†
     Antacid 8.2 10.3 5.1 **
     H2-receptor antagonist 45.4 45.1 45.9
     Other PPI 11.0 6.8 17.6 **
     Prokinetic 8.4 9.7 6.3 **
     Mucosaprotective 5.5 6.5 4.1 **
     Other 2.4 2.0 2.9 *
* p-value < 0.05 comparing specialists with GPs
** p-value < 0.01 comparing specialists with GPs
† Totals may exceed 100% because of multiple answers possible
The majority of the patients included in the study were first time users of lanso-
prazole (83.2%). Previous treatment with omeprazole was seen in 11.0% of all
patients. In general, the patients included in the study had an extensive history of
acid-related drug use (Table 3). 91.1% of the patients had been treated with acid-
related drug therapy before, mainly H2-receptor antagonists (45.4%). Patients
with duodenal ulcers and ptients with ‘duodenitis’ had in 55.1% a history of H2-
receptor antagonists use. Dyspeptic patients were characterised by a high previ-
ous use of prokinetics (14.7%).
Effectiveness
Effectiveness of lansoprazole was measured using three parameters: the change
in indication-related complaints reported by the patients, the change in general
well being of the patient and the assessment by the physician on whether the in-
dication for lansoprazole therapy had disappeared.
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Figure 2
Effectiveness of lansoprazole use
0 20 40 60 80 100
week 8
Dyspepsia week 4
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Reflux oes. week 4
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Ulcers week 4
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Hp erad week 4
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Total week 4
%
disappeared improved
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Table 4
Adverse events in patients receiving lansoprazole
N=5,669 %
Patients reporting adverse events
     No adverse events 4,541 80.1
     1 adverse event 771 13.6
     2 adverse events 234 4.1
     > 2 adverse events 123 2.2
Total number of reported adverse events 1,666 100
Onset of adverse events (per event)
     Within 1 day 363 21.7
     1-13 days 613 36.8
     ³14 days 587 35.2
     Unknown 103 6.2
Severity of adverse events (per event)
     Mild 774 46.5
     Moderate 646 38.8
     Severe 240 14.4
     Unknown 6 0.4
Association of adverse event with lansoprazole (per event)
     Unlikely 353 21.1
     Possible 822 49.3
     Probable 486 29.2
     Unknown 5 0.3
Action taken (per event)
     None 938 56.3
     Dose reduction/stop of therapy 594 35.7
     Switch of therapy 116 7.0
     Other action 11 0.7
     Unknown 7 0.4
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As can be seen in Figure 2 patients reported their indication-related complaints to
have disappeared or improved at week 4 in 88.9% of patients and at week 8 in
90.5% of patients. There were no significant differences in effectiveness between
the various indications. In patients previously using omeprazole, complaints dis-
appeared or improved in 81.2% of patients at week 4 and in 83.5% of patients in
week 8. No differences were seen in disappearance or improvement of com-
plaints between patients switched directly from omeprazole to lansoprazole and
patients with a period of 1 week to 6 months between previous omeprazole use
and lansoprazole therapy.
General well being of the patients was improved in 79.9% of patients at week 4
compared to before start of lansoprazole therapy and in 82.0% of patients at week
8. No significant differences between the indications were found. Patients were
declared cured by their physicians in 35.9% of the cases at week 4 and in 46.8%
at week 8. Their was a significantly higher number of patients with 'duodenitis'
declared cured at week 4, 40.7% (p<0.01) and at week 8, 53.6% (p<0.01). The
judgement on whether a patient was cured was almost exclusively based upon
symptomatology alone, 94.6%. Only in 5.1% it was based on additional endos-
copy or x-rays.
Safety
Of all lansoprazole users 80.1% reported no adverse events during drug expo-
sure. A minority of 2.2% reported more than two adverse events during use. The
onset of the events was soon after start of the therapy, in 21.7% at day one and in
36.8% at day 2 to 13 (Table 4). Of all adverse events 29.2% was probably related
to the lansoprazole exposure, as reported by the physician. In a majority of the
events (56.3%) no action was taken and in 35.7% the lansoprazole dosage was
reduced or discontinued. According to the physician nearly all adve se events
were of mild (46.5%) or moderate (38.8%) severity, whereas 14.4% included
severe adverse events.
In a further analysis (Table 5) patients with adverse events were compared with
patients without adverse events. Patients with adverse events, compared to pa-
tients without adverse events, were significantly more often female. Alcohol con-
sumption of 1-4 units per day was seen significantly more often in patien s with
adverse events. Previous use of PPIs or mucosaprotectives and concomitant use
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of OTC-therapy was significantly more common in patients with adverse events
compared to patients without adverse events.
Table 5
Co-factors of lansoprazole users with and without adverse events
Adverse events Odds ratio
yes
%
(N=1,123)
no
%
(N=4,546)
crude
(95% CI)
adjusted**
(95% CI)
Men 43.5 49.8 (reference) (reference)
Women 56.5 50.2 1.3 (1.1-1.5) 1.4 (1.2-1.6)
Age (years)
     0-30 5.5 7.0 (reference) (reference)
     30-45 19.0 23.4 1.0 (0.8-1.4) 0.9 (0.7-1.3)
     45-60 32.9 32.4 1.3 (1.0-1.7) 1.1 (0.8-1.4)
     60-75 32.2 27.3 1.5 (1.1-2.0) 1.1 (0.8-1.5)
     > 75 10.3 9.9 1.3 (0.9-1.8) 1.0 (0.7-1.4)
No drinking 52.4 57.7 (reference) (reference)
     < 5 units/day 45.5 40.0 1.3 (1.1-1.4) 1.4 (1.2-1.6)
     ³ 5 units/day 1.9 2.2 0.9 (0.6-1.5) 1.0 (0.6-1.4)
Evaluator GP 53.2 62.2 (reference) (reference)
Evaluator specialist 46.8 37.8 1.5 (1.3-1.7) 1.4 (1.2-1.6)
Indication*
     Reflux oesophagitis 61.4 53.5 1.4 (1.2-1.6) 1.2 (1.0-1.5)
     Duodenal ulcer 9.2 11.9 0.7 (0.6-0.9) 0.7 (0.6-1.0)
     Gastric ulcer 3.3 4.0 0.8 (0.6-1.2) 0.9 (0.7-1.4)
     Peptic ulcer 2.0 3.5 0.5 (0.4-0.9) 0.6 (0.4-0.9)
     ‘Gastritis’ 25.6 27.1 0.9 (0.8-1.1) 1.0 (0.9-1.2)
     ‘Dyspepsia’ 10.4 11.3 0.9 (0.7-1.1) 1.0 (0.8-1.3)
     ‘Duodenitis’ 5.0 4.6 1.1 (0.8-1.5) 1.1 (0.8-1.5)
* Compared to patients with any other indication
** Adjusted with conditional logistic regression, including all listed co-factors
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Table 5
(continued) Co-factors of lansoprazole users with and without adverse events
Adverse events Odds ratio
yes
%
(N=1,123)
no
%
(N=4,546)
crude
(95% CI)
adjusted†
(95% CI)
Previous acid related
drug use*
     Antacid 7.1 8.5 0.8 (0.6-1.1) 0.8 (0.6-1.0)
     H2-rec.antagonist 49.1 44.5 1.2 (1.1-1.4) 1.1 (0.9-1.3)
     PPI 17.8 12.9 1.5 (1.2-1.7) 1.2 (1.0-1.5)
     Prokinetic 8.4 8.4 1.0 (0.8-1.3) 0.9 (0.7-1.2)
     Mucosaprotective 7.1 5.1 1.4 (1.1-1.9) 1.4 (1.0-1.8)
OTC-use 9.5 5.7 1.7 (1.4-2.2) 1.5 (1.2-2.1)
Daily dose 60 mg 4.6 4.7 1.0 (0.7-1.4) 0.9 (0.7-1.3)
Co-morbidity
     Gastrointestinal** 5.2 3.7 1.4 (1.1-1.9) 1.5 (1.1-2.0)
     Cardiovascular 15.2 11.1 1.4 (1.2-1.7) 1.4 (1.1-1.7)
     Endocrine 5.2 4.3 1.2 (0.9-1.6) 1.0 (0.7-1.4)
     Respiratory 3.9 3.4 1.2 (0.8-1.6) 1.1 (0.8-1.6)
     Musculoskeletal 4.2 3.0 1.4 (1.0-1.9) 1.3 (0.9-1.9)
     Psychiatric 1.8 2.5 0.7 (0.4-1.1) 0.7 (0.4-1.2)
* Compared to patients with no or other previous acid related drug use
** Excluding acid-related disorders
† Adjusted with conditional logistic regression, including all listed co-factors
Reflux oesophagitis showed to be significantly more prevalent in patients with
adverse events compared to patients without adverse events. Duodenal and peptic
ulcers on the other hand were significantly less prevalent in patients reporting
adverse events. Specialists evaluated significantly more patients with adverse
events compared to GPs. In addition, in 48.6% of the patients with adverse events
co-morbidity was present compared to 39.0% of patients without adverse events
(adjusted OR (95% CI): 1.5 (1.1-1.9)). Non acid-related gastrointestinal co-
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morbidity and cardiovascular disorders showed a significant association with the
occurrence of adverse events.
Distributions of the most frequently (>1%) observed adverse events reported in
our study population and expected frequencies of the most frequently reported
adverse events from clinical trials are listed in Table 6.
Table 6
Adverse events reported in 5,669 patients receiving lansoprazole compared with
expected frequencies on basis of clinical trial data [1]
Frequently reported adverse events Expected % Observed %
Gastrointestinal
     Diarrhoea 3.2 4.1 **
     Abdominal pain 2.2 1.6 *
     Nausea 1.4 2.6 **
     Constipation 1.1 1.1
Central nervous system
     Headache 4.7 2.9 **
     Dizziness 1.0 2.2 **
Respiratory tract
     Pharyngitis 1.8 0.0
     Rhinitis 1.3 0.0
     Cough 0.4 0.1 *
Other
     Skin disorders 1.7 1.8
     Anxiety 0.2 0.1
     Depression 0.2 0.1
     Myalgia 0.4 0.2 *
* p-value < 0.05
** p-value < 0.01
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Diarrhoea, headache and nausea were the most frequently reported adverse
events. When compared to clinical data (expected frequencies), dizziness, nausea
and diarrhoea showed up significantly more in the study patients. On the other
hand headache, cough, myalgia and abdominal pain were reported less frequently
than expected from clinical trials.
DISCUSSION
The main objective of this study was to assess the safety and effectiveness of lan-
soprazole in a population composed by naturally occuring groups of users and to
evaluate the pattern of use of the drug in daily practice in the Netherlands. Data
were collected of 5,669 lansoprazole users evaluated by 374 GPs and 117 spe-
cialists spread over the Netherlands.
The results indicate that lansoprazole was predominantly prescribed in men of
30-60 years of age and women of 45-75 years of age. This distribution reflects
the distribution of a population with acid-related disorders [20].
At the start of the study lansoprazole 30 mg was registered in The Netherlands
for the treatment of reflux oesophagitis and duodenal and gastric ulcers. In this
study lansoprazole was prescribed in 71.0% of the patients for such indications.
However, results indicate that ‘gastritis’ and ‘dyspepsia’ were also frequently
reported indications for which lansoprazole was prescribed, besides the registered
indications. In 72.6% of the patients included by GPs no endoscopy was ever
performed versus 14.7% of the patients evaluated by specialists. In general spe-
cialists perform more diagnostic tests, such as endoscopy, compared to GPs. This
might explain the different frequencies reported in diagnosing reflux oesophagitis
and ‘gastritis’ between GPs and specialists.
In this study in more than 25% of the patients with duodenal ulcers lansoprazole
was used as part of H. pylori eradication therapy. The number of patients in
which lansoprazole was used as part of H. pyl ri eradication therapy increased in
time during the study and was higher in patients evaluated by specialists than
GPs. In recent literature is described that the prevalence of H. pyloriis up to
100% in patients with duodenal ulcers indicating H. pylori eradication therapy in
all of these patients [21].
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The standard prescribed daily dose in this study was as mentioned in the infor-
mation leaflet 30 mg. In a few patients 60 mg per day was prescribed. In these
patients the prescription was frequently part of a H. pylorieradication therapy.
Furthermore, users of lansoprazole in daily clinical practice showed to be patients
with an extensive history of previous acid-related treatment, mainly H2-receptor
antagonists. These previous users might be switched to lansoprazole due to low
efficacy and/or occurrence of adverse events with previously used acid-related
drugs.
Measured as improvement or disappearance of indication-related complaints,
therapy with lansoprazole proved to be highly effective. Over 90% of the patients
experienced a disappearance or improvement of indication-related complaints at
week 8, independently of the indication. These results are comparable with the
results of clinical trials [1]. Characteristic of a pharmacoepidemiological study is
the natural setting in which data are collected. Therefore, unlike in clinical trials,
no testing of effectiveness beyond normal procedures in daily clinical practice
took place. In clinical trials however, there is a strict patient selection resulting in
a study group which differs greatly from the users of newly registered drugs in a
natural setting [16]. The effectiveness found in this study is high taking into ac-
count the fact that patients were only endoscopically examined in 50.3%, that
indications differed from the indications for which lansoprazole is registered in
29% and that complicated patients were included (e.g. with co-morbidity, co-
medication, previous acid-related drug use). In previous omeprazole users the
effectiveness was lower. It is unclear whether the physician switched therapy
from omeprazole to lansoprazole because of the low effectiveness during omep-
razole use. Further research on switching of therapy may provide interesting in-
formation on patients showing lack of effectiveness, low compliance or adverse
drug reactions as a reason for switching.
In various clinical trials [4, 10] patients using lansoprazole 30 mg reported ad-
verse events in 16.9-29.2% and patients using omeprazole 20 mg in 23.8-32.8%,
whereas in this study 19.9% reported one or more adverse events, making the
results comparable. The overall safety profile in this study was similar to the pro-
file of events of clinical trials with lansoprazole as illustrated in Table 6 and
similar to the profile of an analysis of 68 clinical trials with omeprazole [1, 11].
In general the adverse events during lansoprazole use were mild and self-
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limiting. No serious adverse events related to the drug were observed in the study
group. Compared to clinical trials with lansoprazole diarrhoea, nausea and dizzi-
ness showed up significantly more frequently and abdominal pain and headache
less frequently in this study [1]. All women, who had used lansoprazole during
their pregnancy, gave birth to healthy infants. Compared to clinical trials there
were few respiratory tract, psychiatric and musculoskeletal adverse events. In this
study with complicated patients and a non-interventional design adverse events
might be more or less frequently reported compared to clinical trials. To investi-
gate this more specifically two additional studies are set up regarding the occur-
rence of headache and diarrhoea as adverse event in lansoprazole users.
It became clear that lansoprazole users reporting adverse events have a different
‘profile’ compared to lansoprazole users reporting no adverse events. The profile
of lansoprazole users reporting adverse events can be characterised as females,
moderate alcohol users, with concomitant OTC-use, and the presence of co-
morbidity. With this information, patients can be better instructed and informed
about the occurrence of adverse events while using lansoprazole.
In conclusion the patterns of use of lansoprazole in daily practice differ in a small
part of the patients from the information given in the information leaflet. The
drug is also used in patients for the treatment of ‘gastritis’, ‘dyspepsia’, ‘duode-
nitis’, and the eradication of H. pylori. Furthermore it is also prescribed in 60 mg
dosage regimens, in a few pregnant women and in complicated patients with co-
morbidity and co-medication. Nevertheless, therapy with lansoprazole proved to
be highly effective in nearly all naturally occurring lansoprazole users with a va-
riety of acid-related complaints. In 19.9% of the patients adverse events were
reported. Overall these adverse events were mild and self-limiting. Specific pa-
tient groups were identified with a higher risk to develop adverse events.
Because of the setting in daily clinical practice and the large number of included
patients, it can be stated that this study population of naturally occurring groups
of users differed from the population of patients studied in premarketing clinical
trials. However, the findings on safety and effectiveness were comparable with
results of clinical trials with lansoprazole.
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SUMMARY
Background: Proton pump inhibitors (PPI) demonstrate high healing rates of 85-
98% in clinical trials. Due to the limited knowledge regarding response and non-
response to lansoprazole postmarketing and for the reason that resistance to PPIs
is scarce, we investigated determinants possibly associated with non-response.
Methods: Data were used from a prospective, open label, observational follow-up
study in which 10,008 lansoprazole users were followed over time. The study
was designed according to the SAMM guidelines. A matched nested case-control
design was used to compare non-responding (cases) and responding (controls)
lansoprazole users. Non-response was defined as worsening or non-improvement
of symptoms at the first evaluation after at least 8 weeks of use, response as dis-
appearance or improvement of symptoms within 8 weeks of use. Controls were
matched for the evaluating physician.
Results: A total of 186 non-responders and 372 responders of PPI treatment were
identified as cases and controls. Age of over 60 years, heavy smoking and previ-
ous use of PPIs were significantly more common in non-responding patients
compared with responding patients. There were no differences found between the
reported diagnosis rega ding response.
Conclusion: In daily clinical practice, previous use of PPIs, heavy smoking and
an age > 60 years were significantly associated with non-response to treatment
with lansoprazole. Previous use of PPIs in non-responding patients might suggest
resistance to PPIs. The knowledge that non-response drives non-response may
encourage physicians to follow PPI users with previous PPI use more closely.
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INTRODUCTION
In the Netherlands, PPIs are registered for use in patients with gastric ulcer, duo-
denal ulcer and/or GERD. In clinical trials PPIs demonstrated high healing rates
of 85 to 98% for different indications [1, 2]. PPIs selectively inhibit the gastric
parietal cell membrane enzyme, H+/K+-ATPase ('the proton pump') inducing
reduction of gastric acid secretion. This pharmacological profile accomplishes the
high healing rates and rare resistance [1, 3]. Because prescribing physicians may
apply other selection criteria to patients in daily clinical practice when compared
with physicians participating in clinical trials, effectiveness when used for indi-
cations or in dosages other than initially tested may differ from efficacy found in
clinical trials. In an initial observational study we found that indication-related
complaints disappeared or improved in 90.5% of patients after 8 weeks of lanso-
prazole use [4]. In clinical trials, patients have to meet strict selection criteria,
meaning that for example, only patients with endoscopically proven indications
are included, whereas patients with co-morbidity, co-medication and/or previous
use of acid related drugs are often excluded [5]. Furthermore, compliance in
clinical trials is often not comparable with daily practice. In daily clinical prac-
tice, PPIs will also be used in patients with unlabelled and/or unproved diagnosis,
in atypical dosages and in complex situations for example, patients with previous
therapy, co-morbidity and/or co-medication [6-8]. Besides selection of patients,
the assessment of response in clinical trials will also often differ from the as-
sessment in daily clinical practice. In daily clinical practice the response is nearly
always based on symptoms and less frequently on endoscopies, whereas in clini-
cal trials response is not only symptomatically assessed (as changes in symptoms
such as epigastric pain, heartburn, dysphagia), but endoscopies are often part of
the protocol [9]. Due to the limited knowledge regarding response and non-
response to lansoprazole postmarketing and for the reason that resistance to PPIs
is scarce, we investigated determinants possibly associated with non-response,
such as compliance, diagnosis and response to previous treatment [3].
MATERIALS AND METHODS
Design and selection of subjects
A prospective, open label, observational follow-up study was conducted in the
Netherlands in 10,008 lansoprazole users in daily practice during the first four
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years after marketing (January 1994 until April 1998). The aim of the study was
to evaluate the safety, efficacy and the patterns of daily use of lansoprazole [4].
Informed consent was obtained from all patients. No additional in- or exclusion
criteria were considered. A case-control design was used to investigate non-
response. Response was evaluated by changes in symptoms (disappearance, im-
provement, remaining the same, worsening) as assessed by the physician. Cases
were defined as non-responding lansoprazole users and controls as responding
lansoprazole users. The non-responders (N=195) consisted of patients with at
least 8 weeks of use, and no improvement or worsening of symptoms at the first
evaluation after 8 weeks. The responders (N=9,159) included patients in which
an improvement or disappearance of symptoms was reported within 8 weeks of
use, or at the first evaluation after 8 weeks of use. Patients that discontinued ther-
apy within 8 weeks with no improvement or worsening of symptoms (N=479) or
had a follow-up of less than 8 weeks after first use with no improvement or wors-
ening of symptoms (N=175) were excluded from this analysis.
Controls were matched for the evaluating physician in order to limit observer bias
with a case-control ratio of 1:2 [10]. The preceding patient of the evaluating phy-
sician was defined as matched control. In case a so-defined preceding control
patient was not available, the next available patient of the same physician served
as the control. For a small subset of cases and controls an additional case-control
study was performed and matched by physician in a ratio of 1:1.
Measurements
Data were collected during lansoprazole therapy at visits after prescription of lan-
soprazole by reviewing the medical file and by patient questionnaire. The data
collection was designed not to influence normal procedures. The following de-
tails were recorded for all patients: gender, age, alcohol intake, smoking habits,
prescriber and evaluator, indication, daily dose, co-morbidity, adverse events,
previous use of acid reducing drugs and response to lansoprazole therapy. Three
different primary diagnoses were distinguished: peptic ulcer, gastro-oesophageal
reflux disease and other diagnoses (e.g. ‘gastritis’, ‘duodenitis’). No additional
diagnostic tests were requested from the physician with regard to the primary di-
agnosis. The physician recorded the response analogous to normal procedures as
changes in symptoms (disappeared, improved, remained equal, worsened). In
addition, more specific information was collected of a subset of 33 non-
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responding cases and 33 responding controls matched by physician. The details
as stated by the physician included the primary indication of PPI use, if available
conclusions of performed endoscopies, any history of gastric surgery and previ-
ous treatments and outcomes of acid related complaints the year before initial PPI
therapy. From the patient, present symptoms (using a standardised symptom
checklist) before starting PPI therapy were scored, the response to lansoprazole
therapy was questioned (documented as disappeared, improved, remained equal,
worsened), and discontinuation due to non-response was inquired. Compliance
was assessed through the following questions to the patient: the prescribed lanso-
prazole dose, the frequency of missing capsules (scored as never, sometimes,
regular, often) and maximum number of days of missing capsules (if more than
one day).
Analysis
Results were tabulated in absolute values and percentages. Subsets were analysed
according to a matched case-control design with a 1:1 or 1:2 ratio for cases and
controls. Baseline comparisons were calculated using crude and adjusted odds ratios
with a confidence interval of 95%. Adjusted odds ratios were calculated using con-
ditional logistic regression. Statistical significance was defined at p-value < 0.05.
All statistical analyses were performed using SAS and EGRET statistical packages.
RESULTS
A total of 10,008 patients were evaluated regarding determinants associated with
non-response. We identified 186 non-responders and 372 responders of lansopra-
zole treatment by matching on evaluating physician. A case control analysis was
set up to make comparisons among non-responders and responders.
Of all the 558 patients, 62.9% were evaluated by specialists and 37.1% by gen-
eral practitioners (GPs).
In Table 1, the distribution of determinants among cases and controls is pre-
sented. Mean age of cases was 56.1 years (min. 19.0, max. 90.0) and of controls
54.2 years (min. 16.0, max. 91.0). Gender, alcohol use, daily dose of lansoprazole
and co-morbidity were equally distributed between non-responding and re-
sponding patients.
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Table 1
Characteristics of cases (non-responders) and controls (resp ders)
Cases Controls Crude OR Adjusted OR
N=186 (%) N=372 (%) (95% CI) (95% CI)
Men 86 (46.2) 175 (47.1) (reference) (reference)
Women 100 (53.8) 197 (53.0) 1.0 (0.7-1.5) 1.1 (0.7-1.6)
Age (years)
  0-30 5 (2.7) 26 (7.0) (reference) (reference)
  30-45 45 (24.2) 88 (23.7) 2.4 (0.9-6.7) 2.6 (0.9-7.6)
  45-60 55 (29.6) 113 (30.4) 2.4 (0.9-6.6) 2.5 (0.9-7.1)
  60-75 53 (28.5) 104 (28.0) 2.5 (0.9-6.8) 3.0 (1.0-8.8)
  > 75 28 (15.1) 41 (11.0) 3.2 (1.1-9.2) 4.0 (1.3-12.4)
Alcohol use 67 (36.0) 150 (40.3) 0.8 (0.5-1.2) 0.7 (0.4-1.2)
No smoking 130 (69.9) 284 (76.3) (reference) (reference)
  <15 units/day 36 (19.4) 67 (18.0) 1.2 (0.7-1.9) 1.6 (0.9-2.8)
   ³15 units/day 20 (10.8) 21 (5.6) 2.0 (1.1-3.9) 2.5 (1.2-5.1)
Daily dose
  30 mg 166 (89.2) 337 (90.6) (reference) (reference)
  60 mg 19 (10.3) 35 (9.4) 1.1 (0.6-2.2) 1.0 (0.5-2.1)
Indication
  GERD 96 (51.6) 207 (55.7) 0.9 (0.6-1.4) 0.9 (0.6-1.5)
  Ulcer 27 (14.5) 49 (13.2) 1.4 (0.9-2.3) 1.4 (0.8-2.5)
  Other 55 (29.6) 111 (29.8) 1.0 (0.8-1.9) 1.0 (0.8-1.9)
Co-morbidity
  Gastrointestinal (ex acid) 30 (16.1) 68 (18.3) 0.8 (0.5-1.4) 0.7 (0.4-1.3)
  Cardiovascular 21 (11.3) 47 (12.6) 0.9 (0.5-1.5) 0.8 (0.4-1.4)
  Endocrine 11 (5.9) 26 (7.0) 0.8 (0.4-1.7) 0.8 (0.3-1.7)
  Musculoskeletal 8 (4.3) 19 (5.1) 1.3 (0.6-2.7) 1.2 (0.6-2.7)
  Respiratory 13 (7.0) 20 (5.4) 0.8 (0.4-2.0) 1.0 (0.4-2.6)
  Psychiatric 9 (4.8) 12 (3.2) 1.6 (0.6-4.3) 2.1 (0.7-6.1)
Previous drug use
  H2-receptor antagonist 76 (40.9) 165 (44.4) 0.8 (0.6-1.2) 1.0 (0.6-1.5)
  Any PPI 84 (45.2) 80 (21.5) 3.6 (2.3-5.6) 4.1 (2.6-6.5)
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The distribution of indication for therapy, whether or not confirmed by endos-
copy, was similar for cases and controls. An age > 60 years showed to be signifi-
cantly associated with non-response; for the age category 60-75 years the ad-
justed OR (95% CI) was 3.0 (1.0-8.8), while for the age category > 75 years the
adjusted OR (95% CI) was 4.0 (1.3-12.4). Heavy smoking (³15 units/day) was
significantly more frequent in cases as compared with controls (adjusted OR
(95% CI): 2.5 (1.2-5.1)).
Furthermore, previous use of PPIs was very common in cases (45.2%) compared
to controls (21.5%) (adjusted OR (95% CI): 4.1 (2.6-6.5)). In addition, previous
use of other PPIs was documented in 31.2% of cases and 17.2% of controls.
For a subset of 33 non-responders and 33 matched responders additional infor-
mation was gathered. 48.5% of these 66 patients were evaluated by specialists
and 51.5% by GPs. The distribution of characteristics revealed no significant dif-
ferences between cases and controls, the pattern was comparable with the pattern
shown in Table 1. The distribution of indications for therapy was also quite
similar among this subset of cases and controls. None of the 66 patients had a
history of gastric surgery.
Regarding cases, treatment with PPIs during the preceding year was reported in 9
patients and resulted in a disappearance or improvement of acid related com-
plaints in 4 patients, whereas in 5, acid related complaints remained equal. 6
control patients had used PPIs during the last year, resulting in a disappearance or
improvement of acid related complaints in 5 patients, whereas in one patient the
outcome was not known.
Previous use of H2-receptor antagonists was reported by the physician in 3 cases
and 5 controls. In all cases and 4 controls this resulted in an equalising of acid
related complaints. In one control patient the complaints reduced.
Compliance, as assessed by the patient, did not differ between cases and controls.
No intake for more than one day was reported by 9.1% of cases and 9.1% of
control patients. Moreover, the intake of lansoprazole was not skipped or only
occasionally skipped for a day by 90.9% of cases and 90.9% of control patients.
In one case and two control patients the prescribed lansoprazole doses, as docu-
mented by the physician, differed from the information received from the pati nt.
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DISCUSSION
The aim of this follow-up study was to investigate determinants of non-response
to lansoprazole use in daily practice. In an initial observational study we found
that indication-related complaints disappeared or improved in 90.5% of patients
after 8 weeks of lansoprazole use [4]. In this study in daily clinical practice the
response was recorded analogous to normal procedures, meaning that sympto-
matic or less frequently endoscopic diagnostic methods were practised. There
were no significant differences in response to PPI therapy for the various indica-
tions. In clinical studies healing rates are nearly always assessed by endoscopy
and in patients with e.g. GERD, gastric ulcers and NSAID-induced ulcers 8-week
healing rates of respectively 75-92%, 94.4% and 95% are described [1, 11, 12].
Thus, the effectiveness of lansoprazole when used in daily practice was compara-
bly high.
The likelihood that non-response was related to certain determinants was evalu-
ated by the comparison of responding and non-responding patients in daily clini-
cal practice. The study data were derived from a prospective, open label, obser-
vational follow-up study following 10,008 lansoprazole users. To diminish ob-
server bias and to improve power, non-responding patients were matched with
responding patients from the same physician in a ratio of 1:2.
Determinants such as gender, alcohol use, prescribed lansoprazole dose and co-
morbidity were not associated with non-response. Although expected, no differ-
ence was detected regarding the indication of therapy. Unlabelled indications e.g.
'dyspepsia' or ‘gastritis’ (whether or not confirmed by endoscopy) showed no as-
sociation with non-response. Psychiatric co-morbidity might affect compliance in
a negative way and thus affect the response to lansoprazole [7]. Nevertheless we
did not see such an association. Gastrointestinal co-morbidity was also not sig-
nificantly associated with non-responding patients. If this had been the case, this
might have been an indication of the presence of gastrointestinal disorders or
gastrointestinal surgery affecting the PPI absorption or metabolism. We did find a
significant association between non-response and heavy smoking. It is known
that smoking has a role in the pathogenesis of duodenal ulcer disease and that
relapse rates are higher in smokers [13, 14]. Also an age > 60 years showed to be
significantly associated with non-response. Previous use of any PPI, as registered
by the physician, was strongly associated with non-response (adjusted OR (95%
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CI): 4.1 (2.6-6.5)). Higher previous use of PPIs in non-responding patients might
suggest channelling or resistance to PPIs. The small subset revealed that, 5 out of
9 non-responding patients with previous use of PPIs during the preceding year
also had an unsatisfactorily response on this previous PPI. Resistance in PPI u-
ers is rare, but ulcers can be resistant to PPI treatment due to an inadequate sup-
pression of gastric acidity by reduced gastric emptying [3]. If adequate plasma
levels are not achieved gastric acidity may be insufficiently inhibited; this will be
more common with omeprazole than with lansoprazole due to different coatings
[3].
Another factor that has an effect on the response is the patient compliance, in
routine daily practice the control of compliance is especially low. It has been es-
tablished that psychological factors (co-operation, comprehension of treatment
schedule), the disease (acute or chronic, hospitalised or outpatient) and the treat-
ment (frequency of intake, improvement of symptoms, side effects) influence
practice where compliance is low [7, 15]. No differences were found regarding
the compliance, as assessed by the patient, in the small subset. In case of doubt,
gastrin levels can be assessed to evaluate the complianc .
In conclusion, this study was set up to investigate determinants related with the
infrequent occurrence of therapeutic non-response to lansoprazole treatment in
daily practice. Previous use of PPIs, an age above 60 years and a well known co-
factor smoking were significantly associated with non-response, whereas unla-
belled indications showed no relation with non-response to lansoprazole use in
daily practice. Previous use of PPIs in non-responding patients might suggest
resistance to PPIs [3]. The knowledge that non-response drives non-response may
encourage physicians to follow PPI users with previous PPI use more closely.
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SUMMARY
Background: Use of NSAIDs is widespread. It is well known that NSAIDs may
induce acid related disorders and that proton pump inhibitors (PPIs) are used to
prevent and treat these complaints in NSAIDs users. We assessed the prevalence
of PPI use associated with NSAIDs use in daily clinical practice. Furthermore,
we investigated possible associated determinants and trends in time.
Methods: A prospective observational follow-up study of lansoprazole use in the
Netherlands during the first four years after marketing from January 1994 until
April 1998. The prevalence of the simultaneous start of lansoprazole and NSAID
therapy and the use of lansoprazole following NSAID use were assessed as
markers for preventive and possibly NSAID induced use.
Results: From 1994-1997, 8.4% - 19.4% of all lansoprazole users had a history of
NSAID use, whereas in 1.6% - 2.2% of all lansoprazole users lansoprazole was
started together with NSAID therapy. Concomitant use of corticosteroids and/or
anticoagulants as well as female sex and an age between 45 and 75 were revealed
to be associated factors for NSAID related lansoprazole use.
Conclusion: In 1997 up to one out of every five first prescriptions of lansopra-
zole treatment was related to NSAID use. Awareness of NSAID use is pertinent,
since specific patient groups were identified with an increasing risk to develop
acid related disorders.
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INTRODUCTION
NSAID use is very common for a wide range of conditions including arthritis and
musculoskeletal disorders; elderly people and females are especially prone to be
chronic users [1]. It is well known that NSAIDs may induce acid related disor-
ders through both a topical and a systemic effect with a prevalence of ulceration
between 14 and 31% [2, 3]. In fact, NSAID and analgesic use accounts for two
out of every three drug related hospitalizations [4]. Pharmacotherapy, including
PPIs, H2 antagonists and misoprostol, may be used to prevent and treat these acid
related disorders in NSAID users [5, 6].
The major impact of NSAIDs and the increasing use of drugs to treat acid-related
disorders were the rationale to assess the prevalence of PPI use associated with
NSAID use. Two types of NSAID-associated PPI use may be distinguished: pre-
ventive and NSAID-induced use. We performed a study in a large cohort of users
of lansoprazole, a PPI, and investigated the number of patients with possibly pre-
ventive use, or NSAID-induced use. Furthermore, we analysed possible associ-
ated determinants (e.g. history of peptic ulcer, high age, smoking, male sex, indi-
cation, short term use, concomitant corticosteroid or anticoagulants use) and
trends in time [3, 6-10].
MATERIALS AND METHODS
Design
A prospective observational follow-up study including all lansoprazole users by a
sample of 1,071 physicians in The Netherlands during the first four years after
marketing (January 1994 until April 1998) [11]. No inclusion or exclusion crite-
ria were applied other than the use of lansoprazole.
Measurements
Participating physicians collected data including age, gender, smoking behaviour,
primary indication of lansoprazole prescription, daily lansoprazole dose and past
use of acid related drugs. No specific tests were requested from the physician
with regard to the primary diagnosis. Complete medication histories of patients
over six months before starting therapy and during follow-up were retrieved at
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the local pharmacy and available for 6,868 patients in this study. Computerisa-
tion of pharmacy records, and thus the compilation of medication histories, is
almost universal in the Netherlands [12]. The majority of patients (78%) are
designated to a single pharmacy for all reimbursed prescription drugs. Drugs
used were coded according to the Anatomical-Therapeutic-Chemical (ATC) clas-
sification [13].
Analysis
Preventive use of lansoprazole was defined as a simultaneous prescription of lan-
soprazole and a NSAID in patients with no history of acid related drug use during
the previous six months. Possibly NSAID-induced lansoprazole use was defined
as start of lansoprazole therapy in patients chronically using NSAIDs during the
preceding 6 months. The population attr butable risk (PAR) of NSAID-use was
calculated through the method for case-control studies described by Coughlin
[14]. Results were tabulated in absolute values and percentages. Baseli e com-
parisons were calculated using c2-testsagainst non NSAID users.
RESULTS
As can be seen in Table 1, our data set included 6,868 patients with a lansopra-
zole prescription. Of these, 1,053 (15.3%) were associated with NSAID use. We
found 135 (2.0%) patients with preventive lansoprazole prescriptions and 918
(13.4%) with possibly NSAID-induced lansoprazole prescriptions.
Table 1
NSAID related lansprazole use in 6,868 patients (1994-1997)
1994
N (%)
1995
N (%)
1996
N (%)
1997 *
N (%)
Total
N (%)
Lansoprazole users 2,142 2,223 1,821 682 6,868
Possibly NSAID induced 180 (8.4) 265 (11.9) 341 (18.7) 132 (19.4) 918 (13.4)
NSAID prevention 48 (2.2) 32 (1.4) 44 (2.4) 11 (1.6) 135 (2.0)
Total NSAID related 228 (10.6) 297 (13.3) 384 (21.1) 144 (21.0) 1053 (15.3)
* Including patients included from January until April 1998
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A clear trend in time was visible with an increase of all NSAID related lansopra-
zole prescriptions from 10.6% in 1994 up to 21.0% in 1997. The percentage of
possibly NSAID-induced lanzoprazole prescriptions increased in this period from
8.4% to 19.4%, whereas preventive lansoprazole use remained around 2.0% of
all lansoprazole prescriptions during these four years.
Table 2
Determinants associated with (non-)NSAID use
Non NSAID use Preventive
lansoprazole use
NSAID induced
lansoprazole use
N=5,815 (%) N=135 (%) N=918 (%)
Female 2,957 (50.9) 84 (62.2)* 566 (61.7)**
Age
     0-45 1,653 (28.4) 35 (25.9) 225 (24.5)
     45-60 1,925 (33.1) 44 (32.6) 318 (34.6)*
     60-75 1,615 (27.8) 37 (27.4) 270 (29.4)*
     > 75 622 (10.7) 19 (14.1) 105 (11.4)
Smoking 1,571 (27.0) 30 (22.2) 245 (26.7)
Specialist 2,023 (34.8) 33 (24.4)* 344 (37.5)
Past use
     H2-receptor antagonist 2,556 (44.0) 55 (40.7) 388 (42.3)
     PPI 850 (14.6) 19 (14.1) 102 (11.1)**
Primary diagnosis
     Ulcer 945 (16.3) 24 (17.8) 139 (15.1)
     GERD 3,301 (56.8) 77 (57.0) 504 (54.9)
Daily lansoprazole dose
     £ 30 mg 5,521 (94.9) 131 (97.0) 879 (95.8)
     ³ 60 mg 294 (5.1) 4 (3.0) 39 (4.2)
Concomitant use of medication
     Corticosteroids 114 (2.0) 6 (4.4)* 72 (7.8)**
     Anticoagulants 336 (5.8) 7 (5.2) 97 (10.6)**
* p<0.05
** p<0.01
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We assumed a prevalence of 3% of NSAID use in the general population [1, 3,
15]. This leads to estimation of an odds ratio for use of NSAIDs in patient
starting lansoprazole therapy of 5.0, resulting in a population attributed risk
(PAR) of 10.7%. This means that 10.7% of all lansoprazole prescriptions could
be attributed to previous use of NSAIDs.
Other determinants possibly related to NSAID-associated lansoprazole use were
investigated and results are shown in Table 2. Smoking behaviour, past use of
H2-antagonists, primary diagnosis and daily lansoprazole dose were not signifi-
cantly associated with any of the lansoprazole prescriptions. Female sex showed
to be associated with preventive use of lansoprazole in NSAID users (p<0.05) as
well as with possibly NSAID induced lansoprazole use (p<0.01). Age between
45 and 75 years was related with possibly NSAID-induced lansoprazole use
(p<0.05). Preventive lansoprazole therapy was significantly less frequently pre-
scribed by specialists compared to general practitioners (p< 0.05). Past PPI use
was significantly less frequent in patients with possibly NSAID-induced lanso-
prazole use compared to non NSAID users (p<0.001). Concomitant use of corti-
costeroids showed a strong association with preventive lansoprazole use (p<0.05)
and an even stronger relation with NSAID-induced use (p<0.01). In addition,
anticoagulants as co-medication were significantly more frequently prescribed
for patients with NSAID induced lansoprazole prescriptions (p<0.01).
DISCUSSION
NSAID and PPI use is widespread [1, 16]. This was the rationale to assess the
prevalence and possible associated determinants of lansoprazole use associated
with NSAID use in daily clinical practice. We found that in 1997 one out of five
lansoprazole prescriptions was NSAID related. In British general practices, 17%
of the patients on long term acid suppressing treatment were also using NSAIDs,
with or without prescription [16].
Overall during the total study period, 13.4% of all lansoprazole prescriptions
were possibly induced by NSAID use, whereas in 2.0% lansoprazole was pre-
ventively prescribed. The population attributed risk (PAR) was 10.7%, meaning
that 10.7% of all lansoprazole prescriptions can be attributed to previous use of
NSAIDs.
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NSAIDs related preventive and therapeutic lansoprazole use was associated with
concomitant use of corticosteroids, in accordance with previous investigations [3,
9]. Moreover, concomitant use of anticoagulants, female sex and an age between
45 and 75 were associated with possibly NSAID-induced lansoprazole use,
whereas previous PPI use showed a negative association. Awareness of the in-
creasing risk to develop acid related disorders during NSAID use is pertinent.
The introduction of a new class of NSAIDs, the cyclooxygenase-2 enzyme in-
hibitors, with reduced risks of upper gastrointestinal ulceration or gastrointestinal
adverse events may be an improvement in the treatment for conditions such as
arthritis [17].
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SUMMARY
Background: There have been many concerns about industry bias and lack of
scientific justification related to industry sponsored postmak ting cohort studies.
We analysed whether a sponsored postmarketing study with a proton pump in-
hibitor (PPI) resulted in excess prescriptions in participating physicians and
whether patients in such a study reflect the profiles of lansoprazole recipients in
daily clinical practice.
Methods: We performed a prospective, observational study in which 10,008 lan-
soprazole users were followed over time marketing from January 1994 until
April 1998. Basic characteristics of prescribers and patients of this study were
weighed against observational data of the same period of the PHARMO database
representing a general Dutch population.
Results: Results indicated that we followed 12.8% of all new Dutch lansoprazole
users in our study. The patient characteristics of our population were fairly simi-
lar with those of the reference PPI users, regarding age, gender, prescriber and
prescription patterns. Previous PPI use was less frequently reported in our study
as compared with the reference group. Nevertheless, the pattern in time and the
relation with the type of prescriber were comparable between the postmarketing
study and the reference PPI users.
Conclusion: We followed over one out of every eight new Dutch lansoprazole
users in time. With the exception of previous PPI use, we established that the
prescribers and patients in our study were comparable with the reference patients.
This could indicate a selection of relatively non-complicated patients in the
postmarketing study. Furthermore, we found no indicators that the postmarketing
study drove prescriptions in part ci ting physicians.
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INTRODUCTION
Selection of physicians and patients participating in a postmarketing surveillance
or pharmacoepidemiological study may bias the outcome of such a study [1-5].
In 1992 an important analysis was published on industry sponsored post-
marketing studies [6]. It was concluded that postmarketing surveillance st dies
were not always correctly designed and encountered problems with enrolment,
leading to only a limited contribution to the assessment of drug safety. On the
other hand, there is a continuous necessity to rationale the effectiveness and
safety of medicines when used in daily clinical practice after marketing, since
safety is a significant drug therapy outcome [7, 8]. Drug related problems are
probably one of the most frequently occurring and important health risks [9]. Ac-
cording to Wood et al, active postmarketing should be routinely performed and
mandatory when there is a priori reason to suspect that a drug may have adverse
events [10, 11]. This is illustrated by Bennett et al in their investigation of the
adverse event thrombotic thrombocytopenic purpura associated with clopidogrel,
which was an adverse event previously reported with ticlopidine, a drug with a
similar mechanism of action and chemical structure [12].
How can the outcome of a postmarketing study become biased? Selection of phy-
sicians may influence the patient population, the choice of drugs prescribed, and
the outcome measures of the study [13]. Selection of patients may influence the
generalisation of the study through differences in demographic characteristics,
medical history, co-morbidity and co-medication, disease severity or baseline
risk and compliance compared with a normal patient population. The strength of
pharmacoepidemiological research into newly marketed drugs lies in its observa-
tional nature and thus can add to evidence from (pre-registration) clinical re-
search, which is often conducted with selected and skewed populations [13]. Al-
though observational research is by definition non-interventional, additional ac-
tion is often required from participating physicians and sometimes patients, espe-
cially in the prospective follow-up design that most postmarketing studies use in
which inclusion and follow-up is performed through questionnaires [1]. This
leads to an extra workload for the physicians and a burden to the patients, result-
ing in refusal to participate. Other reasons not to participate in studies are reluc-
tance to prescribe new drugs, disapproval of industry-sponsored studies in gen-
eral or lack of knowledge of pharmacoepidemiological research.
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However, if physicians are remunerated for their involvement in a study, this
may lead to more enthusiasm to contribute or even drive prescriptions [1]. The
right balance between scientific work, involvement of physicians and patients
and promotional activities has to be discovered for every postmarketing study.
Even though the SAMM guidelines provide a valuable format for finding the
right equilibrium, postmarketing practice shows various cases of studies leading
to discussion [14, 15].
We performed a large scale postmarketing study into the effects and usage pat-
terns of lansoprazole, a PPI introduced on the Dutch market at the end of 1993
and at that time registered for the treatment of reflux oesophagitis and healing of
gastric and duodenal ulcers [16]. In this study a total of 10,008 users of lansopra-
zole were followed by general practitioners (GPs) and specialists during the first
four years after introduction on the Dutch market. We analysed whether a spon-
sored postmarketing study resulted in excess prescriptions in participating physi-
cians and whether patients in such a study reflect the profiles of lansoprazole re-
cipients in daily clinical practice.
MATERIALS AND METHODS
Design
The prospective, observational follow-up study was carried out in 10,008 lanso-
prazole users in the Netherlands during the first four years after marketing from
January 1994 until April 1998 [16]. No inclusion or exclusion criteria were ap-
plied other than the use of lansoprazole. The study design was aimed at a popu-
lation as representative as possible of the population of lansoprazole recipients
with a clear separation in time between the prescribing of lansoprazole and the
inclusion of the patient in the study in order to minimise the influence of the
study on prescribing behaviour and evaluation, following SAMM guidelines [6].
The overall design has been described in detail elsewhere [16].
Patients
All patients being prescribed lansoprazole were included in the postmarketing
study at the first visit or any later follow-up visit after lansoprazole was pre-
scribed. Patients agreed to participate by giving their free informed consent al-
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lowing access to all relevant clinical and medication data and storage and analy-
ses of these data. To maintain patient anonymity patients were identified by an
identification code only.
No further selection criteria were used, meaning that every lansoprazole user in-
dependent of diagnosis (labelled or unlabelled, diagnostically tested or not) could
enter the study.
The comparison data were collected from PHARMO, a Dutch database of com-
plete medication histories of a population of 450,000 persons [17]. These data
were routinely gathered from automated pharmacy records and contain informa-
tion on all prescription medication from GPs and specialists for non-
institutionalised patients. These data can be generalised to the Dutch population.
All new patients with at least one new prescription for lansoprazole during the
years 1994-1997 were selected (N=2,087). A new patient was defined as having
at least a period of 6 months before start with no prescription for lansoprazole.
Analysis
Characteristics of patients including age, gender, prescriber and previous anti-
ulcer or Helicobacter pylori (H. pylori) eradication therapy, as well as features of
prescribers during four consecutive years including the incidence density of new
lansoprazole prescriptions were compared for the two samples.
Baseline comparisons were calculated using crude rate ratios with a confidence in-
terval of 95%. Statistical significance was defined at p-value < 0.05. Results were
tabulated in absolute values and percentages. All statistical analyses were per-
formed using the SAS statistical package.
RESULTS
In Figure 1, the number of new patients is given for our postmarketing study
(PMS) compared to The Netherlands (PHARMO data standardised to the Dutch
population). Overall, 12.8% of all Dutch patients with new lansoprazole pre-
scriptions were included in our study. This figure ranged from 13.5%, 11.1%.
18.4% to 9.3% for each consecutive year starting from 1994. In 1996 nearly one
out of every five Dutch lansoprazole users was included in our study.
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In Table 1, patient characteristics of lansoprazole users were compared between
patients included in the postmarketing study and patients captured by the
PHARMO Record Linkage System [17]. We included a smaller number of
women (51.4%) in our study as compared to the reference patients (55.7%); the
difference was not significant (OR (95% CI): 0.8 (0.8-1.0). Our reported age dis-
tributions of men and women were comparable with results of the reference pa-
tients for all age categories.
Every GP and specialist in The Netherlands was invited to participate in the
postmarketing study. In total 266 specialists and 805 GPs participated. We found
that 61.6% of the prescriptions of our study came from GPs, whereas GPs ac-
counted for 68.4% of the new PPI prescriptions of the reference patients (OR
(95% CI): 0.7 (0.7-0.8)).
If we compare figures from before 1996 versus after 1996 we noted that GPs of
the reference patients accounted for successively 68.5% and 68.1% of the pre-
scriptions, whereas GPs of the postmarketing study accounted for consecutively
60.5% and 63.0% of the prescriptions. After 1996, the difference was not statisti-
cally significant with an OR (95% CI) of 0.8 (0.7-1.0).
Figure 1  
Number of new lansoprazole users in the Netherlands 
(N=78,740) and the postmarketing study (N=10,008)
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Table 1
Distribution of characteristics of reference patients and postmarketing study
Reference patients Postmarketing study
N=2,087 % N=10,008 %
Men 924 44.3 4,864 48.6
     0-30 years 88 4.2 375 3.7
     30-45 years 230 11.0 1,285 12.8
     45-60 years 296 14.2 1,648 16.5
     60 - 75 years 235 11.3 1,178 11.8
     > 75 years 75 3.6 378 3.8
Women 1,163 55.7 5,144 51.4
     0-30 years 87 4.2 284 2.8
     30-45 years 229 11.0 911 9.1
     45-60 years 358 17.2 1,631 16.3
     60 - 75 years 342 16.4 1,590 15.9
     > 75 years 147 7.0 728 7.3
GP 1,427 68.4 6,162 61.6
Previous anti-ulcer therapy
     PPI 479 23.0 1,478 14.8
     H2-receptor antagonist 1,159 55.5 4,275 42.8
     Anti H. pylori  258 12.4 738 7.4
     None of these 757 36.3 4,491 44.9
Previous use of PPIs was reported in 14.8% of our patients and in 23.0% of the
reference patients (OR (95% CI): 0.6 (0.5-0.7)).
As depicted in Figure 2, we saw a small increase in time in the number of lanso-
prazole users with previous PPI use. This rise was more marked for the reference
patients. Previous use of H2-receptor antagonists and H. pylori eradication sched-
ules were also more common in the patients captured by the reference patients
(both OR (95% CI): 0.6 (0.5-0.7)). In addition, our patients had more often not
used any of these three drug therapies in the past (OR (95% CI): 1.4 (1.3-1.6)).
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In the PHARMO database, specialists can not be identified on an individual
level. Therefore, we limited the analyses regarding incidence density of new lan-
soprazole prescriptions to GPs (Figure 3).
Figure 2
Previous PPI use in time
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The incidence densities of new patients using lansoprazole remained fairly stable
in time and were comparable for both samples of patients. The incidence densi-
ties were respectively 5.1 and 5.6 per 6 months for the reference group and our
study. Overall during the four years, the GPs that participated in the postmarket-
ing study included patients more frequently compared to new patients included
by the reference group of GPs with an overall rate ratio of 1.09 (95% CI: 1.03 –
1.16). In the first 6 months of the study and during the first half of 1996, inci-
dence density of new patients was considerably higher in the postmarketing sur-
veillance group.
DISCUSSION
In this study we compared the sample of physicians and patients taking part in
our postmarketing study with a sample of the general population in order to as-
sess whether the postmarketing study resulted in more prescriptions by the par-
ticipating physicians and whether selection had taken place. Selection may bias
the outcomes and affect the generalisation of the results of pharmacoepidemi-
ological research and is therefore an important subject of study.
We found that during the time frame of our study we included and followed
12.8% of all new lansoprazole users in the Netherlands: 10,008 users. These
numbers depict that we indeed investigated a large sample of lansoprazole users.
Patients from any age and gender category took part in our study, as in daily
practice. This illustrates once more the additional value of postmarketing studies,
because in clinical trials patients with low and high ages are excluded. In addi-
tion, it indicates that the physicians followed the protocol of the study, which
emphasised that any patient with a new lansoprazole prescription be asked to
participate, if willing to sign informed consent.
Our results demonstrate that characteristics of our population were comparable
with the characteristics of the reference patients, with respect to age and gender.
However, we found significantly lower numbers of lansoprazole users followed
by GPs, compared with the reference patients. This may be caused by the fact
that specialists usually are more motivated for prescribing and adopting newly
marketed medicines compared to GPs and therefore also more willing to partici-
pate in clinical research [18-20]. In addition, we found that the difference be-
tween the postmarketing population and the reference group diminished in time
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and became equal. Adoption of a new drug by physicians is highly variable and
often erratic due to differences in prescribing attitudes, formulary policies, and
marketing practices. Chan et al reported that dispensing of recently introduced
NSAIDs achieved their equilibrium values in almost 2 years [21].
Previous use of PPIs was significantly less common in the postmarketing study
compared to the reference patients, nevertheless the patterns of a slow increase in
time of previous PPI use and the relation with the type of prescriber were identi-
cal for the reference patients and the postmarketing study. This could indicate a
selection of relatively non-complex patients in the postmarketing study and thus
represent that physicians were not eager to switch therapy for reason of the study.
The incidence densities of lansoprazole prescriptions by GPs were fairly similar
in time among the reference patients and the postmarketing study. Although in-
viting physicians to participate may possibly influence prescribing, we only
found a small difference. Expressed as a rate fraction we calculated that overall
9% of the patients included by the GPs in the study group, were caused by par-
ticipation in the study. However, there appears to be a short-term effect of par-
ticipation in these studies on the frequency in which new patients are included.
During the first 6 months we saw that 25% of all patients included were because
of participation in the study and a similar pattern was also seen in 1996, during
which year extra marketing activity by the drug company was seen.
Furthermore, the detected differences may be partly explained by the different
sources of data collection, pharmacy based versus observational follow-up. On
the other hand, it is recognised that controlling for patient and prescriber vari-
ables does not diminish the extent of interpractititioner variability in prescribing
rates, especially regarding new drugs [21, 22].
The reference group consisted of 2.6% of all new Dutch lansoprazole prescri-
tions (2,087/78,740), while our postmarketing study involved 12.4% of all new
Dutch lansoprazole users (10,008/78,740).
In conclusion, we found no indicators for a substantial excess of lansoprazole
prescriptions in physicians participating in the postmarketing study. Previous use
of PPIs was significantly less common in the postmarketing study, which could
indicate a selection of relatively non-complex patients. Furthermore, we found
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that the prescribers and patients in our study were to a large extent comparable
with the patients captured by the reference patients, regarding age, gender, pre-
scriber and prescription patterns. Thus we could not confirm seeding bias in our
postmarketing study. We did see that previous use of PPIs was less frequent in
our study, but the pattern in time and the relation with the type of prescriber were
identical for the reference patients and the postmark ting study.
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SUMMARY
Background: The eradication of Helicobacter pylori (H. pylori) has become an
important strategy in the treatment of GI disorders. In this study H. pylori eradi-
cation strategies during a four-year period in a group of patients treated with lan-
soprazole were explored and the use of pre- and post testing methods and their
association with eradication strategy and success was assessed.
Methods: In a follow-up study 527 patients treated with lansoprazole as part of
H. pylori eradication therapy were evaluated from 1994 up to 1998.
Results: According to Dutch and European recommendations developed in 1996-
1997, 70 to 75% of the patients had an indication justifying H. pylori eradication.
In total, in 83.9% of all patients a diagnostic test(s) was used prior to treatment.
In total 22 different drug schedules were used. The triple combinations lansopra-
zole, clarithromycin and amoxicillin or metronidazole were used most commonly
(in 33.6% and 18.4% of all patients respectively). In 28.3% (149/527) eradication
was assessed and in 86.6% (129/149) of these patients H. pylori eradication was
accomplished. Adverse events were reported in 19.4% of all patients. During the
study there was a shift from prescribed dual to (specific) triple schedules,
whereas quadruple schedules showed a small increase in use up to 20-30%. Spe-
cialists more often made use of specific methods for diagnosing compared with
general practitioners (GPs).
Conclusions: Regarding the indications of use, the physicians practised in about
70-75% according to the guidelines. The recommended triple schedules were
used in two out of three patients, but many other schedules were also prescribed.
Pre-treatment diagnostic tests were very often performed; the frequency and pat-
tern of testing did not change over time. Eradication rates were high and compa-
rable with results from clinical trials. Nevertheless, post-treatment testing was
frequent.
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INTRODUCTION
Up to 50% of the world’s population is infected with the bacterial pathogen Heli-
cobacter pylori, the majority without symptoms. The infection is usually ac-
quired during childhood or early adulthood. The pathogen was first cultured in
1982 and since then has become an important target in the treatment of peptic
ulcer disease [1]. H. pylori is the main cause of gastritis and peptic ulcers (in-
ducing 95% of the duodenal ulcers and 80% of the gastric ulcers) and is even a
risk factor for gastric cancer, as three out of four gastric cancers may be attribut-
able to the infection [2]. Recent evidence suggested that H. pylori is also associ-
ated with coronary heart disease, but this association is still under investigation
[3, 4]. Considering the complications of H. pylori infection (15% of those in-
fected will become seriously ill), eradication of H. pyl ri s the main strategy in
treatment of gastritis and peptic ulcers [2]. Lansoprazole is a PPI introduced in
the early 90s and indicated for the treatment of reflux oesophagitis and healing of
gastric and duodenal ulcers. Furthermore, lansoprazole is used in combination
with antibiotics, bismuth subcitrate and/or metronidazole in the treatment of H.
pylori infections [5]. In many comparative and non-comparative clinical trials
PPIs have been examined in H. pylori eradication regimens [6]. Dual therapy was
found to effectively eradicate H. pylori infection in 48-55% of cases; triple drug
schedules showed eradication rates of 68-82% and quadruple schedules eradi-
cated H. pylori n > 90-95% of infected patients [5, 6]. It has been shown that
eradication reduces recurrence or relapse of ulcers [5, 7, 8]. A daily dose of 60
mg of lansoprazole as part of an eradication scheme has shown better results than
a daily dose of 30 mg [5].
Besides effectiveness, safety and cost estimations have to be taken into account
in the treatment of H. pylori infections. Adverse events, although mostly mild,
are common during eradication therapies (18% during dual therapy and 33%
during triple therapy) [6, 9-11]. In patients with chronic duodenal ulcer, H. pylori
eradication reduces the use of long-term acid-suppression and/or ulcer-related
health care resources, while the eradication of H. pylori n non-ulcer dyspeptic
patients is controversial [12-16].
Another important issue is the discussion whether the indication to eradicate
should be based on an assessment of symptoms or on a pre-treatment test [17].
Subsequently, the question arises whether or not success of eradication should be
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verified by a post-treatment test. There are a number of methods used to confirm
H. pylori nfection and to assess eradication rates. The urease testing, histology
and culture require an endoscopy. Non-invasive methods to diagnose H. pylori
include urea breath testing and serology [18]. Recently, several European coun-
tries have adopted guidelines on the treatment of H. pylori. The development of
these guidelines was prompted by the immense choice of drug schedules to
eradicate H. pylori and the increasing number of available methods to test H.
pylori infection. However, little data is available on the actual practice by physi-
cians in H. pylori eradication [19, 20].
The goal of our study was to explore H. pylori eradication strategies during a
four-year period in a group of patients treated with lansoprazole. Furthermore,
we investigated the use of pre- and post testing methods and their association
with eradication strategy and success.
MATERIALS AND METHODS
Design and patient selection
A large prospective observational follow-up study investigating safety, efficacy
and patterns of use in 10,008 lansoprazole users was set up in daily clinical prac-
tice of GPs and specialists. The study protocol was designed according to the
SAMM guidelines (guidelines for company-sponsored Safety Assessment of
Marketed Medicines) on design of postmarketing safety studies and approved by
the Medical Ethics Committee of the Utrecht University Medical Centre [21].
The study data were collected in the Netherlands between January 1994 and
April 1998, these being the first four years after introduction of the drug on the
Dutch market [21]. All patients gave their free informed consent in writing. No
additional in- or exclusion criteria were considered. Of all 10,008 studied lanso-
prazole users, 527 were treated with dual, triple or quadruple H. pylo i eradica-
tion therapies as confirmed by their physician and further investigated in this
study.
Measurements
Baseline patient characteristics including age, gender, smoking habits, alcohol
intake and co-morbidity were measured at the start of lansoprazole treatment.
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Moreover, information was obtained on the primary indication for use of lanso-
prazole prescription and whether or not PPI therapy was part of H. pylori eradi-
cation therapy. Three different primary diagnoses were distinguished: peptic ul-
cer, gastro-oesophageal reflux disease and other diagnoses (e.g. ‘gastritis’, ‘duo-
denitis’). No additional diagnostic tests were requested from the physician with
regard to the primary diagnosis. The methods used to assess H. pylori diagnosis
and eradication were recorded, including endoscopy (urease test, culture or his-
tology), urea breath test and serology. Individual H. pylori eradication schedules
were classified as dual (lansoprazole and antibiotic), triple (lansoprazole in com-
bination with antibiotic(s), bismuth subcitrate and/or metronidazole) or quadruple
(lansoprazole in combination with antibiotic(s), bismuth subcitrate and/or metro-
nidazole) based on the number of different drugs included. Besides the prescribed
drug schedules, the daily dose, duration and starting dates were collected. Com-
pliance of drug intake was assessed by the physician as good (intake of over
80%), moderate (intake between 50 and 80%) and poor (intake of less then 50%)
as well as completion of the course of treatment. Furthermore, the physician
documented whether eradication was tested and achieved. No specific test to as-
sess eradication was requested from the physicians. The physician recorded any
past use of PPIs or H2-receptor antagonists. This information was also collected
from automated pharmacy records.
Analysis
Results were tabulated in absolute values and percentages. Baseline comparisons
were calculated using crude odds ratios with a confidence interval of 95%. Statisti-
cal significance was determined through c2 tests and defined at p<0.05. All statisti-
cal analyses were performed using SAS and EGRET statistical packages.
RESULTS
Over a period of four years data were obtained from 527 lansoprazole users
treated with H. pylori eradication therapies. Baseline characteristics of the pa-
tients are depicted in Table 1. The majority of the 527 patients were male
(59.4%). The age distribution was as follows: 32.0% < 45 years, 35.3% between
45 and 60 years and the remaining 32.7% > 60 years old. Smoking was reported
in 36.2% of the patients and alcohol use in 44.8% of the patients. The prescribed
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daily dose of lansoprazole was most frequently 30 mg (75.1%) or 60 mg (22.6%),
while in a minority of 2.3% of the patients 15 mg was prescribed.
Table 1
General characteristics of patients with H. pylori eradication therapy
N=527 %
Women 214 40.6
Age (years)
     0-30 169 32.1
     45-60 186 35.3
     > 60 172 32.6
 No smoking 336 63.8
     Smoking < 15 units/day 133 25.2
     Smoking ³ 15 units/day 58 11.0
 No Alcohol consumption 291 55.2
     Alcohol consumption  < 5 units/day 225 42.7
     Alcohol consumption  ³ 5 units/day 11 2.1
Daily dose of lansoprazole
     15 mg 12 2.3
     30 mg 396 75.1
     60 mg 119 22.6
Specialist 360 68.3
Previous use of acid reducing drugs
     Proton pump inhibitor 78 14.8
     H2-receptor antagonist 277 52.6
     None of both 207 39.3
Primary Diagnosis
     Ulcer (without GERD) 209 39.7
     GERD (without ulcer) 74 14.0
     Ulcer and GERD 22 4.2
     Other 222 42.1
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Table 1
(continued) General characteristics of patients with H. pylor   eradication therapy
N=527 %
Method of H. pylori  diagnosis
     Any specific method 442 83.9
        Endoscopic: urease test 212 40.2
        Endoscopic: culture 69 13.1
        Endoscopis: histology 200 38.0
        urea breath test 3 0.6
        Serology 42 8.0
     Other not specific method 84 15.9
     Unknown 1 0.2
Co-morbidity present at inclusion
     None 398 75.5
     Other gastrointestinal 38 7.2
     Cardiovascular 46 8.7
     Endocrine 29 5.5
     Respiratory 13 2.5
     Musculoskeletal 12 2.3
     Psychiatric 9 1.7
In total 60 specialists evaluated 68.3% of the patients, 91 GPs evaluated the re-
maining patients. Of all patients 52.6% had used H2-receptor antagonists and
14.8% PPIs in the past, whereas 39.3% had used neither of these acid reducing
drugs. Co-morbidity at the start of the lansoprazole therapy was only present in
24.6% of the patients and mainly included cardiovascular (8.7%), other gastro-
intestinal (7.2%) or endocrine diseases (5.5%).
The primary diagnosis of patients treated with an eradication therapy was most
frequently peptic ulcer without gastro-oesophageal reflux disease (39.7%), in
14.0% oesophageal reflux disease without peptic ulcer and in 4.2% peptic ulcer
with gastro-oesophageal reflux disease. In 42.1% the primary diagnosis was any
other diagnosis such as ‘gastritis’ or ‘dyspepsia’.
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In total 83.9% of all patients were tested for H pylori pre-treatment by histology,
culture, urease test, serology and/or breath test, while in the remaining 15.9% of
the patients a non specific method was claimed to have been used to confirm the
diagnosis including medical history or presented symptoms. Specialists (92.2%)
more often performed specific tests compared to GPs (65.9%). Peptic ulcer pa-
tients were less frequently tested with a specific method (75.3%) compared to
patients with other primary diagnosis (90.5%). In general, the most frequently
performed specific methods were urease test (40.2%), histology (38.0%) and
culture (13.1%). Serology and breath tests were conducted in 8.0% and 0.6% re-
spectively.
According to the Dutch recommendations, 70.0% of our patients had an indica-
tion justifying H. pylori eradication (i.e. gastric ulcer or ‘gastritis’ both endo-
scopically confirmed and specifically tested for H. pylori, or endoscopically con-
firmed duodenal ulcer) [19]. Following the definitions of the European consen-
sus, 74.6% of our patients had a proper indication for H. pylori eradication;
namely peptic ulcer, ‘gastritis’ or ‘dyspepsia’ all specifically tested for H. pylori
[20].
As can be seen in Table 2, in total 22 different combinations of drugs were pre-
scribed for the eradication of H. pylori, namely 4 dual, 11 triple and 7 quadruple
schedules. Triple therapy was most commonly prescribed (64.7%), followed by
quadruple therapy (23.3%) and least commonly dual therapy (12.0%). If type and
dose of antimicrobials and duration of therapy are taken into account over 67
regimens were used. With respect to quadruple schedules, 99.2% of these pa-
tients were treated for 4 days or more, while in one patient the duration of use
was unknown. Regarding triple schedules, the duration of therapy was 7 days or
more in 96.8%, less then 7 days in 0.3% and in the remaining patients (2.9%) the
duration was unknown. Duration of use for dual schedules was 14 days or more
in 54.0% and less then 14 days in 46.0%.
Of the four dual schedules, the most frequently used was lansoprazole in combi-
nation with amoxicillin seen in 8.5% of the patients (45/527). Amoxicillin in a
daily dose of 2000 mg was used in a majority of these patients (34/45), whereas
the minimum and maximum prescribed daily doses were respectively 1000 and
3000 mg. Other dual therapies were prescribed infrequently and were combina-
tions of lansoprazole with clarithromycin, tetracyclin or roxythromycin.
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Table 2
Drug regimens for the eradication of H. pylori
N=527 %
Dual therapy of lansoprazole with: 63 12.0
     Amoxicillin 45 8.5
     Clarithomycin 14 2.7
     Tetracyclin 2 0.4
     Roxythromycin 2 0.4
Triple therapy of lansoprazole  with: 341 64.7
     Clarithomycin + amoxicillin 177 33.6
     Clarithomycin + metronidazole 97 18.4
     Tetracylcin + metronidazole 21 4.0
     Amoxicillin + metronidazole 21 4.0
     Clarithomycin + tinidazol 12 2.3
     Amoxicillin + roxithromycin 5 0.9
     Amoxicillin + bismuth subcitrate 3 0.6
     Metronidazole + bismuth subcitrate 2 0.4
     Clarithomycin + tetracyclin 1 0.2
     Clarithomycin + bismuth subcitrate 1 0.2
     Augmentin + metronidazole 1 0.2
Quadruple therapy of lansoprazole  with: 123 23.3
     Tetracyclin + bismuth subcitrate + metronidazole 100 19.0
     Clarithomycin + bismuth subcitrate + tinidazole 9 1.7
     Amoxicillin + bismuth subcitrate + metronidazole 7 1.3
     Clarithomycin + bismuth subcitrate + metronidazole 3 0.6
     Amoxicillin + clarithomycin + bismuth subcitrate 2 0.4
     Amoxicillin + clarithomycin + metronidazole 1 0.2
     Clarithomycin + bismuth subcitrate + augm ntin 1 0.2
Regarding the 11 different triple therapies, the combination clarithromycin and
amoxicillin was used in 33.6% of all patients (177/527), mainly in daily doses of
1000 mg clarithromycin with 2000 mg amoxicillin (141/177). Another frequently
prescribed triple therapy was the combination lansoprazole, clarithromycin with
metronidazole seen in 18.4% of the patients (97/527). This combination was used
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in 5 different dosage forms, of which metronidazole 1000 mg and clarithromycin
1000 mg was prescribed in 58 of the 97 patients and metronidazole 1000 mg and
clarithromycin 500 mg in 29 of the 97 patients. Other triple therapy schedules
with lansoprazole included metronidazole and tetracyclin (21/527 all daily doses
of 1000 mg), metronidazole and amoxicillin (21/527 in 11 different doses) and
other regimens (25/527). Of the 7 quadruple schedules with lansoprazole the
combination with tetracyclin, metronidazole and bismuth subcitrate was the most
frequently prescribed in 19.0% (100/527). A daily dosage of 2000 mg tetracyclin,
1500 mg metronidazole and 480 mg bismuth subcitrate was the most popular
combination (66/100).
Adverse events were reported in 19.4% of all patients. Most patients experienced
one (10.6%) or two (5.5%) adverse events. The most frequently reported adverse
events were mild in nature and included diarrhoea (4.9%), symptoms/complaints
of mouth/tongue/lip (4.4%), nausea (4.0%), headache (2.7%) and dizziness
(2.3%).
Figure 1  
Prescribed Helicobacter pylori schedules (n=506) for subsequent quarters: 
total number and percentages for dual, triple and quadruple schedules 
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In Figure 1 the starting dates of the prescribed schedules are depicted per subse-
quent quarter in time for a total of four years starting quarter one of 1994. In
1994 eradication therapy was infrequent.
It can be seen that dual schedules were the most frequently used schedules in the
first two years and thereafter the most infrequently prescribed regimens. The use
of triple schedules increased from just above 20% to over 80% of all treatments
and was the most prevalent prescribed treatment. Quadruple schedules were pre-
scribed in less then 20% of the regimens prescribed in 1994, this increased to
30% in later years. These patterns were similar for patients evaluated by GPs and
specialists, although increases and decreases appear to have occurred pproxi-
mately six months earlier in specialists compared to GPs.
Looking in more detail at the prescribed triple schedules (Figure 2) we saw the
first use of triple schedules slowly starting at the end of 1994. During 1994 and
Figure 2
Pattern in time of most frequenltly prescribed triple schedules (n=308 
of 332) per quarter
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1995 the combinations of lansoprazole with either amoxicillin and metronidazole
or tetracyclin with metronidazole were the most commonly prescribed schedules.
Hereafter these schedules were rarely used. In mid 1995 the first use of a combi-
nation of lansoprazole, clarithromycin and amoxicillin was reported, this became
increasingly used in the following years due to the expense of the combination of
lansoprazole, clarithromycin with metronidazole. The results of spring 1997
(quarter 14) were not consistent with the surrounding quarters, but might be ex-
plained by the fact that 10 of the 11 lansoprazole, clarithromycin and metronida-
zole combinations where prescribed by no more than two physicians.
We found no clear time trend for the different methods used to diagnose H. py-
lori. As can be seen in Figure 3, specialists used specific methods, such as histol-
ogy, culture, urease test, serology and/or breath test in 80% to 100% of their pa-
tients and GPs in 60% to 80%. Urease test and histology were the most popular
Figure 3
Use of specific and aspecific tests to diagnose Helicobacter pylori by GPs 
(n=161) versus medical specialists (n=345) for subsequent quarters
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used specific methods especially by specialists, followed by culture where a
small difference was seen between specialists and GPs. In general, breath test and
serology were very infrequently used as a method to diagnose H. pylori. No
trends in time were seen for the breath test, culture, histology or urease test,
while GPs more frequently reported serological tests in the last year of the study
in 1997.
Post-treatment testing may be a sign for continued complaints. In the group of
442 (83.9%) patients with a pre-treatment specific diagnostic test, we looked at
determinants associated with post-treatment testing. Post-treatment testing oc-
curred in 154 of the 442 patients. We found that previous PPI use (20.1% versus
11.1%; OR (95% CI): 2.0 (1.1-3.6)), a 60 mg daily dose of lansoprazole (29.2%
versus 16.7% OR (95% CI): 2.1 (1.3-3.4)) and use of a quadruple schedule
(30.5% versus 20.5% OR (95% CI): 1.7 (1.1-2.7)) were determinants associated
with post-treatment testing.
149 patients (28.3%) had both a pre-treatment test on H. pylori infection and a
post-treatment test on the success of eradication. In these patients endoscopy was
the most commonly used method to assess eradication (87.2%) compared to se-
rology alone and/or breath testing (12.8%). The patients were treated with dual
schedules in 8.7% of cases, triple schedules in 60.4% of cases and quadruple
schedules in 30.9% of cases. Eradication was achieved in 86.6% (129/149).
Eradication rates for dual, triple and quadruple schedules were 69.2% (9/13),
84.4% (76/90) and 95.7% (44/46) respectiv ly.
DISCUSSION
The primary objective of this study was to investigate H. pylori radication
strategies in naturally occurring lansoprazole users. Over a period of four years
we obtained data from 527 lansoprazole users treated with some kind of H. pylori
eradication therapy. In our study, H. p lori eradication was far more frequently
attempted by specialists (68.3%) compared to GPs (31.6%). This seems to be
consistent with normal clinical practice during the study period (1994 –1998). In
the US in 1994, nearly all (99%) gastro-enterologists prescribed H. pylo  erai-
cation therapy, compared to only two thirds of the GPs [22]. The Danish surveil-
lance found a surprisingly extensive use in general practice, where GPs pre-
scribed 62% of all eradication therapies and specialists 27%. According to the
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authors, this pattern might be an indication that H. pylori eradication is not prop-
erly targeted [23].
In a majority of our patients (70%) the indication for H pylori eradication re-
flected the recently introduced Dutch guidelines [19, 20]. This finding is par-
ticularly interesting since the terms ‘gastritis’ and ‘dyspepsia’ were not further
specified as. ‘haemorraghic gastritis’ and ‘functional dyspepsia’ for example in
our study and that our data were predominantly collected before the introduction
of the guidelines. Other studies also indicate that the majority of general practices
act in accordance with current recommendations [24].
As many as 83.9% (442/527) of patients were specifically tested for H. pylori
pre-treatment. In peptic ulcer patients this percentage was lower (75.4%) com-
pared to patients with other primary diagnoses (90.5%), reflecting the Dutch rec-
ommendations. Cost estimates and reimbursement issues need to be taken into
account. This implies that GPs especially will have problems with whom to test
for H. pylori and whom to treat [25]. Dutch guidelines recommend performing
culture, histology or urease testing to diagnose H. pyl ri, however all of these
methods necessitate endoscopy. In our study H. pylori was diagnosed in 75.9%
of the patients by such a method. This is high compared to results of a study in
general practice in Scotland where H. pylori diagnosing was performed in only
one third of patients [26]. No clear changes in the different tests used from 1994
up to 1998 were seen. In a substantial amount of the patients (15.9%) in our
study no tests were used. In these cases the diagnosis of H. pyl r  infection was
based on symptoms and medical history.
In the group of patients with a pre-treatment specific diagnostic test (442/527),
we looked at determinants associated with specific post treatment testing
(154/442). We found that previous PPI use, a 60 mg daily lansoprazole dose and
use of a quadruple schedule were determinants associated with post-treatment
testing. These characteristics might reflect a group of patients previously not re-
sponding satisfactorily to PPIs and as a result justify post-treatment testing. Post-
treatment testing was frequent (34.8%) in our study compared to 15% of the pa-
tients that were tested in the Scottish GP study [26]. Due to the fact that eradica-
tion rates are generally high, the necessity for confirmation is of minor impor-
tance, although routine verification of eradication seems less expensive than
waiting for the disappearance of symptoms [17].
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In our study, as many as 22 different regimens were reported, most of which
were triple schemes (64.7%), followed by quadruple schedules (23.3%) and dual
therapies (12.0%). Dual schedules were mainly used in 1994, prescription of tri-
ple regimens increased during the total study period from 20% to 80%, while
quadruple schedules showed a slow increase in use from 20% to 20-30%. For
specialists this pattern occurred about six months earlier compared to GPs. This
pattern of a slower adoption by GPs compared to specialists has been described
before and maybe related to less available information about new therapies and
more conservative practice styles in general practice [22]. The Danish National
Surveillance of H. pylori eradication therapy revealed less than 1% prescribed
quadruple regimens from January 1994 to June 1996, which may be associated
with the fairly late introduction of H. pylori eradication therapy [23].
The Maastricht Consensus Report recommends simple, well-tolerated therapies
with eradication rates of over 80%. This group prefers a triple therapy for seven
days, using a PPI and two of the following: clarithromycin, a nitro-imidazole
(metronidazole or tinidazole) and amoxicillin [20]. The Dutch guidelines do not
recommend a specific drug regimen; the choice of drug regimen depends on the
local guidelines applicable [19]. Therefore, our findings illustrate that triple
therapies being the most popular prescribed schedule, were in accordance with
the European and Dutch recommendations in 52.0% and 64.7% of cases respec-
tively. The duration of therapy for quadruple and triple regimens were in accor-
dance with the recommendations, while for dual schedules a shorter duration of
therapy was reported in 46.0% of cases. If different dosage schedules were taken
into account, our 527 patients used a total of 67 different schedules. In 1995 the
management of H. pylori nfection was studied in 154 patients in 5 GP-practices
in the United Kingdom. It emerged that 56 different schedules were used, the
most frequently used schedule was a combination of omeprazole and amoxicillin
[6]. Other studies indicate that there is still confusion about the indications for
treatment and the treatment regimens that are likely to be effective in routine
clinical practice [27].
When only patients with confirmed diagnoses and assessments of eradication
with specific tests were taken into account, as is done in clinical trials, the overall
eradication rate in our observational study was 86.6%, 69.2% in dual therapies,
84.4% in triple and 95.7% in quadruple schedules. These results are consistent
with the findings of clinical trials [5, 6].
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In conclusion, we explored 527 H. pylori eradication therapies in naturally occur-
ring lansoprazole users. Regarding the indications for use, the physicians prac-
tised in about 70-75% according to the guidelines. Triple schedules, as recom-
mended, were used in two out of three patients. During the study a change from
prescribed dual to (specific) triple schedules was observed. These patterns were
similar for patients evaluated by GPs and specialists. Pre-treatment diagnostic
tests were often performed; the frequency and pattern of testing did not change
over time. In general, eradication rates were high and comparable with results
from clinical trials. However, post-treatment testing was frequent.
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SUMMARY
Background: Therapies combining antibiotics and proton pump inhibitors (PPIs)
have shown to be effective in clinical trials to eradicate H licob cter pylori (H.
pylori) in peptic ulcer patients. Because this evidence is mainly based on results
of clinical trials in peptic ulcer patients, we assessed the incidence of continued
use of a PPI after H. pylori eradication and evaluated determinants associated
with continued use after H. pylori eradication therapies in daily clinical practice.
Methods: As part of a prospective observational follow-up study of 5,669 lans-
prazole users, 258 patients treated with lansoprazole as part of H. pylori e adica-
tion therapy in daily clinical practice, were followed and evaluated. A case-
control design was used to compare patients with continued use of lansoprazole
versus patients with no continued use of lansoprazole after H. pylori eradication
therapy. Continued use was defined as a new lansoprazole prescription more than
14 days after start of the H. pylori eradication therapy.
Results: Triple therapy was most commonly prescribed (57.4%), followed by
quadruple (21.7%) and dual (20.9%) therapy. We found that 41.1% (106/258) of
patients continued PPI treatment after H. pylo i eradication therapy. Even one out
of three peptic ulcer patients without GERD and treated with triple or quadruple
therapies had continued PPI use.
Conclusion: Continued use may partly be expected by GERD in the diagnosis or
use of sub-effective eradication therapies, but even one out of three peptic ulcer
patients without GERD and treated with triple or quadruple therapies had contin-
ued PPI use. Additional research is necessary to investigate the impact of com-
pliance and possibly other determinants on continued PPI use.
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INTRODUCTION
Therapies combining antibiotics and PPIs have shown to be effective in clinical
trials to eradicate H. pylori n peptic ulcer patients. Triple and quadruple thera-
pies provide the highest eradication rates of > 90%, while for dual therapies
overall eradication rates with a maximum of 60-80% are commonly accepted [1-
5]. Because this evidence is mainly based on results of clinical trials in peptic
ulcer patients, we assessed the incidence of continued use of a PPI after H. pylori
eradication and evaluated determinants associated with continued use after H.
pylori eradication therapies in daily clinical practice. In such a setting there will
be among others a variety of prescribed treatment therapies influencing outcomes
considerably [6].
MATERIALS AND METHODS
As part of a prospective observational follow-up study of 5,669 lansoprazole us-
ers, 258 patients treated with lansoprazole as part of H. pylo i eradication therapy
in daily clinical practice, were followed and evaluated [7]. Physicians collected
data including, age, gender, primary indication of lansoprazole prescription, past
use of acid related drugs, eradication regimen and eradication success or failure.
No specific tests were requested from the physician with regard to the primary
diagnosis and the method used to assess eradication. A case-control design was
used to compare patients with continued use of lansoprazole versus patients with
no continued use of lansoprazole after H. pylori eradication therapy. Continued
use was defined as a new lansoprazole prescription more than 14 days after start
of the H. pylori eradication therapy. Baseline comparisons were calculated yield-
ing odds ratios with a confidence interval of 95%. Odds ratios were adjusted for all
other given determinants using conditional logistic regres ion.
RESULTS AND DISCUSSION
Triple therapy was most commonly prescribed (57.4%), followed by quadruple
(21.7%) and dual (20.9%) therapy. These results were in accordance with litera-
ture stating triple therapy as standard therapy [2]. In total, 20 different combina-
tions of drugs were used, increasing to over 50 individual therapy regimes when
dosages were taken into account. In the majority of patients the duration of eradi-
cation therapy was 5 to 7 days or, less frequently, 8 to 14 days.
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Figure 1
Continued use of PPIs after H. pylori eradication therapy by primary diagnosis
and eradication schedule in 258 patients
Total population
(n=258)
Continued use in 41.1%
GERD +
 (n=40)
Continued use in 55.0%
GERD -
 (n=218)
Continued use in 38.5%
Peptic ulcer +
(n=13)
Continued use in
46.2%
Peptic ulcer -
 (n=27)
Continued use in
59.3%
Peptic ulcer +
(n=104)
Continued use in
31.7%
Peptic ulcer -
(n=114)
Continued use in
44.7%
Dual
(N=5)
Triple/
quadr.
(N=8)
Dual
(N=12)
Triple/
quadr.
(N=15)
Dual
(N=14)
Triple/
quadr.
(N=90)
Dual
(N=23)
Triple/
quadr.
(N=91)
Cont.
use in
40.0%
Cont.
use in
50.0%
Cont.
use in
66.7%
Cont.
use in
53.3%
Cont.
use in
42.9%
Cont.
use in
30.0%
Cont.
 use in
56.5%
Cont.
use in
41.8%
Continued PPI use after Helicobacter pylori eradication
111
We found that 41.1% (106/258) of patients continued PPI treatment after H. py-
lori eradication therapy (Figure 1). Patients with only GERD and patients treated
with dual eradication therapies continued their PPI therapy most frequently in
respectively 55.0% and 53.7%. Patients with a peptic ulcer without GERD and
treated with quadruple and triple eradication therapies (n=90) showed continued
use in 30.0%. A proportion of these patients with duodenal ulcer and treated for
H. pylori may have developed GERD after cure and therefore a PPI was pre-
scribed [8]. A small number of patients with gastric ulcer and treated for H. py-
lori may not have achieved cure yet, as in these patients a short-term treatment
up to 8 weeks is recommended [9]. In general, PPIs may be prescribed as pre-
ventive therapy in peptic ulcer patients requiring chronic NSAID treatment [10].
However, we found only 5.1% (2/39) of patients using long-term NSAIDs among
the patients with peptic ulcers and continued use.
As shown in Table 1, GERD without peptic ulcer as diagnosis was significantly
associated with continued use with an adjusted odds ratio (95% CI) of 2.8 (1.1-
7.2). In patients with only GERD, continued PPI use is expected after H. pylori
eradication therapy as maintenance therapy to prevent recurrences [11]. Of pa-
tients with ‘other’ diagnoses, 44.7% (51/114) continued PPI treatment. A lack of
symptom relief has been reported in patients with nonulcer dyspepsia [12]. How-
ever, contrasting results exist, as also a symptomatic benefit from eradicating H.
pylori in patients with nonulcer dyspepsia has been described [13]. Dual therapy
was more frequently but not significantly reported in patients with continued PPI
use (27.4%) versus patients with no further PPI use (16.5%). Patients treated with
dual H. pylori eradication therapies may continue their PPI therapy due to lower
eradication rates of dual therapies compared to triple and quadruple therapies [1-
5]. In patients with continued PPI use, past use of H2-receptor antagonists was
less common (adjusted odds ratio (95% CI): 0.6 (0.3-1.0); an association with the
primary diagnosis ulcer could not be established.
Evaluation by general practitioner or specialist, as well as gender and age did not
significantly differ between patients continuing PPI use and patients with no
further PPI use. Eradication was achieved in 80.3% (53/66) of the continued us-
ers versus 91.1% (82/90) of the patients with no further lansoprazole use; this
difference was not significant. In the remaining patients eradication success or
failure was not assessed. So, in a daily clinical practice setting, many patients
with H. pylori eradication continued lansoprazole treatment (41.1%).
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Table 1
Determinants of continued use of PPIs after H. pylorieradication therapy
Continued
use
N=106 (%)
No further
use
N=152 (%)
Unadjusted
odds ratio
(95% CI)
Adjusted odds
ratio*
(95% CI)
Female 45 (42.5) 67 (44.1) 0.9 (0.6-1.5) 0.8 (0.5-1.4)
Age
     0-45 36 (34.0) 48 (31.6) (reference) (reference)
     45-60 36 (34.0) 56 (36.8) 0.9 (0.5-1.6) 0.8 (0.4-1.5)
     > 60 34 (32.1) 48 (31.6) 0.9 (0.5-1.7) 0.9 (0.5-1.8)
Specialist 79 (74.5) 116 (76.3) 0.9 (0.5-1.6) 1.1 (0.5-2.1)
Past use
     None of both 46 (43.4) 51 (33.6) (reference) (reference)
     H2-receptor antagonist 50 (47.2) 92 (60.5) 0.6 (0.4-1.0) 0.6 (0.3-1.0)
     PPI 16 (15.1) 24 (15.8) 0.9 (0.5-1.9) 0.9 (0.4-1.8)
Primary diagnosis
     Ulcer without GERD 33 (31.1) 71 (46.7) (reference) (reference)
     Ulcer with GERD 6 (5.7) 7 (4.6) 1.8 (0.6-5.9) 1.6 (0.5-5.4)
     GERD without peptic ulcer 16 (15.1) 11 (7.2) 3.1 (1.3-7.5) 2.8 (1.1-7.2)
     Other ** 51 (48.1) 63 (41.5) 1.7 (1.0-3.0) 1.7 (0.9-3.1)
Eradication regimen
     Quadruple 18 (17.0) 38 (25.0) (reference) (reference)
     Triple 59 (55.7) 89 (58.6) 1.4 (0.7-2.7) 1.2 (0.6-2.5)
     Dual 29 (27.4) 25 (16.5) 2.4 (1.1-5.3) 1.9 (0.8-4.5)
* Other primary diagnosis e.g. ‘gastritis’, 'duodenitis'
** Adjusted for all other determinants
This may partly be expected by GERD in the diagnosis or use of sub-effective
eradication therapies, but even one out of three peptic ulcer patients without
GERD and treated with triple or quadruple therapies had continued PPI use.
There are no indications that other PPIs demonstrate different user profiles [14].
Additional research is necessary to investigate the impact of compliance and pos-
sibly other determinants on continued PPI use [15].
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SUMMARY
Background: Soon after the introduction of the proton pump inhibitor (PPI) lan-
soprazole a 4-year observational follow-up study was started to evaluate the
safety of this drug in naturally occurring groups of patients in the Netherlands.
Results of this study were compared with clinical trial data and the limited pub-
lished data from observational studies.
Methods: A prospective, observational study in which patients with a new epi-
sode of lansoprazole us were followed during use with a maximum of two years.
All (adverse) events during use were documented by the prescriber, irrespective
of possible association with lansoprazole therapy.
Results: 805 General practitioners (GPs) and 266 specialists included a total of
10,008 lansoprazole users with a broad range of diagnoses. Of all patients, 17.4%
reported one or more adverse events. The profile and frequency of reported ad-
verse events was consistent with results from clinical trials and other observa-
tional studies. The most frequently reported adverse events were diarrhoea, head-
ache, nausea, skin disorders, dizziness and generalised abdominal pain/cramps.
There was no new evidence of rare adverse events. Furthermore, no lansoprazole
related unlabeled adverse events of clinical significance were recorded.
Conclusions: Although the patterns of use of lansoprazole in daily practice devi-
ated to some extent from the diagnoses in the information leaflet, lansoprazole
was found to have a highly acceptable safety profile in this large naturally occur-
ring group of users. Reporting rates were higher soon after introduction before
falling to a lower stable level.
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INTRODUCTION
Lansoprazole is a PPI introduced on the Dutch market at the end of 1993 indi-
cated for the treatment of reflux oesophagitis and healing of gastric and duodenal
ulcers [1]. Lansoprazole was firstly introduced as a 30 mg capsule, while in
January 1996 a 15 mg capsule was launched for the same diagnoses. At the time
of introduction, lansoprazole had been evaluated in several thousands of patients
enrolled in clinical trials [2]. The most commonly reported adverse events in
clinical trials included headache, diarrhoea, nausea, dizziness, vomiting, consti-
pation, asthenia and flatulence [3, 4]. Rarely reported adverse events associated
with PPIs in general were dry mouth, gynaecomastia, acute liver injury, visual
disorders and acute polyarthralgia, although regarding the latter two events the
relationship with the use of lansoprazole is still under discussion [5-11]. Besides
data from clinical trials, estimates of the ‘real-world’ safety profile were and still
are scarce [12, 13]. Spontaneous case reports stem from undefined, exposed
populations, in which data was collected in a non-standardised manner. Epidemi-
ological studies provide more reliable measures of risk and can place spontane-
ous reports in perspective [14]. This was one of the reasons to set up a large epi-
demiological prospective follow-up study of lansoprazole users in daily clinical
practice in The Netherlands with the aim to assess the safety, efficacy and pattern
of use of lansoprazole. The study started directly after introduction of the drug on
the market. General results of the first two years of this study are described else-
where [15]. In this article we focus on the reporting of adverse events during lan-
soprazole use by a large group of patients found in daily clinical practice, in-
cluding patients of any age with various diagnoses and underlying diseases. As
described by Weber, higher spontaneous reporting rates exist soon after market-
ing of a drug and this pattern persists for about two years before falling to a sta-
ble lower level [16]. This has even been reported despite the usual trend of in-
creasing prescribing rate [17]. A second objective therefore was to investigate
whether reporting rates of adverse events change in time.
MATERIALS AND METHODS
Design
A prospective, observational follow-up study was carried out in 10,008 lansopra-
zole users in the Netherlands during the first four years after marketing from
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January 1994 until April 1998 [15]. No inclusion or exclusion criteria were ap-
plied other than the use of lansoprazole prior to entry into the study. The study
design included a population as representative as possible of the general popula-
tion (in daily practice lansoprazole was prescribed by specialists as well as GPs),
a non-interventional design, a clear separation in time between the prescribing of
lansoprazole and the inclusion of the patient in the study in order to minimise the
influence of the study on the prescribing behaviour and the evaluation, following
SAMM guidelines [18]. The protocol was approved by the Independent Ethical
Committee of the Utrecht University Medical Centre. The overall design has
been described in detail elsewhere [15].
Patients
All patients having used or using lansoprazole were included in the study at the
first or any later follow-up visit after lansoprazole was prescribed. Patients
agreed to participate by giving their free informed consent allowing access to all
relevant clinical and medication data and storage and analyses of these data. No
further selection criteria were considered, meaning that every lansoprazole user
independent of diagnosis (labelled or unlabeled, diagnostically tested or not)
could enter the study.
Measurements
The physician collected data at the inclusion visit and at each follow-up visit
during lansoprazole therapy with a maximum follow-up of two years using stan-
dardised questionnaires. The data collection was designed not to influence nor-
mal procedures by following routine visits and no preset visit schedule. General
characteristics such as age, gender, specialism of evaluating physician, diagnosis
of lansoprazole therapy, start date of lansoprazole use and evaluation date were
recorded. An adverse event was defined as any undesirable experience including
intercurrent events, drug reactions and clinical abnormalities or clinically signifi-
cant laboratory test abnormalities, occurring during the study. During follow-up,
all (adverse) events irrespective of association with lansoprazole therapy were
documented, including a description of the event, the date of onset and if avail-
able the date the event stopped. Furthermore, the severity of the adverse events
was reported as perceived by the physician and classified as mild, moderate, se-
vere or unknown. According to the ICH/GCP guidelines, a serious adverse event
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was defined as an event resulting in death, is life-threatening, requires inpatient
hospitalisation or prolongation of existing hospitalisation, results in persistent or
significant disability/incapacity or is congenital anomaly/birth defect [19]. The
association of the adverse event with the use of lansoprazole as assessed by the
physician was documented as unlikely, possible, probable or unknown. Further-
more, it was stated whether any action was taken due to the adverse event and
labelled as no action, lansoprazole dose reduction or discontinuation, other ther-
apy, other action or unknown. Where the same event occurred more than once in
one patient, only the first episode was used in the calculations. Labelled adverse
events included events described in the product information and unlabeled events
otherwise.
Analysis
Results were tabulated in absolute values and percentages. Incidence densities
were calculated during follow-up as the number of reported adverse events per
1,000 patient months of exposure. The exposure period was defined as the period
from start of therapy until end of lansoprazole therapy or end of follow-up when
still on therapy. All statistical analyses were performed using SAS statistical
package.
RESULTS
Patient enrolment started in January 1994 following the introduction of lansopra-
zole in the Netherlands in September 1993 and ended April 1998. In total 266
specialists and 805 GPs included respectively 3,846 and 6,162 patients. In Table
1 general characteristics of the 10,008 included patients are shown, including
gender and age distributions. The majority of patients had gastro-oesophageal
reflux disease as diagnosis for lansoprazole therapy (53.6%) or any ulcer
(14.5%), whereas in 29.8% other diagnoses were reported such as ‘gastritis’,
‘dyspepsia’ and ‘duodenitis’. Most patients were treated with 30 mg lansoprazole
per day (88.6%), while 5.7% had a prescription of £ 15 mg and 5.6% of ³ 60 mg
per day. Of all lansoprazole users 82.6% reported no adverse events during lan-
soprazole exposure (n=8,267). A total of 11.9% reported one adverse event, 3.8%
reported two adverse events. During the exposure period, 1.7% reported three or
more adverse events with a mean of 3.4 events per patient. Of patients using £ 15
mg, 30 mg and ³ 60 mg lansoprazole per day respectively 12.0%, 17.5% and
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20.8% reported adverse events. Furthermore, 4 of the 9 patients with an unknown
dosage regimen reported adverse events. There was a significant association be-
tween daily dose and the reporting of adverse events (p<0.001).
Table 1
General characteristics of 10,008 lansoprazole users
N=10,008 %
Men 4,864 48.6
Women 5,144 51.4
Age (years)
     0-30 660 6.6
     30-45 2,196 21.9
     45-60 3,279 32.8
     60-75 2,768 27.7
     > 75 1,106 11.1
Diagnosis of lansoprazole therapy
     GERD without ulcer 5,366 53.6
     Other* 2,982 29.8
     Ulcer without GERD disease 1,454 14.5
     Ulcer with GERD 201 2.0
     Unknown 5 0.1
Daily lansoprazole dose
     £ 15 mg 566 5.7
     30 mg 8,870 88.6
     ³ 60 mg 563 5.6
     Unknown 9 0.0
Patients reporting adverse events
     No adverse events 8,267 82.6
     1 adverse event 1,186 11.9
     2 adverse events 381 3.8
     > 2 adverse events 174 1.7
* Other diagnosis of lansoprazole therapy e.g. ‘gastritis’, ‘duodenitis’
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As is shown in Table 2, in total 2,539 adverse events were reported. Of all ad-
verse events, 49.4% was possibly and 26.6% probably related to the lansoprazole
exposure, as assessed by the physician. In a majority of the events (57.8%) no
action was taken, in 5.6% the lansoprazole dosage was reduced and in 29.0% lan-
soprazole therapy was discontinued.
Table 2
Characteristics of adverse events
N=2,539 %
Evaluating physician
     GP 1,364 53.7
     Specialist 1,175 46.3
Severity of adverse events
     Mild 1,181 46.5
     Moderate 983 38.7
     Severe 366 14.4
     Unknown 9 0.4
Association of adverse event with lansoprazole
     Unlikely 600 23.6
     Possible 1,255 49.4
     Probable 675 26.6
     Unknown 9 0.4
Action taken
     None 1,467 57.8
     Stop of therapy 737 29.0
     Switch of therapy 171 6.7
     Dose reduction 141 5.6
     Other action 4 0.2
     Unknown 19 0.7
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Table 2
(continued) Characteristics of adverse events
N=2,539 %
Specification per body system
     Digestive system 1,323 52.1
     Nervous system 441 17.4
     Skin and appendices 230 9.1
     Body as a whole 114 4.5
     Musculo-skeletal system 94 3.7
     Psyche 72 2.8
     Endocrine/metabolic/nutritional 71 2.8
     Other system 194 7.6
According to the physician nearly all adverse events were of either mild (46.5%)
or moderate (38.7%) severity, whereas 14.4% were characterised as severe ad-
verse events. Most of all 2,539 adverse events concerned the digestive system
(52.1%), nervous system (17.4%) and skin and appendices (9.1%). In 41 patients
(0.4%) a serious adverse event as defined by the ICH/GCP guidelines was re-
ported, including malignant neoplasm (n=13), cardiovascular disease (n=8), rash
(n=2), and pneumonia (n=2) [19]. Of all serious adverse events, 60% included
hospitalisations. Regarding all serious events, no definite causal relationship with
lansoprazole was assessed after evaluation.
Distributions of the most frequently (³ 0.25% or in other words ³ 25 events) ob-
served adverse events are listed in Table 3 in percentages of all patients. The
most frequently reported adverse events were diarrhoea (3.7%), headache (2.5%)
and nausea (2.2%). When compared to available clinical data (expected frequen-
cies), the frequencies of diarrhoea, nausea, constipation and dizziness were simi-
lar [3, 4]. The majority of the skin disorders (1.5%) included pruritus and/or rash.
In our study, headache and vomiting were reported less frequently than expected
from data of clinical trials. In patients aged 65 years or over, we found 2.1% of
patients reporting headache versus 1.6% and 4.0% in clinical trials [3, 4].
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Table 3
Frequencies of adverse events (N³25) observed in 10,008 lansoprazole users and
compared with clinical trial data
Specification adverse event Observed
N
Observed
%
Expected*
%
Expected**
%
Diarrhoea 368 3.7 3.2 3.5
Headache 246 2.5 4.7 8.8
Nausea 222 2.2 1.4 2.0
Vomiting 31 0.3 1.4
Dizziness 183 1.8 1.0 1.6
Generalized abdominal pain/cramps 171 1.7 2.2
Flatulence/gas pain/belching 128 1.3
Skin disorders 203 2.0 1.7
Constipation 103 1.0 1.1 1.0
General weakness/tiredness 50 0.5 <1
Symptoms/complaints mouth/tongue/lip99 1.0
Change in feces/bowel move ents 77 0.8
Disturbances of sleep/insomnia 30 0.3 <1
* Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther 1993;7 Suppl:56-60.
** Colin-Jones DG. Safety of lansoprazole. Br J Clin Pract 1994;Suppl 75:58-66.
To give estimates of ‘real-world’ frequencies of reported adverse events we cal-
culated incidence densities (IDs). In Table 4, IDs of the top 10 of reported events
were compared with expected IDs as described in the PEM study [13]. In our
study, 10,008 patients were evaluated during a mean duration of therapy of 3.42
months, in the PEM study 17,329 patients were followed during a mean duration
of lansoprazole use of 3.34 months. Our top 10 included 7 adverse events of the
top 10 of the PEM study. In addition, we found very similar IDs compared to
these PEM data. Only headache and dizziness was slightly more frequently re-
ported in our study compared to the PEM results.
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Table 4
Incidence Densities (ID) of the top 10 of adverse events per 1,000 patient months
of use during the total treatment period as observed in 10,008 lansoprazole users
and compared with observational data of 17,329 lansoprazole users *
Specification adverse event Observed
N
Observed
ID per 1,000
Expected
ID per 1,000
Diarrhoea 368 10.7 9.9
Headache 246 7.2 4.6
Nausea/vomiting 233 6.8 5.9
Dizziness 183 5.3 2.6
Generalized abdominal pain/cramps 171 5.0 5.7
Flatulence/gas pain/belching 128 3.7 No info
Pruritus 127 3.7 1.4
Constipation 103 3.0 1.8
General weakness/tiredness 50 1.5 3.0
Joint pain 16 0.5 3.3
* Freemantle SN, Pearce GL, Wilton LV, Mackay FJ, Mann RD. The incidence of the most
commonly reported events with 40 newly marketed drugs - a study by Prescription-Event
Monitoring. Pharmacoepidemiol Drug Safety 1997;6;Suppl 1:1-52.
Regarding rarely reported adverse events known from case reports and clinical
trials with PPIs we found gynaecomastia in 2 patients (both assessed mild in se-
verity, one not drug related and one possibly drug related). One case of liver dis-
order, mildly severe and not assessed as lansoprazole related and one moderate
severe and possible lansoprazole related liver function abnormality was docu-
mented. Acute liver injury and haemolytic anaemia were not reported during this
study. A total of 42 patients reported dry mouth. The severity was most fre-
quently mild (n=24), followed by moderate (n=15) and severe (n=3); most often
a possible relationship with use of lansoprazole (n=30) was reported, in 8 patients
a probable relationship and in the 4 others an unlikely relationship with use of the
drug. We found 19 patients with acute polyarthralgia, of which 15 were probably
or possibly lansoprazole related, 4 severe and 8 requiring a lansoprazole dose
reduction or discontinuation.
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Ocular events were reported in 25 patients, including abnormal eye sensations
(n=12), visual symptoms/complaints (n=11), conjunctivitis (n=1) and symp-
toms/complaints eyelids (n=1). The reported abnormal eye sensations included
itching, dryness, swelling, redness and burning/tingling. The visual symp-
toms/complaints included blurred vision (n=7), temporary blindness/severe vi-
sion disorder (n=2), spotting during car driving (n=1) and acute blindness in one
patient with a medical history of temporal arthritis and polymyalgia rheumatica
(n=1). Of all vision disorders, three events were deemed probably related (i.e.
itching, conjunctivitis, other symptoms/complaints eyelids) and 13 events possi-
bly related with the use of lansoprazole (i.e. once blurred vision and 12 patients
with abnormal eye sensations), whereas 9 events were unlikely related with use
of the drug. The incidence density of lansoprazole related vision disorders was
10.5 per 10,000 person years (i.e. 2.9 per million treatment days).
There were 1,930 probably or possibly lansoprazole related events of all 2,539
adverse events. 509 of these 1,930 events were not labelled in the applicable
product information for lansoprazole (26.4%). Most unlabelled events were re-
ported in a frequency of less than 25 (i.e. less than 2.5 per 1000). However,
flatulence/gas and pain/belching was reported 108 times, change in faeces/bowel
movements 66 times and symptoms of the mouth such as sensitive tongue and
changes in taste 35 times. 69 of the 509 unlabeled events were assessed as severe
adverse events. Nearly all of these 69 events were reported only once or twice
and of clinical insignificance. There were three clinically significant events of the
69, namely malignant neoplasm oesophagus (n=3), death (n=2) and malignant
neoplasm prostate (n=1). These six events were reported by the physicians as
serious adverse events [19]. The conclusion after review by experts was that no
or no definitive causal relationship between these serious adverse events and the
treatment with lansoprazole was established. Furthermore, flatulence/gas
pain/belching was reported seven times and baldness/losing hair three times as
probably or possibly lansoprazole related, severe and unlabeled events.
To analyse the influence of time after registration on the reporting of adverse
events IDs were calculated for subsequent periods of time. During the first 2
years 5,669 patients were followed during 21,084 months of lansoprazole use,
whereas in the second period 4,339 patients were evaluated during 13,224
months of use. The ID per 1,000 patient months of use of any adverse event was
74.0 during the total study period. The ID during the first 2 years after launch
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(1994-1995) was 78.7 and the ID of the next two years was 66.4. Especially
probably drug related events were less frequently reported in the last 2 years of
the study (ID 14.8) compared to the first 2 years (ID 22.7).
To analyse this influence of time in more detail, IDs were calculated for subse-
quent quarters (periods of three months) starting quarter 4 of 1993. As can be
seen in Figure 1, the IDs were high soon after launch (quarter 2 and 3) and be-
came stable in the following period. This pattern was even more marked for se-
vere and/or probably lansoprazole related adverse events. Results of the latest
quarters (Q14 up to Q18) showing a rapid decrease followed by a quick increase
of IDs were reasonably artefacts due to a low number of exposure months and a
delayed cessation of the study.
Figure 1
Incidence Densities of reporting of adverse events (n=2,539) for subsequent 
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DISCUSSION
The main objective of this study was to assess the safety of lansoprazole in a
population composed by users in daily clinical practice and to evaluate the influ-
ence of time after registration on the reporting of adverse events.
In clinical trials patients receiving the usual daily dose of 30 mg of lansoprazole
reported one or more adverse events in 30.0% [2]. In this observational study
17.4% of the 10,008 evaluated patients reported one or more adverse events.
There was a significant positive association between lansoprazole dose and the
reporting of adverse events. It was expected that in this observational study re-
porting rates were lower compared to clinical trials due to the study design,
available information on labelled events etc.
In general, the adverse events during lansoprazole use were mild and self-
limiting. It was seen that in 30% of all adverse events the dose of lansoprazole
was stopped and in 6% the dose was reduced. In nearly 50% a possible and in
one out of four a probable relationship with the use of lansoprazole was docu-
mented by physician. The reporting rate of serious adverse events of 0.4% was
comparable with the 0.6% as reported in clinical trials [4]. No serious adverse
events related to lansoprazole were observed in the study group.
The overall safety profile of lansoprazole in this study was similar to the profile
of events in clinical trials and observational studies with lansoprazole and com-
parative agents [2-4, 12, 13, 0]. Frequencies were comparable with results from
clinical trials with the major exception that we found lower rates of headache and
vomiting. In clinical trials headache was reported in 4.7% and 8.8% respectively
of all patients and in 1.6% and 4.0% in patients aged 65 years or over using
pooled data from international trials [3, 4]. The proportion of patients aged 65
years or over was considerably (three times) higher in our study compared to
clinical trials, which may be an explanation of our lower rate of reporting head-
ache.
In general we found very similar IDs as found in the PEM study, although com-
parisons between results of observational cohort studies are difficult due to mul-
tiple possible differences. Possible existing differences include e.g. diagnoses for
which the drug has been used, prescriber, prescribed doses, duration of use, age
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and sex distributions, publicity, calendar year, initial rate of sale, different pattern
of usage of a drug [12, 13, 21].
Regarding rare adverse events we found similar profiles as described in literature
[5-11]. From clinical trials, very few numbers are available about e.g. dry mouth,
gynaecomastia to make comparisons in reporting rates. In 3 patients blind-
ness/severe vision disorder was documented. None of these events were related
to lansoprazole use, as assessed by the physician, while according to the WHO
database, the ID of drug related blindness/severe vision events was 0.022 per
million treatment days [8]. Garcia Rodriguez did investigate ocular events in
more detail through a retrospective cohort study in general practice with omepra-
zole [9]. He found no inflammatory lesions, whereas vascular lesions of the eye
(e.g. amaurosis fugax) were found with an ID of 2.8 per 10,000 person years. In
our study the ID of any drug related vision disorder was 10.5 per 10,000 person
years. However, none of these disorders were classified as severe, as assessed by
the physician. Besides, patients with certain medical histories e.g. eye disorders,
cancer, hypertension, diabetes were excluded from the cohort by Rodriquez and
not by us.
In general practice, it is known that unlabelled drug related adverse events are
more frequently reported compared to labelled events [22]. Th re is a selective
reporting bias for adverse events with greatest clinical concern. In our study, we
found three probably or possibly lansoprazole related and unlabeled events re-
ported over 25 times, namely flatulence/gas pain/belching (n=108), change in
faeces/bowel movements (n=66) and symptoms tongue (n=35). Many of these
events could result from the treatment as well as from the disease.
Regarding the time trend, we found higher reporting rates soon after marketing of
the drug before falling to a lower stable level. Especially probably lansoprazole
related adverse events were more frequently reported during the first year after
introduction. It is consistent with Weber’s theory that the reporting of adverse
events to a new drug does not proceed at a uniform rate, but higher spontaneous
reporting rates exist soon after marketing of a drug and this pattern persists be-
fore falling to a stable lower level [17].
In conclusion, this 4-year observational follow-up study was started to evaluate
the safety of lansoprazole in naturally occurring groups of patients in the Neth-
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erlands. 805 GPs and 266 specialists included a total of 10,008 lansoprazole users
with a broad range of (un)registered diagnoses. Of all patients, 17.4% reported
one or more adverse events. The profile and frequency of reported adverse events
was consistent with results from clinical trials and observational studies, whereas
the proportion of patients aged 65 years or over was considerably (three times)
higher in our study compared to clinical trials. The most frequently reported ad-
verse events were respectively diarrhoea, headache, nausea, skin disorders, dizzi-
ness and generalised abdominal pain/cramps. In our study, headache and vomit-
ing were reported less frequently than expected from data of clinical trials. There
was no new evidence of rarely reported adverse events. Furthermore, no lanso-
prazole related unlabeled adverse events of clinical significance were recorded.
Chapter 5.1
132
REFERENCES
1. Prezal 15/30. In: Repertorium: overzicht van door het College ter Beoor-
deling van Geneesmiddelen geregistreerde informatieteksten van farmaceu-
tische spécialités [in Dutch]. Utrecht: Nefarma; ‘s Gravenhage, edition 98/99.
2. Langtry HD, Wilde MI. Lansoprazole. An update of its pharmacological
properties and clinical efficacy in the management of acid-related disorders.
Drugs 1997;54(3):473-500.
3. Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther 1993;7
Suppl:56-60.
4. Colin-Jones DG. Safety of lansoprazole. Br J Clin Pract 1994;Suppl 75:58-
66.
5. Teare JP, Spedding C, Whitehead MW, Greenfield SM, Challacombe SJ,
Thompson RPH. Omeprazole and dry mouth. Scand J Gastroenterol
1995;30:216-8.
6. Garcia Rodriguez LA, Jick H. Risk of gynaecomastia associated with cimet-
idine, omeprazole, and other antiulcer durgs. BMJ 1994;308:503-6.
7. Garcia Rodriguez LA, Wallander M, Stricker BHCh. The risk of acute liver
injury associated with cimetidine and other acid-suppressing anti-ulcer drugs.
Br J Clin Pharmacol 1997;43:183-8.
8. The ADR signals analysis project (ASAP) team: Lindquist M, Pettersson M,
Edwards IR, Sanderson J, Taylor N, Fletcher P et al. Omeprazole and visual
disorders: seeing alternatives. Pharmacoepidemiol Drug Safety 1996;5:27-
32.
9. Garcia Rodriguez LA, Mannino S, Wallander M, Lindblom B. A cohort
study of the ocular safety of anti-ulcer drugs. Br J Clin Pharmacol
1996;42:213-6.
10. Schönhöfer PS, Werner B. Ocular damage associated with proton pump in-
hibitors. BMJ 1997;314:1805.
11. Meier CR, Jick H. Omeprazole, H2 blockers and polyarthralgia: case-control
study. BMJ 1997;315:1283.
12. Mann RD, Wilton LV, Pearce GL, Mackay FJ, Dunn NR. Prescription-Event
Monitoring (PEM) in 1996 - A method of non-interventional observational
cohort pharmacovigilance. Pharmacoepidemiol Drug Safety 1997;6;Suppl
3:S5-S11.
13. Freemantle SN, Pearce GL, Wilton LV, Mackay FJ, Mann RD. The inci-
dence of the most commonly reported events with 40 newly marketed drugs -
Safety review of 10,008 lansoprazole users
133
a study by Prescription-Event Monitoring Pharmacoepidemiology and Drug
Dafety 1997;6;Suppl 1:1-52.
14. Miwa LJ, Jones JK, Pathiyal A, Hatoum H. Value of epidemiologic studies
in determining the true incidence of adverse events. The non-steroidal anti-
inflammatory drug story. Arch Int Med 1997;157(18):2129-36.
15. Leufkens H, Claessens A, Heerdink E, EijkJ van, Lamers C. A prospective
follow-up study of 5,669 users of lansoprazole in daily practice. Aliment
Pharmacol Ther 1997;11:887-97.
16. Weber JCP. Mathematical models in adverse drug reaction assessment. In:
D’Arcy PF, Griffin JP (Eds). Iatrogenic diseases. Oxford: Oxford University
Press, third edition 1986:102-7.
17. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflam-
matory drugs. In: Rainsford KD, Velo G (eds). Side effects of antiinflam-
matory/analgesic drugs. New York: Raven Press 1984;6:1-7.
18. Medicines Control Agency, Committee on Safety of Medicines, Royal Col-
lege of General Practitioners, British Medical Association and Association of
the British Pharmaceutical Industry (November 1993). Guidelines for com-
pany-sponsored safety assessment of marketed medicines (SAMM). Br J
Clin Pharmacol 1994;38:95-7.
19. Clinical Safety Data Management: Definitions and Standards for expedited
reporting. In: ICH Harmonised Tripartite Guideline. Adopted by CPMP, No-
vember 94, issued as CPMP/ICH/377/95.
20. Freston JW, Rose PA, Heller CA, Haber M, Jennings D. Safety profile of
lansoprazole. The US Clinical Trial Experience. Drug Saf 1999:20:195-205.
21. Speirs CJ. Prescription-related adverse reaction profiles and their use in risk-
benefit analysis. In: Iatrogenic diseases, 3rd ed. D’Arcy PF, Griffin JP (Eds),
Oxford University Press, Oxford, 1986:93-101.
22. Martin RM, Kapoor KV, Wilton LV, Mann RD. Underreporting of suspected
adverse drug reactions to newly marketed (‘black triangle’) drugs in general
practice: observational study. BMJ 1998;317:119-120.
Chapter 5.2
Incidence of headache in lansoprazole users:
which determinants contribute?
Angela A.M.C. Claessens MD 1,2, Eibert R. Heerdink PhD1,
Jacques Th.M.van Eijk PhD3, Cornelis B.H.W. Lamers MD PhD4 and
Hubert G.M. Leufkens PhD1
1. Department of Pharmacoepidemiology and Pharmacother py, Utrecht Insti-
tute for Pharmaceutical Sciences (UIPS), Utrecht, The Netherlands
2. Kendle, Utrecht, The Netherlands
3. Department of Medical Sociology, Health Care Studies, Faculty of Medicine,
University of Maastricht, Maastricht, The Netherlands
4. Department of Gastroenterology and Hepatology, Leiden University Medical
Centre, Leiden, The Netherlands
Submitted for publication
Chapter 5.2
136
SUMMARY
Background: In clinical trials, headache is one of the most frequently reported
adverse events (frequency 1.3-8.8%), while results of one observational study
indicate that headache is the fifth most frequently reported adverse event (inci-
dence densities 2.5-4.6 per 1,000 patient months of exposure) during proton
pump inhibitor (PPI) use. However, there are no observational studies performed
regarding the occurrence and features of headache during use of PPIs in daily
practice. For this reason this study was set up with the aim to assess the incidence
and characteristics of headache and to investigate possible associated co-factors
in PPI users in daily practice.
Methods: Data were used from a prospective, observational study in which
10,008 lansoprazole users were followed over time. The study was designed ac-
cording to the SAMM guidelines. A nested case-control design was used to com-
pare PPI users reporting headache with PPI users reporting no headache.
Results: The frequency of headache was 2.5% and the incidence density 7.2 per
1,000 patient months of PPI use. Tension headache was seen in two out of three
patients with headaches and migraine in the remaining patients. The analysis of
co-factors revealed that women, patients with previous use of analgesics and p-
tients reporting several adverse events, were at risk to develop headache during
PPI use. Patients with headache also, significantly more often, reported diar-
rhoea, nausea and dizziness. A de-challenge of PPI therapy resulted in a cessation
or reduction of the headache in 80.0% (20/25).
Conclusion: In conclusion, as can be expected headache was reported less fre-
quently in this study compared to clinical trials with lansoprazole. The incidence
density was comparable with other observational data of lansoprazole and ome-
razole users. The most commonly reported type of headache during lansoprazole
use was tension headache. Besides several commonly accepted co-factors such as
female gender and a history of analgesic use, we also found the reporting of other
adverse events to be associated with the reporting of headache during lansopra-
zole use. The cessation of headache after a discontinuation of use of the PPI and
the observed dose relationship suggested that headache was indeed a side-effect
of lansoprazole use.
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INTRODUCTION
The PPI lansoprazole was introduced in The Netherlands in the fall of 1993 and
is indicated for the treatment of reflux oesophagitis and healing of gastric and
duodenal ulcers. The tolerability of PPIs has been thoroughly investigated in
(randomised) clinical trials and headache is the most common adverse event re-
ported, in 2.9-6.9% of omeprazole users, 3.8-8.8% of lansoprazole users, 1.3% of
pantoprazole users and 2.4-6.0% of rabeprazole users. [1-6]. Estimates of the
‘real-world’ frequency and characteristics of headache as an adverse event during
lansoprazole use are scarce. Such epidemiological studies with large groups of
complex patients followed in daily practice provide more reliable measures of
risk compared to clinical trials [7]. In the PEM study, the Incidence Density of
headache during lansoprazole and omeprazole use was the fifth most often re-
ported adverse event, in 4.6 and 2.5 per 1,000 patient months of exposure re-
spectively [8]. The mechanism of headache in lansoprazole users, if any is yet
unclear [1, 2]. Also, headache is shown to be a risk factor for self-reported peptic
ulcers [9]. Co-factors associated with the occurrence of headache in the general
population may be present such as younger age, female sex, caffeine consump-
tion, co-morbidity (myocardial ischemia, stroke, hypertension and arthritis), pre-
vious episodes of headache, drug exposure and co-medication [10-12].
Furthermore, it must taken into account that results of an observational study on
newly marketed drugs indicated that headache is reported in the top ten of ad-
verse events of all 40 investigated drugs [8].
Therefore, this study was set up to investigate the incidence and characteristics of
headache and to identify the value of co-factors associated with headache in natu-
rally occurring lansoprazole users. Analysis of co-factors associated with the oc-
currence of headache may lead to identification of patients at risk.
MATERIALS AND METHODS
Design
The study data were derived from a prospective follow-up study conducted in the
Netherlands in 10,008 naturally occurring users of lansoprazole during the first
four years after introduction (January 1994 until April 1998). The study protocol
Chapter 5.2
138
was designed according to the SAMM guidelines (guidelines for company-
sponsored Safety Assessment of Marketed Medicines) on design of postmarket-
ing safety studies and approved by the Medical Ethical Committee of the Utrecht
University Medical Centre [13]. Methods of this study have been described in
detail previously [14].
Data were analysed according to a nested matched case-control design with a 1:1
or 1:2 ratio for cases and controls. Retrospectively, cases were defined as lanso-
prazole users reporting headache as an adverse event. The preceding patient, of
the same evaluating physician, not reporting headache during the total follow-up
period was taken as the matched control, in order to limit observer bias [15]. In
case the so-defined preceding control patient was not available, the next available
patient of the same physician served as the control.
Patients
Patients were prescribed lansoprazole as part of daily practice. At any follow-up
visit after the first prescription of lansoprazole, patients still using or having used
lansoprazole were eligible for inclusion. Patients had to give their free written
informed consent. No additional in- or exclusion criteria were considered [14].
Measurements
Data were collected at the inclusion visit and at follow-up visits thereafter during
lansoprazole therapy by reviewing the medical file and by patient questionnaire.
There was no further interference due to the study during the patient visit. The
daily practice situation was followed as closely as possible. No additional diag-
nostic tests were requested from the physician with regard to the indication or
any co-morbidity.
Baseline patient characteristics including age, gender, smoking habits and alco-
hol intake were recorded at the inclusion visit. Moreover information was ob-
tained about the daily dose of lansoprazole, indication for use and relevant co-
morbidity. All (adverse) events irrespective of being linked to lansoprazole ther-
apy were documented including the onset, severity, possible relationship with
lansoprazole use, action taken and outcome. The physician reported severity and
association of the events.
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In addition, for lansoprazole users reporting headache from January 1996 on-
wards (n=83), as well as for the preceding patient of the same physician supple-
mentary questionnaires were completed. We received 35 completed question-
naires from patients with headaches (response 35/83, 44.6%). Two of the 35
questionnaires were not valid (5.7%), because the physician reported that during
lansoprazole use no headache was reported in contradiction with information re-
ceived at an earlier stage. At the same time, the same physicians were requested
to complete an equal number of similar questionnaires for patients not reporting
headache and evaluated from January 1996 onwards. We received 42 completed
questionnaires (response 42/83, 50.6%). In six of the 42 questionnaires the physi-
cian reported that headache was reported during lansoprazole use after the study
period. These patients were excluded. Our response rate was comparable with the
overall response rate of 53% found in the UK after requesting postmarketing data
on new drugs [16].
The patient questionnaires were used to collect specific data about characteristics
of episodes of headache three months prior to and during lansoprazole intake,
including duration, onset, location and a thorough symptom checklist. Further-
more, possibly related co-factors including prior and current use of alcohol, caf-
feine and analgesics were recorded. The symptom checklist was used to classify
headache into migraine, cluster headache and/or tension headache, according to
international guidelines [17].
Complete prescription medication histories were obtained through pharmacy rec-
ords from six months retrospectively and during the lansoprazole therapy. The
physician requested the appropriate pharmacy to collect the pharmacy records.
Drugs used were coded according to the anatomical-therapeutic-chemical (ATC)
classification [18].
Analysis
Current drug use was determined as drug use at the moment of onset of head-
ache, whereas past drug use was defined as drug use during the six months prior
to the onset of headache. For each control without headache the moment of onset
of headache of the matched case was used as a reference value to estimate current
and past use of co-medication and current doses.
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Results were tabulated in absolute values and percentages. Baseline comparisons
were calculated yielding crude and adjusted odds ratios with a confidence interval of
95%. Adjusted odds ratios were calculated using conditional logistic regression.
Incidence densities were calculated during follow-up as the number of reported
adverse events per 1,000 patient months of exposure. The exposure period was
defined as the period from start of therapy until the end of lansoprazole therapy
or the end of follow-up when still on therapy. Statistical significance was assumed
at p-value < 0.05. All statistical analyses were performed using SAS and EGRET
statistical packages.
RESULTS
This study was set up to investigate the incidence and characteristics of headache
and to identify the value of co-factors associated with headache in 10,008 natu-
rally occurring lansoprazole users. The frequency of headache in daily practice of
lansoprazole users was 2.5% (246/10,008) and the incidence density 7.2 per
1,000 patient months of use.
The reporting of headache was dose related. Headache was reported in 2.7%
(15/563), 2.5% (225/8870) and 1.1% (6/566) of patients using 60 m , 30 mg and
15 mg lansoprazole per day respectively. Headache was significantly more often
reported by 30 mg users compared to 15 mg users (OR (95% CI): 2.4 (1.1-5.5).
Eventually, 226 cases and 442 matched controls were identified from all lanso-
prazole users. In Table 1 the distribution of characteristics among cases and co-
trols is shown as well as the crude odds ratio for each characteristic. Adjusted
odds ratios were calculated through conditional logistic regression with each pos-
sible co-factor included in the logistic model. It was found that female sex (ad-
justed OR (95% CI): 1.6 (1.1-2.3)) and the reporting of other adverse events
(adjusted OR (95% CI): 2.5 (1.7-3.6)) were significantly associated with the re-
porting of headache. Cases reported more frequently (53.5% versus 32.8%) other
adverse events and on average more (1.8 versus 1.5) other adverse events as
compared to controls. The most frequently (> 5%) reported adverse events were
all reported more often in cases compared to controls, namely dizziness (15.9%
versus 2.9%), nausea (13.3% versus 4.5%), diarrhoea (11.9% versus 7.0%), ab-
dominal pain (8.0% versus 3.2%) and flatulence/gas pain/belching (6.6% versus
2.7%).
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Table 1
Distribution of characteristics among cases and matched controls
Cases Controls
N=226 % N=442 % Crude Odds
Ratio
(95% CI)
Adjusted Odds
Ratio*
(95% CI)
Women 137 60.6 224 50.7 1.5 (1.1-2.2)1.6 (1.1-2.3)
Age (years)
   0-30 12 5.3 19 4.3 (reference) (reference)
   30-45 48 21.2 92 20.8 0.8 (0.4-1.7)0.6 (0.3-1.5)
   45-60 83 36.7 148 33.5 0.8 (0.4-1.8)0.7 (0.3-1.5)
   60-75 71 31.4 135 30.5 0.8 (0.4-1.7)0.6 (0.3-1.4)
   > 75 12 5.3 48 10.9 0.3 (0.1-0.8)0.2 (0.1-0.6)
Smoking 54 23.9 115 26.0 0.9 (0.6-1.3)0.9 (0.6-1.3)
   Unknown 0 0.0 1 0.2
Alcohol consumption 106 46.9 213 48.2 0.9 (0.7-1.3)1.1 (0.7-1.6)
   Unknown 0 0.0 1 0.2
Daily dose of lansopra-
zole
   £ 30 mg 211 93.4 407 92.1 (reference) (reference)
   ³ 60 mg 15 6.6 35 7.9 0.8 (0.3-1.7)0.9 (0.4-2.1)
First use of lansoprazole 194 85.8 376 85.1 0.9 (0.5-1.6)0.9 (0.5-1.7)
Indication of lansopra-
zole therapy
   GERD 147 65.0 267 60.4 1.3 (0.9-1.9)1.3 (0.8-2.0)
   Ulcer 30 13.3 57 12.9 1.1 (0.6-1.8)1.2 (0.7-2.3)
Co-morbidity 84 37.2 164 37.1 1.0 (0.7-1.4)1.0 (0.7-1.5)
Any other adverse event
reported
121 53.5 145 32.8 2.5 (1.7-3.5)2.5 (1.7-3.6)
* adjusted by conditional logistic regression for each possible co-factor
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An age of 75 years or more was significantly less often documented in cases in
contrast to controls (adjusted OR (95% CI): 0.2 (0.1-0.6)). Smoking habits, alco-
hol intake, prescribed lansoprazole dose and first use of lansoprazole seemed to
be well balanced between cases and controls. No differences were found between
the groups regarding the indication for lansoprazole use. Lansoprazole therapy
was prescribed for the eradication of Helicobacter pylori in 4.0% of the cases
versus 6.4% of the controls. Co-morbidity (excluding acid related diseases) was
documented in 37.2% and 37.1% of the cases and the controls respectively. The
profile of co-morbidity was similar for both groups of patients. Of all cases and
controls 54.0% and 53.6% respectively were evaluated by speci lists.
For a total of 170 cases and 317 controls in a ratio of 1:1 or 1:2 medication histo-
ries were retrieved. Table 2 shows a higher current use of analgesics and NSAIDs
in cases compared to controls.
Table 2
Current and past co-medication among cases and matched controls
Cases Controls
N=226 % N=442 % Crude Odds
Ratio
(95% CI)
Adjusted
Odds Ratio†
(95% CI)
Current drug use*
   Any cardiovascular drug32 18.8 67 21.1 0.8 (0.5-1.3) 0.6 (0.3-1.5)
   Benzodiazepines 24 14.1 46 14.5 1.0 (0.5-1.7) 0.9 (0.4-2.3)
   Oral antibiotics 21 12.4 47 14.8 0.8 (0.4-1.6) 0.7 (0.4-1.6)
   Analgesics 19 11.2 27 8.5 1.7 (0.9-3.4) 1.4 (0.5-3.6)
   NSAIDs 9 5.3 13 4.1 1.4 (0.5-3.5) 1.8 (0.5-5.6)
Past co-medication**
   Any cardiovascular drug28 16.5 51 16.1 0.9 (0.5-1.5) 1.4 (0.5-3.5)
   Benzodiazepines 28 16.5 41 12.9 1.3 (0.7-2.3) 1.6 (0.7-3.6)
   Oral antibiotics 12 7.1 42 13.2 0.5 (0.2-0.9) 0.4 (0.2-0.9)
   Analgesics 26 15.3 35 11.0 1.3 (0.7-2.4) 0.9 (0.4-2.0)
   NSAIDs 16 9.4 37 11.7 0.8 (0.4-1.6) 0.6 (0.3-1.6)
* current drug use: drug use at the moment of onset of headache
** past co-medication: drug use during six months prior to the onset of headache
† adjusted by conditional logistic regression for variables mentioned in Table 2
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Analysis of co-medication in the 6 months preceding the use of lansoprazole
showed a slightly higher use of benzodiazepines and analgesics in cases. Due to
the limited numbers, these differences between cases and controls in current and
past drug use were not statistically significant.
Regarding cardiac medications, current use of beta-blocking drugs was, not sig-
nificantly, more habitual in 9.4% of cases as compared to 7.6% of controls (un-
adjusted OR (95% CI): 1.2 (0.6-2.5). We found that past use of oral antibiotics
was less frequent in cases as compared with controls. This association was sig-
nificant after adjusting for all variables mentioned in Table 1 (adjusted OR (95%
CI): 0.4 (0.2-0.9).
In addition, from a subset of 33 cases and 36 controls supplementary question-
naires were completed (Table 3). The headache was predominantly mild (50.4%)
or moderate (35.8%) in severity. An association with the study drug was de-
scribed most commonly as either probable (29.7%) or possible (55.7%). In
54.5% no action was taken due to the headache, whereas a dose reduction of lan-
soprazole was reported in 6.1% and a discontinuation in 39.3%. The time of on-
set of the headache was in 42.4% within 2 hours and in 54.5% beyond 2 hours
after intake of lansoprazole. Headaches were predominantly present during the
day (63.6%), bilaterally located (81.8%) and described as oppressive (69.7%)
with accompanying signs and/or symptoms as preference for rest (66.7%) and a
negative impact on daily activities (54.5%). Based upon the above mentioned
characteristics the headaches could be classified as tension headache (21/33,
63.6%), migraine with/without aura (8/33, 24.2%) and not classifiable headache
(4/33, 12.1%).
Of all 25 patients having ceased lansoprazole treatment during the follow-up pe-
riod, 48.0% (12/25) reported a discontinuation of headache, 32.0% (8/25) a re-
duction of headache and 20.0% (5/25) no effect. Two patients restarted lansopra-
zole treatment after a discontinuation leading to the occurrence of the same head-
ache as before.
Previous episodes of headache were documented in 36.4% of the cases (12/33)
and 22.2% of the control patients (8/36) (unadjusted OR (95% CI): 2.0(0.6-6.6).
The classification of the headache was in 10 out of the 12 cases the same during
lansoprazole use as before. Use of analgesics during the three months prior to the
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start of the lansoprazole treatment was frequent in cases (n=14, 42.4%) and
documented less frequently but significantly (n=4, 11.1%) in control patients
(unadjusted OR (95% CI): 5.9 (1.5-25.1).
Table 3
Characteristics of headache during lansoprazole intake
N=33 %
Onset of headache
   < 2 hours after intake lansoprazole 14 42.4
   > 2 hours after intake lansoprazole 18 54.5
   Unknown 1 3.0
Headache mainly present
   In morning 2 6.1
   During the day 21 63.6
   In the evening 2 6.1
   Otherwise 8 24.2
Severity of headache
   Mild 13 39.4
   Moderate 8 24.2
   Severe 2 6.1
Association of headache with lansoprazole
   Unlikely 5 15.2
   Possible 18 54.5
   Probable 10 30.3
Location headache
   Unilateral 5 15.2
   Bilateral 27 81.8
   Unknown 1 3.0
Type of  headache
   Beating 5 15.2
   Oppressive 23 69.7
   Otherwise 5 15.2
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Table 3
(continued) Characteristics of  headache during lansoprazole
N=33 %
Accompanying signs/ymptoms
   Aggravation of head. during exercise 13 39.4
   Restlessness during headache 6 18.2
   Preferring resting during headache 22 66.7
   Negative effect on daily activities 18 54.5
   Nausea  or vomiting 8 24.2
   Sensitive for light/noise 7 21.2
Classification of headache
   Tension headache 21 63.6
   Migraine with/without aura 8 24.2
   Not classifiable 4 12.1
Action taken
   None 18 54.5
   Discontinuation of lansoprazole 13 39.3
   Dose reduction of lansoprazole 2 6.1
   Other action 0 0
The intake of alcohol and caffeine was more frequently reduced in cases as con-
trols. Four cases had reduced or stopped intake of alcohol and/or caffeine. Of the
controls, one patient reduced alcohol intake and increased caffeine intake,
whereas another control increased caffeine intake while alcohol intake was un-
changed.
DISCUSSION
The aim of this study was to investigate the incidence and characteristics of
headache and to identify the value of co-factors associated with headache in natu-
rally occurring lansoprazole users. Data were used from a large prospective fol-
low-up study in 10,008 lansoprazole users in daily clinical practice incorporating
patients with different indications, co-morbidity and the use of co-medication.
The incidence density of headache was 7.2 per 1,000 person-years of lansopra-
zole use and comparable with other observational data stating 4.6 per 1000 per-
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son-years [8]. Our frequency of patients reporting headache was relatively low
(2.5%), compared to the frequency reported in clinical trials with lansoprazole
(3.8-8.8%) [1, 2, 14]. This frequency was significantly dose re ated. In observa-
tional studies, as ours, a general underreporting of adverse events can be ex-
pected as compared to clinical trials with follow-up visits required by protocol
instead of visits occurring in daily clinical practice. Therefore, we feel that our
data more closely represents the natural frequency of headache in lansoprazole
users than data from selected patients in clinical trials.
From literature little is known about characteristics of headache during lansopra-
zole use We found that based upon the reported characteristics the headaches
could be classified as tension headache (21/33, 63.6%), migraine with/without
aura (8/33, 24.2%) and not classifiable headache (4/33, 12.1%). This pattern re-
sembles the situation in the general population where tension headache represents
72.3% of all recurrent headaches [19].
Among headache patients as compared to lansoprazole users not reporting head-
ache, there were significantly more women. The association with gender is con-
sistent with data from clinical trial literature stating a frequency of 5.6% in
women and 4.5% in men using lansoprazole [3]. In clinical trials headache was
reported in 8.4% of patients using 60 m  lansoprazole and in 3.8% of patients
using 30 mg [3]. Patients with an age of 75 years or more were at a lower risk to
develop headache during lansoprazole therapy, a phenomenon also identified in
the general population where older age groups showed lower prevalences of
headache [11, 20].
The number of patients with other adverse events and the average number of ad-
verse events were considerably higher in patients reporting headache compared
to patients reporting no headache. Patients with headache reported diarrhoea,
nausea and dizziness significantly more often. All these adverse events are
known as common adverse events related with the use of PPIs in general [3-5].
An explanation is that there exists a group of patients who report adverse events
more readily. Another explanation is that certain combinations of gastrointestinal
and neurological adverse events may occur together in users of PPIs. However,
no clinical evidence of this has been published. An association with co-morbidity
could not be established, although described in literature [20, 21].
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Past use of analgesics was significantly more frequent in patients with headache
during lansoprazole use. It is known that in the general population, unrelated to
the use of lansoprazole, headache is associated with non-prescription analgesic
use. Headache sufferers often use analgesic drugs [22, 23].
In conclusion, the incidence density of headache was comparable with other o-
servational data. The type of headache was in two out of three patients classifi-
able as tension headache. The analysis of co-factors revealed that women and
patients with a history of use of analgesics were at risk to develop headache dur-
ing lansoprazole use. These co-factors are both well-known co-factors associated
with the occurrence of headache in the general population [10, 20]. We addition-
ally found that the reporting of other adverse events was associated with the o-
currence of headache during lansoprazole use. A de-challenge of lansoprazole
therapy resulted in a cessation or reduction of the headache in 20 out of 25 pa-
tients. This together with the existing dose relationship made the association with
the drug intake very plausible.
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SUMMARY
Background: Diarrhoea is one of the most frequently reported adverse events
during proton pump inhibitor (PPI) use in any setting. Because of the limited
available information, this study was set up with the aim to assess the incidence
and characteristics of diarrhoea and to investigate possible associated co-factors
in PPI users in daily practice.
Methods: Data were used from a prospective, observational study in which
10,008 lansprazole users were followed over time (1994-1998). The study was
designed according to the SAMM guidelines. A nested case-control design was
used to compare PPI users reporting diarrhoea with PPI users reporting no diar-
rhoea.
Results: The frequency of diarrhoea was 3.7% and the incidence density 10.7 per
1,000 patient months of PPI use. The diarrhoea was most commonly loose and
occurred on average 4.4 times per day. The analysis of co-factors revealed that
patients with concomitant use of oral antibiotics and patients reporting several
adverse vents, were at risk to develop diarrhoea during PPI use. A de-challenge
was positive in 38 out of 48 patients and a re-challenge in 4 out of 4.
Conclusions: In conclusion, diarrhoea was as frequently reported in our study as
compared with clinical trials and observational data of lansoprazole users. Be-
sides alcohol use, we found the concomitant use of oral antibiotics and the re-
porting of certain other adverse events to be associated with the reporting of diar-
rhoea during lansoprazole use. Although a relationship with the PPI intake
seemed very plausible, we suggest that use of alcohol and/or oral antibiotics as a
cause of diarrhoea must be taken into consideration in lansoprazole users.
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INTRODUCTION
Lansoprazole is a PPI introduced on the Dutch market at the end of 1993 indi-
cated for the treatment of reflux oesophagitis and healing of gastric and duodenal
ulcers. At the time of introduction, lansoprazole had been evaluated in several
thousands of patients enrolled in clinical trials [1]. Diarrhoea was one of the most
common adverse events reported in clinical trials with PPIs, namely in 3.0-3.5%
of patients using 30 mg lansoprazole, 1.9-3.7% using 20 to 40 mg omeprazole,
1.5% using 40 to 120 mg of pantoprazole and 2.0-3.0% using 10 to 20 mg rabep-
razole [1-4]. In patients with an age of 65 years or more a frequency of diarrhoea
of 4.7% is documented [1]. During long-term treatment, diarrhoea occurred in
1.9% to 5% of lansoprazole users compared to 3% of omeprazole users [1]. Be-
sides clinical trial data, estimates of the ‘real-world’ safety profile are more im-
portant but until now scarce [5]. In the PEM study, diarrhoea had the second
highest Incidence Density of 9.9 and 4.0 per 1,000 patient months of exposure
during respectively lansoprazole and omeprazole use [6]. Furth rmore, little is
known about the characteristics of diarrhoea as an adverse event during lansopra-
zole use, such as the severity, consistency, colour, accompanying symptoms, on-
set and contribution to dosage changes.
One hypothesis behind the occurrence of diarrhoea during lansoprazole use is
that the high degree of acid suppression achieved by PPIs may lead to bacterial
contamination of the upper gut resulting in diarrhoea by various mechanisms [7-
9]. Especially in the elderly, in whom acid reducing drugs are commonly pre-
scribed, this may be of particular importance [10]. Several studies indicated that
short term PPI treatment increased bacterial colonisation, whereas long term in-
hibition of gastric acid did not lead to small intestinal bacterial overgrowth [9-
11].
Furthermore, the existence of co-factors has to be taken into account. Possible
co-factors associated with the occurrence of diarrhoea may be all diseases in-
volving the osmotic load, the secretion into the intestinal lumen, failure of ion
absorption and/or an altered intestinal motility [12]. PPIs are frequently used in
combination with other drugs to eradicate Hel obacter pylori (H. pylori). Most
of those regimens have diarrhoea as a commonly reported adverse event [13-15].
An analysis of co-factors such as the use of certain substances (e.g. magnesium
salts, theofylline, caffeine, laxatives) and present co-morbidity (e.g. infections,
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irritable bowel syndrome and inflammatory diseases) may lead to identification
of patients at risk of developing diarrhoea while taking lansoprazole. Therefore,
this study was set up to investigate characteristics of diarrhoea and to identify the
value of co-factors associated with diarrhoea in daily practice of lansoprazole
users, including patients of any age with various indications and underlying dis-
eases. Data were used from a large epidemiological prospective follow-up study
of lansoprazole users in daily clinical practice in The Netherlands [16].
MATERIALS AND METHODS
Design
A prospective, observational follow-up study was carried out in 10,008 naturally
occurring users of lansoprazole in the Netherlands during the first four years after
marketing in the fall of 1993 [16]. The study design included a clear separation in
time between the prescribing of the drug and the inclusion of the patient in the
study in order to minimise the influence of the study on prescribing behaviour,
according to the SAMM guidelines [17]. The overall design has been described
in detail elsewhere [16].
Data were analysed according to a nested matched case-control design with a 1:1
or 1:2 ratio for cases and controls. Retrospectively, cases were defined as lanso-
prazole users reporting diarrhoea as an adverse event. The preceding patient of
the same evaluating physician, not reporting diarrhoea during the total follow-up
period, was taken as the matched control, this was done in order to limit observer
bias [18]. In case the so-defined preceding control patient was not available, the
next available patient of the same physician served as the control.
Patients
All patients having used or currently using lansoprazole were included in the
study at the first visit or any later follow-up visit after lansoprazole was pre-
scribed. Patients agreed to participate by giving their free informed consent al-
lowing access to all relevant clinical and medication data and storage and analy-
ses of these data. No inclusion or exclusion criteria were applied other than the
use of the study drug, meaning that every lansoprazole user independent of indi-
cation could enter the study.
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Measurements
Data were collected at the inclusion visit and at each follow-up visit during lan-
soprazole therapy with a maximum follow-up of two years. The data collection
was designed not to influence normal procedures. General characteristics such as
age, gender, alcohol intake, smoking, specialism of evaluating physician, indica-
tion, daily dose of lansoprazole therapy and co-morbidity were recorded.
All (adverse) events whether considered associated or not with lansoprazole ther-
apy were documented. The severity of the adverse events was reported as per-
ceived by the physician and classified as mild, moderate, severe or unknown. The
association of the adverse event with the use of lansoprazole as assessed by the
physician was documented and coded as unlikely, possible, probable or un-
known. Where the same event occurred more than once in one patient, only the
first episode was used in the calculations. More than one event in the same class
could be coded for one patient.
In addition, for lansoprazole users reporting diarrhoea from January 1996 on-
wards, as well as for the preceding patient of the same physician, supplementary
questionnaires were completed. We received 114 completed questionnaires (re-
sponse 114/274, 41.62%), making 48 valid cases and controls (48/114, 42.1%).
Besides any history of gastrointestinal surgery, detailed information on episodes
of diarrhoea three months before lansoprazole therapy and during lansoprazole
therapy were documented. This information included consistency, colour, fre-
quency, duration, onset, accompanying symptoms (i.e. abdominal pain, blood,
mucus, fever), the effect of fasting, action taken (e.g. discontinuation, restart of
lansoprazole therapy), effects of action on diarrhoea, diarrhoea in environment
and the question if the patient had been abroad in the last three months.
Analysis
Current drug use was determined as drug use at the moment of onset of diar-
rhoea, whereas past drug use was defined as drug use during the six months prior
to the onset of diarrhoea. For each control without diarrhoea the moment of onset
of diarrhoea of the matched case was used as a reference date to estimate current
and past use of co-medication and current doses.
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Results were tabulated in absolute values and percentages. Baseline comparisons
were calculated using crude and adjusted odds ratios with a confidence interval of
95%. Adjusted odds ratios were calculated using conditional logistic regression.
Incidence densities were calculated during follow-up as the number of reported
adverse events per 1,000 patient months of exposure. The exposure period was
defined as the period from the start of therapy until the end of lansoprazole ther-
apy or the end of follow-up when still on therapy. Statistical significance was as-
sumed at p-value < 0.05. All statistical analyses were performed using SAS and
EGRET statistical packages.
RESULTS
In this study, data were used from 10,008 lansoprazole users with the aim to as-
sess the incidence and characteristics of diarrhoea and to identify the value of
cofactors associated with diarrhoea in daily practice. Diarrhoea was the most fre-
quently reported adverse event in 3.7% of the patients, the incidence density was
10.7 per 1,000 months of exposure. The reporting of diarrhoea was dose related,
although not significantly. Diarrhoea was reported in 5.0% (28/563), 3.7%
(325/8870) and 2.5% (14/566) of patients using ³ 60 mg, 30 mg and £ 15 mg
lansoprazole respectively per day (p=0.08).
All cases with diarrhoea (n=368) were compared with patients not reporting diar-
rhoea during lansoprazole therapy and evaluated by the same physician according
to a nested matched case-control design with a 1:1 or 1:2 ratio for cases and con-
trols. For 346 cases one or two matched control patients were available resulting
in 675 matched controls. Of 22 cases no matched control patient was available.
The results of this matched case-control analysis are shown in Table 1. The Odds
Ratios are adjusted by conditional logistic regression for sex, age, smoking,
drinking, dose, indication, any other adverse event and any other co-morbidity.
Specialists evaluated 52.9% of all patients, while 47.1% was seen by a general
practitioner. There were no significant differences in gender, age, smoking and
prescribed daily doses between cases and controls. Alcohol consumption was
reported slightly more frequently in cases compared to controls (adjusted OR
(95% CI): 1.5 (1.1-2.1)). Cases frequently had more ulcers compared to controls
(adjusted OR (95% CI): 1.5 (1.1-2.1)).
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Table 1
General characteristics of diarrhoea cases and matched controls
Cases Controls Crude OR Adjusted OR
N=346 % N=675 % (95% CI) (95% CI)
Women 193 55.8 363 53.8 1.1 (0.8-1.4) 1.2 (0.9-1.6)
Age (years)
   0-30 19 5.5 42 6.2     (reference)     (reference)
   30-45 57 16.5 131 19.4 1.0 (0.5-1.8) 0.9 (0.5-1.8)
   45-60 103 29.8 205 30.4 1.1 (0.6-2.0) 1.1 (0.6-1.9)
   60-75 120 34.7 217 32.2 1.3 (0.7-2.3) 1.3 (0.7-2.3)
   > 75 47 13.6 80 11.9 1.4 (0.7-2.7) 1.4 (0.7-2.8)
Smoking 89 25.7 189 28.0 0.9 (0.7-1.2) 0.9 (0.7-1.2)
   Unknown 1 0.3 0 0
Alcohol consumption 184 53.2 310 45.9 1.4 (1.0-1.8) 1.5 (1.1-2.1)
Daily PPI dose
   £ 30 mg 317 91.6 628 93.0     (reference)     (reference)
   ³ 60 mg 29 8.4 47 7.0 1.3 (0.7-2.2) 1.4 (0.7-2.8)
Indication of therapy
   GERD 215 62.1 426 63.1 0.9 (0.7-1.3) 0.9 (0.7-1.2)
   Ulcer 47 13.6 94 13.9 1.0 (0.7-1.5) 1.5 (1.1-2.1)
H. pylori eradication 47 13.6 59 8.7 2.7 (1.6-4.6) 1.4 (0.8-2.5)
Other adverse event(s) 134 38.7 172 25.5 1.9 (1.4-2.6) 0.9 (0.6-1.3)
   Other gastrointestinal 81 23.4 84 12.4 2.2 (1.5-3.1) 1.3 (0.7-2.6)
   Neurological 45 13.0 51 7.6 1.8 (1.2-2.9) 2.1 (1.5-3.0)
   Dermatological 12 3.5 25 3.7 0.9 (0.4-1.8) 1.6 (1.0-2.5)
   General 11 3.2 13 1.9 1.7 (0.7-4.1) 0.8 (0.4-1.8)
Co-morbidity (excl. acid) 134 38.7 257 38.1 1.0 (0.8-1.4) 0.9 (0.6-1.4)
   Cardiovascular 61 17.6 99 14.7 1.2 (0.9-1.8) 0.8 (0.5-1.3)
   Gastrointestinal 41 11.8 76 11.3 1.1 (0.7-1.6) 1.1 (0.7-1.6)
   Endocrine 27 7.8 44 6.5 1.2 (0.7-2.1) 1.0 (0.6-1.5)
   Musculoskeletal 19 5.5 24 3.6 1.6 (0.9-3.0) 1.2 (0.7-2.0)
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Lansoprazole therapy as part of a H. pylori eradication regimen was more com-
mon in cases than in controls. However the difference was not significant (ad-
justed OR (95% CI): 1.4 (0.8-2.5)). Of all cases 38.7% reported one or more
other adverse events compared to 25.5% of the controls (adjusted OR (95% CI):
0.9 (0.6-1.3)). Neurological adverse events (adjusted OR (95% CI): 2.1 (1.5-3.0))
and dermatological adverse events (adjusted OR (95% CI): 1.6 (1.0-2.5)) were
reported significantly more frequently by cases. Co-morbidity seemed to be well
balanced between cases and controls.
Table 2
Co-medication among diarrhoea cases and matched controls
Cases Controls Crude OR Adjusted OR
N=255 % N=473 % (95% CI) (95% CI)
Current drug use*
   Cardiovascular drugs 43 16.9 95 20.1 0.8 (0.5-1.2) 0.4 (0.2-0.8)
   - Beta-blocking drugs 15 5.9 40 8.5 0.6 (0.3-1.2) 0.3 (0.1-0.9)
   - Ace-inhibitors 8 3.1 14 3.0 1.2 (0.5-3.0) 0.9 (0.1-6.8)
   Benzodiazepines 17 6.7 37 7.8 0.9 (0.5-1.6) 0.9 (0.4-2.0)
   Oral antibiotics 14 5.5 11 2.3 2.6 (1.1-6.4) 2.7 (1.0-6.9)
   Analgesics 9 3.5 18 3.8 0.8 (0.3-2.0) 1.0 (0.4-2.7)
   NSAIDs 7 2.7 11 2.3 1.2 (0.4-3.4) 1.2 (0.4-3.9)
   Antidiarrhoea drugs 4 1.6 4 0.8 3.0 (0.5-17.0) 2.5 (0.4-15.8)
Past co-medication**
   Cardiovascular drugs 62 24.3 100 21.1 1.1 (0.7-1.7) 1.2 (0.7-2.0)
   - Beta-blocking drugs 25 9.8 41 8.7 1.2 (0.8-1.7) 2.1 (1.1-3.9)
   - Ace-inhibitors 9 3.5 15 3.2 1.0 (0.6-1.7) 1.8 (0.8-4.1)
   Benzodiazepines 45 17.6 82 17.3 1.2 (0.5-3.1) 1.6 (0.2-12.2)
   Oral antibiotics 54 21.2 114 24.1 1.0 (0.6-1.4) 1.0 (0.6-1.6)
   Analgesics 26 10.2 63 13.3 0.7 (0.4-1.1) 0.5 (0.3-0.9)
   NSAIDs 32 12.5 60 12.7 1.1 (0.6-1.8) 1.0 (0.6-1.8)
   Antidiarrhoea drugs 3 1.2 8 1.7 0.7 (0.2-3.0) 0.5 (0.1-2.4)
* current drug use: drug use at the moment of onset of diarrhoea
** past co-medication: drug use during six months prior to the onset of diarrhoea
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For a total of 255 cases and 473 controls in a ratio of 1:1 or 1:2 medication histo-
ries were retrieved. Results are shown in Table 2. The Odds Ratios are adjusted
by conditional logistic regression for sex, age, smoking, drinking, dose, indica-
tion, any other adverse event and any other co-morbidity. Table 2 shows a higher
current use of oral antibiotics in cases compared to controls (adjusted OR (95%
CI): 2.7 (1.0-6.9), while cardiovascular drug use was less frequent in cases (ad-
justed OR (95% CI): 0.4 (0.2-0.8). Analysis of co-medication in the 6 months
preceding the use of lansoprazole showed a slightly higher use of beta-blocking
drugs in cases (adjusted OR (95% CI): 2.1 (1.1-3.9) and a little lower use of an-
algesics in cases (adjusted OR (95% CI): 0.5 (0.3-0.9).
Of a subset of 48 of the 368 patients reporting diarrhoea and 48 matched patients
reporting no diarrhoea additional information was collected. The pattern of gen-
eral characteristics between the 48 cases and controls was similar with the pattern
given in Table 1.
As can be seen in Table 3, according to the physician the severity of the diar-
rhoea in the 48 cases was most frequently either mild (39.6%) or moderate
(39.6%), whereas 20.8% was characterised as severe. As assessed by the physi-
cian, 45.8% was possibly and 35.4% probably related to the lansoprazole expo-
sure. The diarrhoea was most frequently loose (66.7%), followed by watery
(31.3%) or alternately loose and watery (2.1%). The colour was lighter compared
to normal in 54.2% of cases, in 39.6% of equal colour and in the remaining cases
(6.3%) darker. The diarrhoea occurred with a mean frequency of 4.4 times per
day (min. 1, max. 16 times) and continued for 11.7 days as a mean (min. 2, max.
42 days). Accompanying symptoms were abdominal pain/cramps (41.7%), mu-
cus (12.5%), fever (2.1%) and/or blood (2.1%). None of the cases had been
abroad during the three months preceding the onset of diarrhoea and only one
case reported the occurrence of diarrhoea in his environment. Of all cases, 87.5%
(42/48) had no previous episode of diarrhoea three months before starting lanso-
prazole, compared to 95.8% (46/48) of the controls. All those previous episodes
of diarrhoea included loose stools. Of four cases the diarrhoea might be ex-
plained by present co-morbidity. One case was known with Irritable Bowel Syn-
drome in combination with diverticulitis, one with Irritable Bowel Syndrome,
one with a history of alcohol abuse and one with hypertension in combination
with diabetes mellitus. None of the controls had co-morbidity.
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Table 3
General characteristics of diarrhoea during lansoprazole intake
N=48 %
Severity of diarrhoea
   Mild 19 39.6
   Moderate 19 39.6
   Severe 10 20.8
Association of adverse event with lansoprazole
   Unlikely 9 18.8
   Possible 22 45.8
   Probable 17 35.4
Consistency of diarrhoea
   Watery 15 31.3
   Loose 32 66.7
   Alternately watery/Loose 1 2.1
Color compared to normal faeces
   Lighter 26 54.2
   Darker 3 6.3
   Equal 19 39.6
Accompanying symptoms
   Abdominal pain / cramps 20 41.7
   Mucus 6 12.5
   Blood 1 2.1
   Fever 1 2.1
Diarrhoea reason for discontinuation lansoprazole 23 47.9
All six cases reporting episodes of diarrhoea preceding and during lansoprazole
treatment noted that the diarrhoea during lansoprazole use was in general the
same as that prior to lansoprazole use (regarding consistency, colour, fr quen y
per day, accompanying symptoms). Discontinuation of therapy led to a cessation
of the diarrhoea in only one of the six patients. In 47.9% (23/48) of the cases lan-
soprazole therapy was discontinued because of the diarrhoea, leading to a dis-
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continuation of the diarrhoea in 69.6% (16/23) of cases, a reduction of the diar-
rhoea in 8.7% (2/23) and no effect in 17.4% (4/23) of the cases (one patient un-
known). In addition, 52.1% (25/48) of the patients ceased lansoprazole treatment
for other reasons and the diarrhoea discontinued in 64.0% (16/25), reduced in
16.0% (4/25) and continued in 16.0% (4/25) of the patients (one patient un-
known). In four patients with a discontinuation of the diarrhoea after stopping
therapy due to diarrhoea, lansoprazole treatment was restarted and all four r-
ported the re-occurrence of the same diarrhoea without blood, mucus and/or fe-
ver. These four patients were not familiar with diarrhoea in the past.
DISCUSSION
The main objective of this study was to investigate characteristics of diarrhoea
and to identify the value of co-factors associated with diarrhoea in lansoprazole
users in daily practice.
Data were used from a large prospective, observational follow-up study in 10,008
lansoprazole users in Dutch daily practice [16]. Diarrhoea was the most fre-
quently reported adverse event in 3.7% of the patients, the incidence density was
10.7 per 1,000 months of exposure. The frequency was comparable with results
from clinical trials with lansoprazole stating frequencies of 3.0-3.5% [7, 8]. The
incidence density was similar with available information stating an incidence
density of 9.9 from observational studies [5].
The case control analyses revealed no differences in age, gender, smoking be-
haviour, daily lansoprazole dose and co-morbidity among patients reporting diar-
rhoea compared to patients reporting no diarrhoea.  Cases used alcohol or oral
antibiotics significantly more frequently compared to controls. Excessive con-
sumption of alcohol may be associated with increased gastrointestinal symptoms,
such as diarrhoea [19]. In addition, patients reporting diarrhoea recognised sig-
nificantly more other adverse events compared to the control patients, especially
neurological and dermatological events. Lansoprazole therapy as part of a H.
pylori eradication regimen was more common in cases than in controls, although
not significantly. So in these patients, as well as in patients with the indication
ulcers, the diarrhoea might be caused partly through the use of one of the other
prescribed medicines [13-15]. This is also demonstrated by the higher current use
of oral antibiotics.
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In this study we investigated 48 patients reporting diarrhoea during lansoprazole
use in detail. As assessed by the physician, 81.2% of the onset of diarrhoea was
possibly or probably related with lansoprazole use and 60.4% was moderate or
severe. The consistency was most frequently loose (66.7%), commonly accom-
panied by abdominal pain/cramps (41.7%), the colour lighter then normal faeces
(54.2%) and occurred on average 4.4 times a day. The diarrhoea was in 47.9% of
cases the reason to discontinue lansoprazole treatment. Previous episodes of diar-
rhoea in the three months preceding the intake of lansoprazole were infrequent in
cases and controls. If present, these episodes were not related with lansoprazole
use, and could frequently be explained by present co-morbidity.
Of all patients with diarrhoea, any discontinuation of lansoprazole treatment led
to a cessation or reduction of the diarrhoea in 79.2% (38/48). So, at least a prob-
able association between the onset of diarrhoea and lansoprazole therapy was
confirmed in nearly four out of five patients with diarrhoea. Excluding patients
with previous episodes of diarrhoea led to the same figures (78.6%, 33 of 42). In
four of the patients renewed lansoprazole intake reinitiated the diarrhoea, which
confirmed a definite relationship between the intake of lansoprazole and the oc-
currence of diarrhoea.
In conclusion, diarrhoea is as frequently reported in our study as in clinical trials
and observational studies with lansoprazole. A probable relationship between the
occurrence of the diarrhoea and the use of lansoprazole was identified. A re-
challenge was positive for all four tested patients. Besides alcohol use, concomi-
tant antibiotic use and the reporting of other adverse events, no other co-factors
could be found which were associated with the onset of diarrhoea during lans-
prazole use. Although a relationship with the PPI intake seemed plausible, we
suggest that use of alcohol or antibiotics as a cause of diarrhoea must also be
taken into consideration in these patients.
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SUMMARY AND DISCUSSION
At the start of this thesis we have underlined the importance of drug safety as a
key topic in the evaluation of drug therapy outcomes. Due to the fact that drug
prescribing, the characteristics of drug users, and drug taking behaviour in real
life may be different compared to clinical trials, there is a continuous need to
monitor and evaluate what drugs do when they are used in routine daily clinical
practice [1-3]. In the choice of an appropriate study design to do so, several sce-
narios are feasible [4-6]. Essentially, one may choose out of field studies and
automated database studies [2]. The limitations of automated databases are
widely discussed in the literature [2, 7]. In case one wants to study the effects of
the early use of a new drug in the market, field studies may be the strategy of
choice because many databases have the inherited disadvantage of lack of rele-
vant clinical and lifestyle data, variability of prescribing lead ng to small num-
bers and selected patterns of early prescriptions, and a lag time between the mo-
ment of drug prescribing and availability of the data [5, 8].
The development of strategies for building field cohorts of recipients of a new
drug looks promising. However, such strategies are by nature very costly and
time consuming, and represent a risk of seeding pressure in the form of driving
prescriptions, in particular when the pharmaceutical industry is sponsoring the re-
search. The establishment of European guidelines for Safety Assessment of Mar-
keted Medicines (SAMM) in 1994 has been a major progress in improving sci-
entific standards and postmarketing surveillance practices [9]. In this context, the
initiative was taken to set up a postmarketing study (named ‘Peptic Survey’) di-
rectly after the introduction of the proton pump inhibitor (PPI) lansoprazole to
the Dutch market in the fall of 1993. In total 4-years of follow-up data was col-
lected in order to evaluate patterns of use, safety and effectiveness of this new
compound in naturally occurring groups of patients in the Netherlands (1994-
1998). In this thesis, background, concept and results of this study are presented
and discussed.
Response to PPI therapy
Major methodological aspects as well as the main results of the follow-up study
are captured in Chapter 2. Chapter 2.1 describes the design of a prospective, open
label, observational follow-up study. The design incorporated five of the six  rec-
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ommendations of the European SAMM guidelines [9]. So a population as repre-
sentative as possible of the general population was followed over time, the design
was non-interventional and there was a clear separation in time between the pr-
scribing of the drug and the inclusion of the patient in the study. Physicians could
include as stipulated in the protocol a maximum number of patients per two years
follow-up time. All Dutch general practitioners (GPs), internists and gastro-
enterologists were approached with the request to participate. In order to avoid
inclusion bias, participating physicians and pharmacists were remunerated with
only a modest fee equivalent to the reimbursement of their time spent to com-
plete the record forms or geneat  the medication histories. All patients having
used or using lansoprazole could be includ d in the study at the first visit or any
later follow-up visit after lansoprazole was prescribed by giving their written in-
formed consent. No further selection criteria or prescribing protocols were ap-
plied.
We used the total cohort to make comparisons between groups of different expo-
sure patterns (follow-up design) or between different outcomes (nested case con-
trol design). The Medical Ethics Committee of the Utrecht University Medical
Centre has approved the protocol. Patients could be identified by an identification
code only. All data and documents related to patients were kept in strict confi-
dence and in accordance with the official privacy regulations. Data were col-
lected at the inclusion visit and at each follow-up visit during lansoprazole ther-
apy, with a maximum follow-up of two years, by reviewing the medical file and
by patient questionnaire. The data collection aimed not to influence normal pro-
cedures in any way. No additional diagnostic tests were requested from the phy-
sician regarding the diagnosis and measurement of patient outcomes. Medical
data were recorded by partici ting physicians, while pharmacists provided drug
dispensing records related to the study patients. Data-entry, -validation and -
analyses were performed by an independent Contract Research Organisation.
Additionally, the overall results of the first 5,669 evaluated patients included by
374 GPs and 117 specialists regarding the safety, effectiveness and patterns of
daily use were given in this chapter.
We found that the patterns of use of lansoprazole in daily practice deviated from
the recommendations given in the patient information leaflet. The drug was also
used in patients for the treatment of ‘gastritis’, ‘dyspepsia’, ‘duodenitis’, and the
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eradication of Helicobacter pylori (H. pylori). This phenomenon has also been
reported by Bashford et al; in 1998 they found that 46% of new PPI prescriptions
were outside the licensed indications [10]. Furthermore, w  noticed that PPIs
were also prescribed in 60 mg dosage regimens, in a few pregnant women and in
complicated patients with co-morbidity and co-medication.
Nevertheless, lansoprazole was found to be safe in this naturally occurring group
of users. Specific patient groups were identified with a higher risk to develop ad-
verse events. The profile of lansoprazole users reporting adverse events could be
characterised by females, moderate alcohol users, concomitant OTC-users, and
patients with the presence of co-morbidity. With this information, patients can be
better instructed and informed about the occurrence of adverse events while us-
ing lansoprazole [11].
Effectiveness appeared to be comparable to results found in clinical trials in the
registered indications for lansoprazole. The effectiveness found in our study was
high, taking into account the fact that patients were only endoscopically exam-
ined in 50.3% of patients, that 29% of the patients did not have licensed indica-
tions and that patients with complex morbidity were included. We found similar
results for the total study group of 10,008 patients, as illustrated in Chapters 2.2
and 5.1.
In Chapter 2.2, we looked at patients not responding appropriately to lansopr-
zole treatment. As clinical trials usually demonstrate high healing rates of 85-
98%, there is growing interest in how non-response to PPI treatment in routine
daily clinical practice can be explained and understood [11, 12].
We used a matched nested case-control design to compare non-responding
(cases) and responding (controls) lansoprazole users. Non-response was defined
as worsening or non-improvement of symptoms at the first evaluation after at
least 8 weeks of use, response as disappearance or improvement of sympto s
within 8 weeks of use, or at the first evaluation after 8 weeks of use. Controls
were matched by evaluating physician. We found that an age of over 60 years,
heavy smoking and previous PPI use were strongly associated with non-response.
This knowledge that non-response to previous therapy drives non-response may
encourage physicians to follow users with previous PPI use more carefully.
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Drivers of prescriptions for lansoprazole
Chapter 3 elaborates on the question as to which factors drive the prescription of
PPIs. In Chapter 3.1 we considered the association between lansoprazole use and
exposure to NSAIDs. It is well known that NSAIDs may induce acid related dis-
orders and that PPIs are used to prevent and treat these acid related disorders in
NSAID users [13, 14]. We found that one out of five PPI prescriptions were di-
rectly NSAID-related. A history of NSAID was present in 19.4% of all PPI pre-
scriptions, whereas in 1.6% PPIs were prescribed for the reason of prevention.
Concomitant use of corticosteroids and/or anticoagulants, as well as female sex
and an age betw en 45 and 75 were revealed to be associated factors for NSAID
related PPI use.
In Chapter 3.2 we evaluated the question whether or not physicians are triggered
to prescribe a drug more frequently through participation in an industry spon-
sored postmarketing study, and whether thereby selection bias of patients may
occur. Basic characteristics of the postmarketing study group were weighed
against data of the population based PHARMO Record Linkage System which
provides a reasonably valid reference representing the Dutch market place [15].
Results indicated that physicians participating in the postmarketing study fol-
lowed one out of eight of all new lansoprazole users in the Netherlands (12.8%
based on comparison with PHARMO records). We could not find evidence of
excessive prescribing of lansoprazole by participating physicians. Expressed as a
rate fraction we calculated that overall 9% of the patients included by the GPs in
the study group, were attributable to participation in the study. The basic patient
characteristics (i.e. age, gender) of the postmarketing population were quite simi-
lar when compared with the profiles of lansoprazole users in the reference popu-
lation.
We found a slightly higher proportion of prescriptions by medical specialists
when compared to GPs. An interesting finding was that patients included in the
postmarketing study had less likelihood of being previous users of peptic ulcer
drugs (OR (95% CI): 0.6 (0.5-0.7), indicating that there was a greater likelihood
of including patients with relatively minor gastrointestinal disorders in the post-
marketing surveillance study. Nevertheless, the patterns of a slow increase in
time and the relation with the type of prescriber were identical in the reference
patients and the postmarketing study.
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Helicobacter pylori eradication therapy analyses
In Chapter 4 we investigated H. pylori eradication therapies that included lanso-
prazole. The role of PPIs in the eradication of H. pyl rihave became very im-
portant in recent years [11, 16].
Participating physicians provided data on 527 patients treated with lansoprazole
as part of H. pylori eradication therapy from 1994 until April 1998. According to
Dutch and European recommendations developed in 1996-1997, 70 to 75% of the
patients had an indication justifying H. pylori eradication, as is represented in
Chapter 4.1. These findings are consistent with the results of other studies indi-
cating that the majority of prescribers act consistently with current recom-
mendations [17]. In 83.9% of all patients a diagnostic test(s) was used prior to
treatment. In line with results of a study performed in a clinical practice setting in
the US, a considerable variation in the choice of treatment schedules was found,
22 different drug schedules were prescribed [18]. The triple combinations lanso-
prazole, clarithromycin and amoxicillin or metronidazole were used most fre-
quently (in 33.6% and 18.4% of all patients resp ctively). The recommended tri-
ple schedules were used in two out of three patients.
In a subset of the population with eradication therapies we were able to reveal
data on pre- and post testing of H. pylori (N=149). Eradication rates based on the
data in this subgroup were as high as 86.6% (129/149) and comparable with the
findings of clinical trials [11, 16, 19, 20]. Adverse events were reported in 19.4%
of all patients. During the study there was a shift from prescribing dual to (spe-
cific) triple schedules, whereas quadruple schedules showed a small increase in
use up to 20-30%. In general, GPs were slower in prescribing H. pylori eradica-
tion therapies compared to specialists, reflecting a more conservative practice
style in general practice [21]. In line with this we found that specialists were also
more likely to do pre- and post testing of H. pyl ri. The medley of prescribed
eradication schedules and the variability of indications of treatments showed that
there was ample confusion at the time of the study on how to approach H. pylori
infections. Today, (inter)national guidelines provide a useful framework for deci-
sion making in clinical practice [22]. The justification for post testing is still a
matter of discussion [23]. As eradication rates are usually high, the necessity of
post eradication confirmation could be of minor importance.
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Chapter 4.2 examined continued use of PPIs following H. pylori eradication.
Therapies combining antibiotics and PPIs have shown to be effective in clinical
trials to eradicate H. pylori n peptic ulcer patients. Triple and quadruple thera-
pies provide the highest eradication rates of >90%, while for dual therapies over-
all eradication rates with a maximum of 60-80% are commonly accepted [11, 16,
18-20]. We evaluated restarting treatment with PPIs after eradication was com-
pleted and found that 41.1% of patients indeed did. The occurrence of GERD in
the diagnosis could be an explaining factor, but even in one out of three peptic
ulcer patients without GERD and treated with triple or quadruple therapies, we
found continuation of PPI treatment. So far, there is no evidence that eradication
schemes including lansoprazole as PPI are less efficacious. Additional research is
necessary to investigate the impact of non-compliance and possibly other deter-
minants on continued PPI use.
Safety of PPI treatment
Chapter 5 discusses the safety of lansoprazole. In Chapter 5.1 data on the overall
safety profile of lansoprazole in daily practice is presented. 805 GPs and 266
specialists included a total of 10,008 lansoprazole users with a broad range of
diagnoses. Of all patients, 17.4% reported one or more adverse events. The pro-
file and frequency of reported adverse events was consistent with results from
clinical trials and other observational studies [24-27]. The most frequently re-
ported adverse events were diarrhoea, headache, nausea, skin disorders, dizziness
and generalised abdominal pain/cramps. Regarding rare adverse events, such as
dry mouth, gynaecomastia and blindness/severe vision disorders, we found com-
parable profiles as described with PPIs in literature [28-34]. Furthermore, no lan-
soprazole related unlabelled adverse event of any clinical significance was re-
corded. In line with Weber’s theory, we found that the reporting of adverse
events related to lansoprazole did not proceed at a uniform rate, higher rates pr-
vailed soon after marketing with a stable lower pattern occurring after two years
[35].
In Chapter 5.2, a study is described with the aim to assess the incidence and
characteristics of headache and to investigate possible associated co-factors in
PPI users in daily practice. In clinical trials, headache is one of the most fre-
quently reported adverse events (frequency 1.3-8.8%), while results of an obser-
vational study indicate that headache is the fifth most frequently reported adverse
Summary and discussion
173
event (incidence densities 2.5-4.6 per 1,000 patient months of exposure) during
PPI use [11, 24-26, 36, 37]. However, there are no specific observational studies
performed regarding the occurrence and features of headache during use of PPIs
in daily practice. We showed that the frequency of headache was 2.5%. As can
be expected, headache was reported less frequently in this study compared to
clinical trials with lansoprazole [11]. The incidence density was 7.2 per 1,000
patient months of PPI use and so comparable with other observational data of
lansoprazole and omeprazole users [26]. Tension headache was seen in two out
of three patients with headaches. Using a matched case-control design, patients
reporting headache or not, were compared. Besides several commonly accepted
co-factors such as female gender and a history of analgesic use, we also found
the reporting of other adverse events to be associated with the reporting of head-
ache during lansoprazole use [38, 39]. Patients with headache also significantly
more often reported diarrhoea, nausea and dizziness. The cessation of headache
after discontinuation of PPI use and the found dose relationship, suggested that
headache was indeed a side-effect of lansoprazole use.
Diarrhoea is also a frequently reported adverse event during PPI use in any set-
ting [24, 25]. Because of the limited information available, a study was set up
with the aim to assess the incidence and characteristics of diarrhoea and to inves-
tigate possible associated co-factors in PPI users in daily practice [40]. As given
in Chapter 5.3, the frequency of diarrhoea was 3.7% and the incidence density
10.7 per 1,000 patient months of PPI use, and comparable with results of clinical
trials and observational data of lansoprazole users [11, 24-26]. The diarrhoea was
most commonly loose and occurred on average 4.4 times per day. We used a
matched nested case-control design to compare patients reporting diarrhoea with
patients not reporting diarrhoea. The analysis of co-factors revealed that patients
with alcohol use, concomitant use of oral antibiotics and patients reporting sev-
eral adverse events, were at risk to develop diarrhoea during PPI use. Excessive
consumption of alcohol may be associated with increased gastrointestinal symp-
toms, such as diarrhoea [41]. Lansoprazole therapy as part of a H. pylo i eradica-
tion regimen was in cases more common than in controls, although not signifi-
cantly. So in these patients, as well as in patients with the indication ulcers, the
diarrhoea might be caused partly through the use of one of the other prescribed
medicines i.e. antibiotics [42-44]. This is also demonstrated by the higher current
use of oral antibiotics. A de-challenge was positive in 80.0% (38/48) and a re-
challenge in 100% (4/4). Although a relationship with the PPI intake seemed
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very plausible, we suggest that use of alcohol or antibiotics as a cause of diar-
rhoea must also be taken into consideration in lansoprazole users.
CONCLUSIONS
The series of studies captured in this thesis have one common source, a prospec-
tive, open label, follow-up study to evaluate patterns of use, safety and effective-
ness of the PPI lansoprazole in a naturally occurring group of patients in the
Netherlands (1994-1998). Of a population of over 10,000 patients starting trea-
ment with lansoprazole, data on medical history, co-morbidity, drug use, disease
course and clinical follow-up have been collected. Clinical record forms of this
cohort have been completed representing in total 35,000 users-months of follow-
up. Indeed, a very time consuming and costly operation, resulting in a wealth of
data and opportunities to study specific questions related to the postmarketing of
a new drug. In this case a PPI: lansoprazole.
The study was designed and performed according to the SAMM guidelines.
Briefly, this means basically no in- or exclusion criteria with respect to patient
enrolment in the study, a modest remuneration for participating physicians and,
most importantly, a separation in time between the moment of prescription of the
study drug (i.e. lansoprazole) and the moent of inclusion of the patient in the
study in order to avoid seeding prescriptions. By doing so, a large cohort of
10,008 patients was constructed and followed over time. The highest standards of
professional conduct and confidentiality were maintained throughout the study.
What have we learned from all this?
A primary interest of the study was to evaluate patterns of use of lansoprazole.
The drug has been used for a variety of indications, frequently also beyond the
official labelling of peptic ulcer and reflux oesophagitis. The study on the seed-
ing of prescriptions revealed that in the limited number of cases when seeding
was seen it most likely occurred in patients with relatively minor peptic disor-
ders, including unlicensed indications. One out of five lansoprazole prescripti ns
was NSAID related. The use of corticosteoids, anticoagulants, female gender
and an age between 45 and 70 years were strongly associated with NSAID in-
duced PPI-use. Awareness of the increasing risk to develop acid related disorders
during NSAID use has been increased during the study period.
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Lansoprazole was used in many different combinations with the aim to eradicate
H. pylori. The medley of prescribed eradication schedules and the large variety in
pre- and post testing for the existence of H. pyl ri confirmed a great need for
guidelines and protocols to ensure treatment success. Both international and na-
tional guidelines are now in place. It was a peculiar finding that many patients
with H. pylori eradication continued lansoprazole treatment (41.1%). Even one
out of three peptic ulcer patients without GERD and treated with triple or quad-
ruple therapies had continued PPI use after H. pylo i eradication therapy. This
result has been repeatedly found in other studies, and represents an important
message for today’s pharmacotherapy in not being too optimistic in achieving
expected benefits of new therapies.
Regarding safety, we found that 17.4% of all studied patients reported adverse
events. No unlabelled events were detected. The profile and frequency of occur-
rence were analogous to results of clinical trials and other observational studies.
The reporting rates of adverse events decreased in time. We found that certain
patients had a higher risk to develop adrse events, namely women, alcohol
consumers, OTC-users and patients with co-morbidity. The type of headache
during PPI use seemed to be most often tension headache and the occurrence was
associated with female gender, a history of analgesic use and the tendency of also
reporting other adverse events. The onset of diarrhoea during PPI use was related
with the reporting of other adverse events, alcohol use and the concomitant use of
antibiotics, an important finding for ensuring treatment compliance with H. py-
lori eradication schemes including antibiotics.
The main findings of our observational study were in accordance with the results
of clinical trials and observational studies with lansoprazole and other PPIs, both
in terms of effectiveness and safety. In addition, we were able to gain more in
depth insight into the patterns of use of a new drug launched on the Dutch mar-
ket. Peptic Survey was designed as a field follow-up study bringing data from
various sources (e.g. medical charts, clinical record forms, pharmacy records,
patient questionnaires) together in one research database. This approach is most
appealing when prescribing of a new drug is highly variable at the moment of
product launch in the market place and when drug exposure is not yet sufficiently
covered by automated databases. A major concern remains the costs and time
burden of building such large cohorts of recipients of a new drug in the market.
Industry will continue to play a major role in funding these studies. A critical
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appraisal of a possible conflict of interest remains necessary [45]. Fortunately,
some recent examples of such cohort studies, both field and database driven,
have shown the feasibility of achieving an acceptable balance of industry and
scientific interests in conducting postmarketing research [46-49]. The post-
marketing project described in this thesis certainly does not represent a panacea
for solving all problems, but has surely contributed to the knowledge base of
conducting sound postmarketing studies of new drugs.
Summary and discussion
177
REFERENCES
1. Moore TJ, Psaty BM, Furberg CD. Time to act on drug safety. JAMA
1998;279:1571-3.
2. Storm BE (ed). Pharmacoepidemiology. Chichester: John Wiley & Sons,
third edition, 2000.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in
hospitalized patients. JAMA 1998;27 :1200-5.
4. Jick H, Garcia Rodriguez LA, Pérez-Gutthann S. Principles of epidemiologi-
cal research on adverse and beneficial drug effects. Lancet 1998;352:1767-
70.
5. Stricker BHCh, Barendregt M, Herings RMC, Jong-van den Berg LTW de,
Cornel MC, Smet PAGM de. Ad hoc tracing of a cohort of patients exposed
to acitretine (Neotigason) on a nation wide scale. Eur J Clin Pharmacol
1992;42:555-7.
6. Egberts AC, Meyboom RH, Koning GH de, Bakker A, Leufkens HG. Non-
puerperal lactation associated with antidepressant drug use. Br J Clin Phar-
macol 1997;44:277-81.
7. Shapiro S. The role of automated record linkage in the postmarketing sur-
veillance of drug safety: a critique. Clin Pharmacol Ther 1989;46:371-86.
8. Feenstra J, Veld BA in 't, Linden PD van der, Grobbee DE, Stricker BH.
Risk factors for mortality in users of ibopamine. Br J Clin Pharmacol
1998;46:71-7.
9. Waller PC, Wood SM, Breckenridge AM, Rawlins MD. Why the Safety As-
sessment of Marketed Medicines (SAMM) guidelines are needed. Br J Clin
Pharmacol 1994;38:95-7.
10. Bashford JNR, Norwood J, Chapman SR. Why are patients prescribed proton
pump inhibitors? Retrospective analysis of link between morbidity and pre-
scribing in the General Practice Research Database. BMJ 1998;317:452-6.
11. Langtry HD, Wilde MI. Lansoprazole. An update of its pharmacological
properties and clinical efficacy in the management of acid-related disorders.
Drugs 1997;54:473-500.
12. Leufkens H, Claessens A, Heerdink E, Eijk J van, Lamers C. A prospective
follow-up study in 5,669 users of lansoprazole in daily practice. Aliment
Pharmacol Ther 1997;11:887-97.
Chapter 6
178
13. La Corte R, Caselli M, Castellino G, Bajocchi G, Trotta F. Prophylaxis and
treatment of NSAID-induced gastroduodenal disorders. Drug Saf
1999;20:527-43.
14. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal
complications related to use of nonster idal anti-inflammatory drugs. A
meta-analysis. Ann Intern Med 1991;1 5:787-96.
15. Herings RMC, Stricker BHCh, Nap G, Bakker A. Pharmaco-m rbidity link-
age: a feasibility study comparing morbidity in two pharmacy-based expo-
sure cohorts. J Epid Comm Health 1992;46:136-40.
16. Penston JG, McColl KEL. Eradication of Helicobacter pylori: an objective
assessment of current therapies. Br J Clin Pharmacol 1997;43:223-43.
17. Zoorob RJ, Jones GN, Mainous AG 3rd, Hagen MD. Practice patterns for
peptic ulcer disease: are family physicians testing for Helicobacter pylori?
Helicobacter 1999;4:243-8.
18. Fennerty MB, Lieberman DA, Vakil N, Magaret N, Faigel DO, Helfand M.
Effectiveness of Helicobacter pylori therapies in a clinical pr ctice setting.
Arch Intern Med 1999;159:1562-6.
19. Boer WA de, Etten RJXM van, Schade RWB, Ouwehand ME, Schneeberger
P, Tytgat GNJ. 4-Day lansoprazole quadruple therapy: a highly effective cure
for Helicobacter pylori infection. Am J Gastroenterol 1996;91:1778-82.
20. Hulst RWM van der, Keller JJ, Rauws EAJ, Tytgat GNJ. Treatment of
Helicbacter pylori infection in humans: a review of world literature. Helico-
bacter 1996;1:6-19.
21. Fendrick AM, Hirth RA, Chernew ME. Differences between generalist and
specialist physicians regarding Helicobacter pylori and peptic ulcer disease.
Am J Gastroenterol 1996; 1:1544-8.
22. Anonymous. Current European concepts in the management of H. pylori in-
fection. The Maastricht Consensus Report. European H. pylori Study Group.
Gut 1997;41:8-13.
23. Bodger K, Heatley RV. Testing to check success of treatment to eradicate
Helicobacter pylori. BMJ 1996;312:1361-2.
24. Colin-Jones DG. Safety of lansoprazole. Aliment Pharmacol Ther 1993;7
Suppl:56-60.
25. Colin-Jones DG. Safety of lansoprazole. Br J Clin Pract 1994;Suppl 75:58-
66.
26. Freemantle SN, Pearce GL, Wilton LV, Mackay FJ, Mann RD. The inci-
dence of the most commonly reported events with 40 newly marketed drugs -
Summary and discussion
179
a study by Prescription-Event Monitoring. Pharmacoepidemiol Drug Saf
1997;6;Suppl 1:1-52.
27. Freston JW, Rose PA, Heller CA, Haber M, Jennings D. Safety profile of
lansoprazole. The US Clinical Trial Experience. Drug Saf 1999;20:195-205.
28. Teare JP, Spedding C, Whitehead MW, Greenfield SM, Challacombe SJ,
Thompson RPH. Omeprazole and dry mouth. Scand J Gastroenterol
1995;30:216-8.
29. Garcia Rodriguez LA, Jick H. Risk of gynaecomastia associated with cimet-
idine, omeprazole, and other antiulcer durgs. BMJ 1994;308:503-6.
30. Garcia Rodriguez LA, Wallander M, Stricker BHCh. The risk of acute liver
injury associated with cimetidine and other acid-suppressing anti-ulcer drugs.
Br J Clin Pharmacol 1997;43:183-8.
31. The ADR signals analysis project (ASAP) team: Lindquist M, Pettersson M,
Edwards IR, Sanderson J, Taylor N, Fletcher P et al. Omeprazole and visual
disorders: seeing alternatives. Pharmacoepidemiol Drug Safety 1996;5:27-
32.
32. Garcia Rodriguez LA, Mannino S, Wallander M, Lindblom B. A cohort
study of the ocular safety of anti-ulcer drugs. Br J Clin Pharmacol
1996;42:213-216.
33. Schönhöfer PS, Werner B. Ocular damage associated with proton pump in-
hibitors. BMJ 1997;314:1805.
34. Meier CR, Jick H. Omeprazole, H2-blockers and polyarthralgia: case-control
study. BMJ 1997;315:1283.
35. Weber JCP. Epidemiology of adverse reactions to nonsteroidal antiinflam-
matory drugs. In: Rainsford KD, Velo G (eds). Side effects of antiinflam-
matory/analgesic drugs. New York: Raven Press 1984;6:1-7.
36. Fitton A, Wiseman L. Pantoprazole. A review of its pharmacological proper-
ties and therapeutic use in acid-related disorders. Drugs 1996;51:460-82.
37. Langtry HD, Markham A. Rabeprazole. A review of its use in acid-related
gastrointestinal disorders. Drugs 1999;58:725-42.
38. Olesen J. Analgesic headache. BMJ 1995;3 0:479-80.
39. Rasmussen BK. Epidemiology of headache. Cephalalgia 1995;15:45-68.
40. Miwa LJ, Jones JK, Pathiyal A, Hatoum H. Value of epidemiologic studies
in determining the true incidence of adverse events. The non-steroidal anti-
inflammatory drug story. Arch Int Med 1997;157:2129-36.
Chapter 6
180
41. Fields JZ, Turk A, Durkin M, Ravi NV, Keshavarzian A. Increased gastro-
intestinal symptoms in chronic alcoholics. Am J Gastroenterol 1994;89:382-
6.
42. Bayerdorffer E, Lind T, Dite P, Bardhan KD, O'Morain C, Delchier JC et al.
Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter
pylori infection. Eur J Gastroenterol Hepatol 1999;11:Suppl 2:S19-22;Dis-
cussion S23-4.
43. Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S et al. Impact of
rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter
pylori infection – comparison with omeprazole and lansoprazole. Aliment
Pharmacol Ther 1999;13:741-6.
44. Pohle T, Stoll R, Kirchner T, Heep M, Lehn N, Bock H et al. Eradication of
Helicobacter pylori with lansoprazole, roxithromycin and metronidazole – an
open pilot study. Aliment Pharmacol Ther 1998;12:1273-8.
45. Leufkens HG, Urquhart J. Prescriber profile and postmarketing surveillance
[Letter]. Lancet 1993;342:1178.
46. Speirs C, Wagniart F, Poggi L. Perindopril postmarketing surveillance: a 12
month study in 47,351 hypertensive patients. Br J Clin Pharmacol
1998;46:63-70.
47. Staa TP van, Leufkens H, Abenhaim L, Cooper C. Postmarketing surveil-
lance of the safety of cyclic etidronate. Pharmacotherapy 1998;18:1121-8.
48. Wehnert A. The European Post-marketing Observational Serdolect (EPOS)
Project: increasing our understanding of schizophrenia therapy. Int Clin Psy-
chopharmacol 1998;13 Suppl 3:S27-30.
49. Gracon SI, Knapp MJ, Berghoff WG, Pierce M, DeJong R, Lobbestael SJ,
Symons J, Dombey SL, Luscombe FA, Kraemer D. Safety of tacrine: clinical
trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc
Disord 1998;12:93-101.
Samenvatting
Samenvatting
183
SAMENVATTING
In hoofdstuk 1 van dit proefschrift hebben we het grote belang van de veiligheid
van geneesmiddelen bij het evalueren van geneesmiddelengebruik onderstreept.
Het voorschrijven van geneesmiddelen, de kenmerken van de gebruikers en de
wijze van gebruik kunnen in de dagelijkse klinische praktijk afwijken van de si-
tuatie in klinisch onderzoek. Daarom is er continu behoefte aan het bewaken en
evalueren van hetgeen geneesmiddelen doen in de dagelijkse klinische praktijk.
Er zijn verschillende scenario’s met betrekking tot de opzet van een onderzoek
toepasbaar.
Men kan kiezen tussen veldonderzoek en onderzoek met geautomatiseerde gege-
vensbestanden. De beperkingen van onderzoek met geauto a iseerde gegevens-
bestanden zijn uitgebreid beschreven in de literatuur. Indien men onderzoek wil
doen naar de effecten van het eerste gebruik van een recent op de markt geïntro-
duceerd geneesmiddel heeft veldonderzoek de voorkeur. Geautomatiseerde gege-
vensbestanden hebben namelijk als nadeel dat belangrijke klinische gegevens
ontbreken, dat door de grote variatie in voorschrijven er sprake is van kleine
aantallen en geselecteerde vroege voorschriften en er een vertraging is tussen het
moment van voorschrijven en de beschikbaarheid van de gegevens.
De ontwikkeling van methoden voor de opzet van veldonderzoek met groepen
gebruikers van nieuwe geneesmiddelen lijkt veelbelovend. Echter, deze metho-
den zijn van nature kostbaar, nemen veel tijd in beslag en met name bij onder-
zoek dat door de farmaceutische industrie wordt gesponsord kan dit leiden tot een
stimulatie van het voorschrijven, ook wel ‘seeding’genoemd. De totstandkoming
van Europese richtlijnen voor het vaststellen van de veiligheid van geregistreerde
geneesmiddelen (SAMM) in 1994 heeft een grote bijdrage geleverd in het ver-
beteren van wetenschappelijke standaarden en de praktijk van postmarketing sur-
veillance. In deze context is het initiatief genomen voor de opzet van de postmar-
keting studie (genaamd ‘Peptic Survey’) direct na de introductie van de proton
pomp remmer (PPI) lansoprazol in het najaar van 1993. Gedurende 4 jaren zijn
(vervolg-)gegevens verzameld ten einde de patronen van gebruik, de veiligheid
en de effectiviteit van dit nieuwe geneesmiddel te evalueren bij gebruikers in de
dagelijkse klinische praktijk in Nederland (1994-1998). In dit proefschrift wor-
den de achtergronden en resultaten van deze studie weergegeven en bediscussi-
eerd.
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Reactie op PPI therapie
De belangrijkste methodologische aspecten alsmede de algemene resultaten van
de follow-up studie zijn beschreven in hoofdstuk 2. In hoofdstuk 2.1 wordt de
opzet van de prospectieve, open label, observationel  follow-up studie weerge-
geven. In de opzet was rekening gehouden met de Europese SAMM richtlijnen.
Dit betekent dat een groep zo representatief als mogelijk voor de algemene po-
pulatie was gevolgd in de tijd. De studie was zonder interventies en er was een
duidelijke scheiding in de tijd tussen het voorschrijven van het geneesmiddel en
de insluiting van de patiënt in de studie. De artsen mochten een bepaald maxi-
mum aantal patiënten insluiten per twee jaar follow-up, zoals vermeld in het
protocol. Alle Nederlandse huisartsen, internisten en gastro-enterologen werden
benaderd voor deelname. Om bias in de deelname te voorkomen, werden de
deelnemende artsen en apothekers beloond met een bescheiden bijdrage, een t-
gemoetkoming voor de tijd nodig voor het invullen van de gegevens of het ver-
vaardigen van de medicatie-overzichten. Alle patiënten die lansoprazol gebruik-
ten of hadden gebruikt konden worden ingesloten in de studie bij het eerste of
een volgend bezoek nadat lansoprazol was voorgeschreven en mits schriftelijk
toestemming was verkregen. Andere selectie-criteria of voorschrijfprotocollen
waren niet van toepassing.
We hebben de totale groep deelnemers gebruikt om vergelijkingen te maken tus-
sen groepen met verschillende blootstellingen (follow-up opzet) en verschillende
uitkomsten (genest case-control-onderzoek). De Medisch Ethische Commissie
van het Utrecht Universit it Medisch Centrum had het protocol goedgekeurd.
Patiënten konden alleen door een identificatie code worden geïdentificeerd. Alle
gegevens en patiënt gerelateerde documenten werden vertrouwelijk behandeld in
overeenstemming met de officiële privacy regelgeving. Gegevens werden verza-
meld tijdens het bezoek waarbij de patiënt in de studie werd ingesloten en de
daaropvolgende bezoeken gedurende lansoprazol gebruik met een maximum van
twee jaar follow-up. Dit werd gedaan door middel van het bestuderen van de me-
dische status en vragenlijsten voor de patiënt. Het streven was om de normale
procedures op geen enkele wijze tijdens de gegevensverzameling te beïnvloeden.
De arts werd niet verzocht om extra diagnostische testen uit te voeren voor het
vaststellen van de diagnose of de effecten. De medische gegevens werden vast-
gelegd door de deelnemende artsen, terwijl de apothekers zorg droegen voor de
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geneesmiddelenoverzichten van de patiënten. De gegevens werden door een on-
afhankelijke Contract Research Organisatie ingevoerd in een databestand, gev-
lideerd en geanalyseerd. In hoofdstuk 2.1 werden verder de algemene resultaten
met betrekking tot de veiligheid, effectiviteit en de patronen van dagelijks ge-
bruik getoond van de eerste 5.669 geëvalueerde patiënten die door 374 huisartsen
en 117 specialisten waren ingesloten. We zagen dat de patronen van lansoprazol
gebruik afweken van de aanbevelingen in de IB1-tekst. Het geneesmiddel werd
namelijk ook gebruikt voor de behandeling van ‘gastritis’, ‘dyspepsia’, ‘duode-
nitis’, en de eradicatie van Helicobacter pylori (H. pylori). Verder registreerden
we voorschriften van lansoprazol in een dosis van 60 mg, bij een aantal zwangere
vrouwen en bij gecompliceerde patiënten met co-morbiditeit en gebruik van co-
medicatie. Desondanks bleek lansopr zol bij deze groep gebruikers in de dage-
lijkse klinische praktijk veilig. Er werden specifieke patiënten groepen geïdenti-
ficeerd met een groter risico voor het optreden van bijwerkingen. Lansoprazol
gebruikers die bijwerkingen rapporteerden waren vrouwen, matig alcohol ge-
bruikers, gelijktijdig OTC gebruikers en patiënten met co-morbiditeit. Met de
verkregen informatie kunnen patiënten beter worden geïnstrueerd en voorgelicht
over het optreden van bijwerkingen tijdens lansoprazol gebruik. De effectiviteit
bleek vergelijkbaar met de resultaten gevonden in klinisch onderzoek bij de ge-
registreerde indicaties. De effectiviteit in onze studie was hoog, met name gezien
het feit dat slechts 50.3% endoscopisch was onderzocht, dat 29% van de patiën-
ten een indicatie buiten de geregistreerde indicaties had en dat patiënten met
complexe morbiditeit ingesloten waren. We vonden dezelfde resultaten voor de
totale groep van 10.008 patiënten, zoals weergegeven in hoofdstukken 2.2 en 5.1.
In hoofdstuk 2.2 keken we naar patiënten die niet adequaat reageerden op de
lansoprazol behandeling. Omdat klinisch onderzoek veelal hoge genezingsper-
centages toont van 85-98%, is er een toenemende interesse hoe het niet-reageren
op een PPI behandeling in de dagelijkse klinische praktijk verklaard kan worden.
We hebben gebruik gemaakt van een genest case-control-onderzoek met mat-
ching om niet-reagerende (cases) en reagerende (controles) gebruikers van lanso-
prazol te vergelijken. Het niet-reageren was gedefinieerd als het verslechteren of
niet verbeteren van de symptomen bij de eerste evaluatie na tenminste 8 weken
van behandeling, terwijl reageren was gedefinieerd als het verdwijnen of verbete-
ren van de symptomen bij de eerste evaluatie binnen 8 weken van behandeling of
bij de eerste evaluatie na 8 weken van therapie. Controle patiënten werden ‘ge-
matched’ op evaluerende arts. We vonden dat een leeftijd boven de 60 jaar, hevig
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roken en gebruik van PPI's in het verleden sterk waren geassocieerd met het niet-
reageren. Deze kennis dat het niet-reageren op een PPI het niet-reageren stimu-
leert kan de arts gebruiken bij het zorgvuldig vervolgen van patiënten die al eer-
der een PPI gebruikten.
Stimuleren van voorschriften van lansoprazol
Hoofdstuk drie gaat in op de vraag welke factoren het voorschrijven van PPI's
stimuleren. In hoofdstuk 3.1 wordt de associatie tussen lansoprazol gebruik en de
blootstelling aan NSAID's belicht. Het is welbekend dat NSAID’s zuurgerela-
teerde afwijkingen kunnen induceren en dat PPI's worden toegepast bij de pre-
ventie en behandeling van deze zuurgerelateerde afwijkingen bij NSAID's ge-
bruikers. We vonden dat één op de vijf PPI voorschriften direct gerelateerd was
aan NSAID's. Inductie door NSAID gebruik verklaarde 19,4% van alle PPI voor-
schriften, terwijl bij 1,6% van alle PPI voorschriften preventie de indicatie van
het PPI gebruik was. Gelijktijdig gebruik van corticosteroïden en/of anticoagu-
lantia, het vrouwelijk geslacht en een leeftijd tussen de 45 en 75 bleken factoren
te zijn die samenhingen met NSAID gerelateerd PPI gebruik.
In hoofdstuk 3.2 evalueerden we de vraag of artsen aangezet worden tot het voor-
schrijven van medicatie door deelname aan een door de industrie gesponsorde
postmarketing studie en of hierbij selectie-bias van patiënten was opgetreden.
Algemene kenmerken van de postmarketing studie groep werden gelegd naast
gegevens van het PHARMO Record Linkage System. De resultaten gaven aan
dat de artsen die deelnamen aan de postmarketing studie één op de acht (12,8%)
van alle nieuwe Nederlandse lansoprazol gebruikers evalueerden. We konden
geen aanwijzigingen vinden voor het overmatig voorschrijven van lansoprazol
door de deelnemende artsen. We berekenden dat in het algemeen 9% van de door
huisartsen ingesloten patiënten kon worden toegeschreven aan de deelname aan
de studie. De basale kenmerken van de patiënten van de postmarketing populatie
waren vrij vergelijkbaar (bijv. leeftijd, geslacht) met het profiel van de lansopra-
zol gebruikers in de referentie groep. We vonden een gering groter aandeel voor-
schriften bij medisch specialisten in vergelijking met huisartsen. Een interessante
bevinding was dat onze patiënten de zes maanden voorafgaand aan de postmar-
keting studie minder vaak geneesmiddelen voor de behandeling van peptische
ulcera hadden gebruikt (OR (95% BI): 0,6 (0,5-0,7)). Dit geeft aan dat waar-
schijnlijk meer patiënten met relatief milde gastro-intestinale afwijkingen in de
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postmarketing studie zijn ingesloten. Desondanks waren de patronen van een
langzame toename in de tijd en de relatie met het type voorschrijver identiek tus-
sen de referentie groep en de postmarketing studie.
Analyse van Helicobacter pylori eradicatie therapie
In hoofdstuk vier onderzochten we H. pylori therapieën waarin ook lansoprazol
werd gebruikt. De rol van H. pylori en de rol van PPI's bij de eradicatie van H.
pylori is de afgelopen jaren zeer belangrijk geworden. De deelnemende artsen
hebben gegevens verzameld van 527 patiënten die met lansoprazol werden be-
handeld als onderdeel van een H. pylori eradicatie therapie in de periode januari
1994 tot april 1998. Volgens de Nederlandse en Europese aanbevelingen, ont-
wikkeld in 1996-1997, had 70 tot 75% van de patiënten een indicatie waar een H.
pylori eradicatie voor nodig was. Dit is weergegeven in hoofdstuk 4.1. In 83,9%
van alle patiënten was er een diagnostische test(en) voor aanvang van de behan-
deling verricht. De triple combinaties lansoprazol, clarithromycine en amoxicilli-
ne of metronidazol werden het meest toegepast (respectievelijk in 33,6% en
18,4% van alle patiënten). De aanbevolen triple combinatie werd bij twee van de
drie patiënten gebruikt.
In een subgroep van de populatie met een eradicatie therapie hadden we infor-
matie over het testen op H. pylori (N=149) voor aanvang of na behandeling. De
eradicatiepercentages, uitgaande van de gegevens in deze subgroep, waren hoog
met 86,6% (129/149) en vergelijkbaar met de bevindingen uit klinisch onder-
zoek. Bijwerkingen werden gemeld door 19,4% van alle patiënten. Gedurende de
studie was er een verschuiving van voorgeschreven dual naar (specifieke) triple
schema's, terwijl quadruple schema's een geringe toename in gebruik van 20-30%
lieten zien. In het algemeen liepen de huisartsen achter op de specialisten in het
voorschrijven van H. pylori eradicatie therapieën. Overeenkomstig vonden we
dat specialisten meer geneigd waren om voor aanvang- of na behandeling op de
aanwezigheid van H. pylori te testen. De variatie in voorgeschreven schema's en
de variatie in indicaties voor behandeling lieten ons zien dat er ten tijde van de
studie veel verwarring bestond over de wijze waarop H. pylori infecties aange-
pakt diende te worden.
Hoofdstuk 4.2 gaat in op voortdurend gebruik van PPI’s na H. pylorieradicatie.
Uit klinisch onderzoek is gebleken dat combinatietherapieën van antibiotica met
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PPI’s effectief zijn voor eradicatie van H. pylori bij patiënten met peptische ulce-
ra. Triple en quadruple therapieën hebben de hoogste eradicatie-percentages
(>90%), terwijl dual therapieën in het algemeen een eradicatie-percentage van
maximaal 60-80% hebben. We hebben gekeken naar een nieuwe behandeling
met PPI’s na eradicatie en we zagen dit in 41,1% van de patiënten. De diagnose
GERD kan hierbij een verklarende factor zijn, maar desondanks vonden we bij
één op de drie patiënten met peptische ulcera zonder GERD en behandeld met
triple of quadruple schema’s, een voortzetting van de PPI behandeling. Tot nu toe
is er nog geen aanleiding om te veronderstellen dat eradicatie-schema’s waarbij
lansoprazol als PPI wordt toegepast minder effectief zijn. Extra onderzoek is
noodzakelijk om het effect van non-compliance en andere mogelijke bepalende
factoren voor het voortzetten van PPI gebruik te bestuderen.
Veiligheid van PPI behandeling
Hoofdstuk 5 bediscussieert de veiligheid van lansoprazol. In hoofdstuk 5.1 wordt
het algemene veiligheidsprofiel van lansoprazol in de dagelijkse klinische prak-
tijk gepresenteerd. 805 huisartsen en 266 specialisten hebben in totaal 10.008
lansoprazol gebruikers ingesloten met een scala aan diagnoses. Van alle patiën-
ten, rapporteerde 17,4% één of meer bijwerkingen. Het profiel en de frequentie
van de gerapporteerde bijwerkingen kwam overeen met d  r sultaten uit klinisch
onderzoek en andere observationele studies. De meest frequent gemelde bijwer-
kingen waren diarree, hoofdpijn, misselijkheid, huidafwijkingen, duizeligheid en
algemene buikpijn/buikkrampen. Met betrekking tot zeldzame bijwerkingen, zo-
als droge mond, gynaecomastie en blindheid/ernstige visus stoornissen, werden
er identieke profielen gevonden zoals beschreven in de literatuur over PPI’s.
Verder werden geen onbekende lansoprazol gerelateerde bijwerkingen van kli-
nisch belang gemeld. Overeenkomstig de theorie van Weber vonden we dat het
melden van bijwerkingen, gerelateerd aan lansoprazol, in de loop van het onder-
zoek veranderde. Direct na marketing waren er relatief meer meldingen terwijl na
twee jaar het aantal afn m en stabiliseerde.
In hoofdstuk 5.2, wordt een studie beschreven bij PPI gebruikers in de dagelijkse
klinische praktijk met als doel de incidentie en de kenmerken van hoofdpijn te
bepalen en mogelijk gerelateerde co-factoren op te sporen. In klinisch onderzoek
gedurende PPI gebruik is hoofdpijn één van de meest frequent gerapporteerde
bijwerkingen (frequentie 1,3-8,8%), terwijl resultaten van een observationele
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studie aangeven dat hoofdpijn de vijfde bijwerking in voorkomen is (incidenti-
cijfer 2,5-4,6 per 1.000 patiënt maanden van blootstelling). Er zijn echter geen
observationele studies uitgevoerd naar het voorkomen en de kenmerken van
hoofdpijn bij PPI gebruik in de dagelijkse klinische praktijk. We vonden een fre-
quentie van hoofdpijn van 2,5%. Zoals viel te verwachten, werd hoofdpijn in de-
ze studie minder vaak gemeld dan in klinisch onderzoek met lansoprazol. Het
incidentiecijfer was 7,2 per 1.000 patiënt maanden van PPI gebruik en dus ver-
gelijkbaar met gegevens van andere observationele studies met lansoprazol en
omeprazol gebruikers. Spanningshoofdpijn werd gezien bij twee van de drie pati-
enten met hoofdpijn en migraine bij de rest. Door gebruik te maken van een case-
control-onderzoek met matching, werden patiënten die wel of niet hoofdpijn
meldden vergeleken. Naast een aantal bekende co-factoren zoals vrouwelijk ge-
slacht en analgetica-gebruik in het verleden, zagen we dat het melden van andere
bijwerkingen geassocieerd was met het rapporteren van hoofdpijn tijdens lanso-
prazol gebruik. Patiënten met hoofdpijn meldden ook significant vaker diarree,
misselijkheid en duizeligheid. H t feit dat de hoofdpijn verdween na het stoppen
van het PPI gebruik en de gevonden associatie met de dosis maken aannemelijk
dat hoofdpijn inderdaad een bijwerking was van lansoprazol gebruik.
Diarree is een eveneens vaak gemelde bijwerking tijdens PPI gebruik in klinisch
en observationeel onderzoek. De beperkt beschikbare informatie hierover was de
aanleiding om een studie op te zetten met als doel de incidentie en de kenmerken
van diarree vast te stellen en mogelijk gerelateerde co-factoren te onderzoeken
bij PPI gebruik in de dagelijkse klinische praktijk. Zoals weergegeven in hoofd-
stuk 5.3, bedroeg de frequentie van diarree 3,7% en het incidentiecijfer 10,7 per
1.000 patiënt maanden van PPI gebruik. De resultaten zijn vergelijkbaar met de
bevindingen bij lansoprazol gebruikers in respectievelijk klinisch en observatio-
neel onderzoek. De diarree was meestal brijig van consistentie en trad gemiddeld
4,4 keer per dag op. We hebben gebruik gemaakt van een genest case-control-
onderzoek met matching om patiënten te vergelijken die wel of niet diarree
meldden. De analyse van de co-factoren bracht aan het licht dat patiënten die al-
cohol gebruikten, gelijktijdig orale antibiotica gebruikten en ook andere bijwer-
kingen meldden, een grotere kans hadden op het ontwikkelen van diarree tijdens
PPI gebruik. Excessieve inname van alcohol kan gerelateerd zijn aan een toena-
me in het optreden van gastro-intestinale symptomen zoals diarree. Lansoprazol
therapie maakte in cases, alhoewel niet significant, vaker deel uit van een H. py-
lori eradicatie schema in vergelijking met controles. Bij deze patiënten en bij pa-
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tiënten met ulcera als indicatie zou de diarree mede veroorzaakt kunnen worden
door het gebruik van een van deze voorgeschreven geneesmiddelen. Dit is ook
zichtbaar aan het frequenter gebruik van orale antibiotica. De diarree verdween in
80,0% (38/48) bij het stoppen van de lansoprazol therapie en kwam weer terug in
100% (4/4) bij het opnieuw gebruiken van lansoprazol. Alhoewel een relatie met
PPI gebruik plausibel leek, raden we aan om het gebruik van alcohol en antibioti-
ca als oorzaak van de diarree in overweging te nemen bij lansoprazol gebruikers.
Appendix I
Invitation letter
This letter was used to inform physicians
about the contents of the project and to invite them to participate.
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Utrecht, <date>
Dear colleague,
In September 1993 the proton pump inhibitor PrezalÒ (lansoprazole) was intro-
duced for the treatment of reflux-oesophagitis and peptic ulcers.
Pharmacoepidemiology is an excellent instrument to evaluate the patterns of use
in daily practice and desired and not desired effects of this drug in a large patient
population. Janssen-Cilag B.V. and Aventis Pharma B.V. endorse the importance
of pharmacoepidemiology and have taken the initiative to conduct such research
with PrezalÒ.
Kendle, a clinical research institute, will coordinate this project in conjunction
with the Department of Pharmacoepidemiology and Pharmacotherapy of the
University Utrecht.
The project will start in January 1994. The protocol is approved by the Medical
Ethics Committee of the Utrecht University Medical Centre and the design fol-
lows the guidelines as recently described in literature. This means that only pa-
tients already using PrezalÒ wil  be invited to participate in the project. We
kindly request you to collect a limited number of data of these patients. The re-
sults of this project will be reported bi-annually.
We would highly appreciate if you would be willing to participate in this project.
In this manner, you can significantly contribute to the collection of data that will
give you and your colleague’s useful information to ensure justified drug use. A
summary of the protocol of this project is enclosed.
You can make known your interest by completing the attached reply form.
Please, do not hesitate to contact me in case of questions.
Kind regards,
Mrs. A. Claessens, MD
Kendle
Encl.
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REPLY FORM
Name: -
Function: -
Address: -
Zip code/ City: -
Telephone: -
O    Does want to participate in the project Peptic Survey
O    Does want to receive additional information of the project Peptic Survey
Date: Signature:
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SUMMARY
An open non-randomized retrospective postmarketing surveillance
to assess the safety and efficacy and to outline the pattern
of daily use of PrezalÒ in the Netherlands.
Introduction In September 1993 the proton pump inhibitor PrezalÒ (lanso-
prazole) was introduced for the treatment of reflux-
oesophagitis and peptic ulcers. Clinical studies demonstrated
that with PrezalÒ healing appears quicker and more often com-
pared with H2-receptor antagonists. The number of adverse
events was limited and the reported events were mild in sever-
ity and transient. As usual, these clinical studies are performed
in strictly described patient populations of relatively limited
size. However, to evaluate the use of PrezalÒ in daily practice
larger groups of patients are necessary.
Objective To get insight into the pattern of use of PrezalÒ in daily prac-
tice and the desirable and undesirable experiences in a large
patient population.
Medication PrezalÒ capsules (30 mg lansoprazole per capsule).
Participation Expected 5,000 – 10,000 patients.
Duration projectAt least 2 years.
Procedure PrezalÒ will be prescribed in daily practice by a large number
of participating General Practitioners and specialists. Patients
already using PrezalÒ and returning to their physician will be
verbally and in writing informed about the project.
If patients agree to participate in the project, written informed
consent will be obtained. The following data will be collected:
demographics, medical history, diagnosis, symptoms, therapy
and (un)desirable experiences. Each time the patient visit the
physician follow-up data will be gathered once more. The
pharmacist of the patient will be requested to generate a medi-
cation history list of the patient of the previous 6 months.
Start project January 1994.
Appendix II
Patient information and informed consent
This information leaflet was handed out to all potential participating patients and
the contents were discussed with the physician. If patients agreed to participate
their written informed consent was obtained to allow access to all relevant clini-
cal and medication data and storage and analyses of these data.
Appendix II
196
PATIENT INFORMATION
An open non-randomized retrospective postmarketing surveillance
to assess the safety and efficacy and to outline the pattern
of daily use of Prezal® in the Netherlands.
Your general practitioner or gastro-enterologist / internist informed you about a
project concerning Prezal®, coordinated by Kendle, a clinical research institute, as-
sociated with the University Utrecht.
In this postmarketing surveillance project desirable and undesirable effects of a new
drug will be evaluated in large patient-population. Prezal® has become available on
the market recently. The drug is used in patients with reflux-oesophagitis or peptic
ulcers.
Up to now, clinical studies, with Prezal® in over 2,000 patients with duodenal ul-
cers, gastric ulcers and reflux-oesophagitis have demonstrated a more rapid and fre-
quent healing without significant side effects compared to most other acid-
suppressants.
Prezal® is well tolerated; the incidence of side effects is comparable with other anti-
acids. Gastrointestinal symptoms (diarrhoea 1.3%, constipation 1.0%, abdominal
pain 0.5% and nausea 0.6%) and neurological disorders (headache 1.3%, dizziness
1.3%) are the most frequent occurring side effects. Other side effects include skin
rash (0.6%) and itch (0.4%). All side effects are mild in severity and transient.
The purpose of this postmarketing surveillance is to gain better informed about the
safety and efficacy of Prezal® in large populations. We would like you to participate
in this project which means that your physician will request information on your
medical history and demographics and will register the symptoms and possible ad-
verse events of the drug.
Co-medication prescribed 6 months prior to the start of the project and during the
entire project will be obtained from pharmacy records. This information will be sent
to the University of Utrecht, so your physician will not receive this information. At
each visit your physician will complete another check-list on the occurrence of ad-
verse events and details about your disease.
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You are free to withdraw at any time from further participation, without the need to
give reasons and without prejudice to further treatment. All information will be
stored and analysed anonymously and will be treated confidentially. Information
will only be made available anonymously to authorized representatives from the
health authorities and/or sponsor of Prezal®. Any risk of the use of Prezal® is in-
sured by the sponsor providing that you have followed the instructions given by the
physician.
If you would like to discuss anything regarding the postmarketing surveillance, you
can contact your physician.
Name: Telephone:
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WRITTEN INFORMED CONSENT FORM
An open non-randomized retrospective
postmarketing surveillance
to assess the safety and efficacy
and to outline the pattern
of daily use of Prezal®
in the Netherlands.
I am fully informed about the nature and objectives of the postmarketing surveil-
lance and have given free informed consent. I am free to withdraw at any time from
further participation, without the need to give reasons and without prejudice to fur-
ther treatment.
I agree that my physician will request the pharmacy to collect my pharmacy records.
I also agree that my medical and pharmacy records will be documented and ana-
lysed anonymously.
Patient
Name:
Date: ___ / ___ / ___ Signature:
Physician
Name:
Date: ___ / ___ / ___ Signature:
Identification code:
Dankwoord
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DANKWOORD
Vele mensen hebben een bijdrage geleverd aan het tot stand komen van dit proef-
schrift. Eind 1993 kreeg U-Gene Research (thans Kendle) opdracht tot begelei-
ding van een groot postmarketing surveillance project in opdracht van Aventis
Pharma B.V. en Janssen-Cilag B.V. Ik werd gevraagd voor dit project de coördi-
natie op mij te nemen. In 1995 stimuleerden Tom Schwarz, Marianne Floor en
Bert Leufkens me op basis van dit project een proefschrift te schrijven. Derhalve
wil ik op de eerste plaats Tom, Marianne en Bert bedanken voor het initiatief van
toen en het vertrouwen dat ze in me stelden. Tijdens het promotietraject veran-
derde U-Gene Research in Kendle en traden er meer veranderingen op. Echter
wat bleef was het vertrouwen in mij en het ter beschikking stellen van tijd voor
de afronding van het proefschrift door Ronald Koning en Yvonne van Megen. Ik
heb dat zeer op prijs gesteld!
Zoals reeds aangegeven was zonder prof. r. Bert Leufkens het proefschrift nooit
gestart en zeker niet voltooid. Bert, in zijn rol als promotor, was er steeds om
wetenschappelijke input en onderbouwingen aan te dragen op het moment dat ik
dacht waar zijn we nu eigenlijk mee bezig. Je had initiatieven te over, deels zijn
ze uitgevoerd en deels zijn ze van tafel verdwenen. Want eens moet het af zijn.
Dank je wel, ik heb je begeleiding als zeer leerzaam en plezierig ervaren.
Als tweede promotor wil ik prof. dr. Cock Lamers bedanken voor het geven van
vele adviezen op het gebied van de gastro-enterologie, het  en het niet uit het oog
verliezen van de realiteit van de data. Ik hoop dat ik je reisschema niet teveel heb
verstoord.
Dr. Rob Heerdink was mijn co-promotor en zorgde veelal op de donderdag voor
ondersteuning bij de afdeling farmacoepidemiologie en farmacotherapie. Ik was
één van je vele dagjes-mensen. Je werd vaak belaagd door e-mail, desondanks
had je altijd even tijd voor het geven van advies en was immer in voor koffie en
uitwisseling van nieuwtjes op velerlei terrein. Zonder je medewerking waren de
analyses in EGRET en de verwerking van de medicatielijsten onmogelijk. Dank
je wel voor je adviezen, hulp en de plezierige samenwerking.
Tevens wil ik graag de vele anderen bij de disciplinegroep Farmaco-
epidemiologie en Farmacotherapie bedanken voor hun interesse en gezelligheid.
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Welmoed Meijer is mijn zeer gewaardeerde steun en toeverlaat geweest tijdens
het grootste deel van dit project. Je hebt tientallen artsen in het land bezocht. Tij-
dens beide periodes van zwangerschapsverlof heb je mijn taken met betrekking
tot het project waargenomen. Je was altijd bereid en in staat tot medewerking,
ook bij moeilijke of weinig inspirerende taken. Heel veel dank.
Ook wil ik graag de vele andere (oud-)collega’s van Kendle bedanken voor hun
medewerking en betrokkenheid. Met name Audrey, Lotte, Ron, Harm, wederom
Welmoed, Cecile, Margot en Anjo voor het bezoeken en instrueren van honder-
den artsen, Sarah voor het corrigeren van de engelse teksten en Ronald, Indra,
Armand, Toon en vele anderen bij de verwerking van de bijna 20.000 evaluatie-
formulieren en ruim 11.000 medicatielijsten.
Bovendien ben ik de honderden huisartsen en specialisten uit Nederland en de
tientallen medewerkers van Aventis Pharma B.V., Janssen-Cilag B.V. erkentelijk
die elk op hun eigen wijze een bijdrage hebben geleverd aan de verzameling van
gegevens van lansoprazol gebruikers.
Aventis Pharma B.V. en in de eerste fase ook Janssen-Cilag B.V. ben ik zeer veel
dank verschuldigd. Jullie initiatief in 1993 tot het opzetten van dit project heeft
geleid tot het schrijven van dit proefschrift. Met name Yvonne van Megen, Joop
van Oene en Kristelle Nusteling hebben een grote wetenschappelijke bijdrage
geleverd. Bedankt voor het steeds maar weer lezen en beoordelen van de manu-
scripten. De sturing van Marja Pronk door het stellen van deadlines en het orga-
niseren van vele projectteam- en adviesraad vergaderingen was een belangrijke
rode draad in het verloop van het project. Gezamenlijk is het gelukt om gegevens
van meer dan 10.000 lansoprazol gebruikers te verzamelen.
De adviesraad is alle jaren elke drie maanden trouw bijeengekomen. Onderwer-
pen als compliance, non respons en seeding waren favoriete thema’s. Ook werd
er veel gesproken over eten. Te denken valt aan het symposium met de titel
‘Food for Thoughts’ en aan de culinaire omlijstingen tijdens de adviesraden. Het
officiële afscheidsetentje hebben we zodoende zelf bereid in een Kookstudio.
Naast de (co-)promotoren maakte prof. dr. Jacques van Eijk deel uit van de ad-
viesraad. De methodologie stond steeds centraal bij je, zoals de selectie van art-
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sen en patiënten en het beschrijven van de data. Je geduld, precisie en altijd snel
becommentariëren van de artikelen heb ik zeer gewaardeerd.
Dr. Ron Herings wil ik graag bedanken voor zijn idee dat leidde tot het artikel
over NSAID gebruik en voor het gebruik van PHARMO-gegevens voor het ma-
nuscript over ‘seeding’.
Ik bedank de leden van de leescommisie prof. dr. A.W. Broekmans, prof. dr.
J.Th.M. van Eijk, dr. M.E. Numans, prof. dr. A.J. Porsius en dr. B.H.Ch. Stricker
voor de snelle beoordeling van mijn manuscript.
Welmoed Meijer en Roel Franken, bedankt voor jullie aanvaarding van de taak
als paranimf. Alvast dank voor jullie begeleiding en ondersteuning bij de promo-
tie.
Mam en Pap, bedankt voor jullie altijd aanwezige vertrouwen in mij en de flexi-
bele hulp variërend van oppassen tot allerlei huis-tuin-en-keuken klusjes.
Joost, de inhoud van het proefschrift is niet jouw terrein. Echter je steun bij het
schrijven en afronden van het proefschrift was er alle jaren en was onmisbaar.
Koen, Floor en Lotte, jullie komst gedurende het bezig zijn aan dit boekwerk
heeft gezorgd voor een aangename maar soms ietwat scheve balans tussen wer-
ken en ontspanning. Zullen we dan ook morgen naar de dierentuin gaan of liever
naar het zwembad?
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